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Vitamin D plays a role in musculoskeletal (MSK) health through genomic and non-genomic 
pathways. In the UK, SACN used a 25(OH)D concentration of 25 nmol/L as the basis for 
setting the (Recommended Nutrient Intake) RNI of 10 µg/day based on MSK outcomes 
(rickets, osteomalacia, falls, muscle strength and function).  In setting vitamin D 
recommendations for North Americans, the IOM used a 25(OH)D concentration of 50 nmol/L 
as the basis for setting the (Recommended Dietary Allowances) RDA of 15 µg/day, based on 
the relationship between 25(OH)D and bone outcomes (rickets, osteomalacia, bone mineral 
density and calcium absorption). The differing thresholds used to define “vitamin D 
adequacy” may be due to (1) different MSK outcomes and approaches used to underpin the 
DRVs (2) geographical differences in vitamin D status and response to vitamin D 
supplementation and exposure to sunlight.  Since vitamin D biomarkers and vitamin D supply 
required for optimum MSK function are not agreed universally, this thesis is set out to 
determine the effect of vitamin D supply on muscle function and to determine the association 
between commonly-used vitamin D biomarkers [25(OH)D and PTH] and muscle function 
[Grip Strength (GS), Timed-up and Go (TUG)] and bone health [quantitative ultrasound] in 
older adults using two different studies from the North East of England (55° North). In 
addition, because sunlight exposure is known to influence vitamin D biomarkers and response 
to vitamin D supplementation, this thesis also attempted to quantify the impact of sun 
exposure on vitamin D status in both studies.  The first study was a Randomized Control Trial  
(RCT) of monthly vitamin D supplementation (12000 IU, 24000 IU and 48000 IU vitamin 
D3) for 1 year on MSK health [Vitamin D in Older People study- VDOP (n=379; age >70 
years)]. The second study was a follow-up study of older adults at moderate risk of colon 
cancer [the Biomarkers of Risk of Colon Cancer Follow-Up study - BFU (n=47, age >49 
years)].  Baseline findings from the VDOP study showed that plasma 25(OH)D concentration, 
<25 nmol/L was associated with lower odds [OR 0.34, 95% CI, 0.166 -  0.691] of higher 
muscle function, compared with plasma 25(OH)D concentrations ≥ 25 nmol/L, after adjusting 
for the season of blood sampling and relevant confounders.  Serum PTH was not associated 
with any MSK parameter at baseline.  Vitamin D supplementation with 12000IU, 24000IU or 
48000 IU monthly for one year increased 25(OH)D concentrations in a dose dependent 
manner, but had no effect on GS or TUG.  Using a detailed sun exposure questionnaire to 
derive a composite sunshine exposure score, personal UV exposure failed to predict post-
intervention 25(OH)D concentration in any of the vitamin D treatment groups.  Findings from 
the BFU study showed that serum 25(OH)D concentration was not associated with GS, TUG 
or QUS in older adults.  Serum PTH concentration was associated with QUS but not GS or 
TUG.  Holiday visits was the only sun exposure variable which was associated with serum 
25(OH)D concentration (p=0.042) at baseline in VDOP study.  Sixteen participants were 
vitamin D deficient (25 – 50 nmol/L) at follow-up which increased from 7 participants at 
baseline over the 12 year follow-up period since the initial phase of data collection.  In 
summary, low dose vitamin D supplementation improved vitamin D status in older adults 
such that vitamin  D deficiency was prevented but it failed to improve muscle function.  In 
line with SACN recommendations it may be prudent to maintain serum 25(OH)D > 25 
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Chapter 1 Literature Review 
1.1 Introduction  
Vitamin D is classified as a secosteroid compound and it is a fat-soluble vitamin. The two 
major forms of vitamin D are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). 
Vitamin D2 (C28H44O) differs from vitamin D3 (C27H44O) in the side chain attached to the 
secosteroid skeleton and it has an additional methyl group on the 24th carbon atom and a 
double bond between 22nd and 23rd carbon atoms (Norman, 2008) (Figure 1.1). Vitamin D2 is 
produced by plants, while vitamin D3 is synthesized in the skin upon Ultraviolet B radiation 
(UVB). Studies show that D3 is the predominant source of vitamin D in most humans and, 
therefore, makes a bigger contribution to vitamin D status (SACN, 2016; and reviewed later 
in this chapter). Rickets, the bone disease caused by inadequate vitamin D, was first described 
in details by F. Glisson in 1650 (Wolf, 2004).  
 
 
Vitamin D2       Vitamin D3  
 Figure 1.1 : Chemical structures of vitamin D2 and D3 (Source : SACN, 2016) 
 
The aims of this literature review section is to describe,  
1. The physiological and nutritional aspects of vitamin D including the biomarkers of 
vitamin D status. 
2. The determinants of vitamin D status including the role of sun exposure. 
3. The evidence base for the role of vitamin D biomarkers (sun exposure and different 
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1.2 Vitamin D Synthesis and Metabolism 
Vitamin D can be synthesized in the skin upon UVB (wavelength 290 – 320 nm) radiation. 
Exposure to sufficient sunlight is important for maintaining optimum vitamin D status, because 
there are few vitamin D rich foods (Holick, 2007) and for most people, these are eaten in 
insufficient amounts to meet vitamin D needs. Most of the UVB radiation from the sun is 
absorbed by the ozone layer and only 1% reaches the earth at noon time in the areas near the 
equator. The energy content of the UV rays and wave length of UV rays are inversely related. 
Thus, UVB has more energy compared with Ultraviolet A Radiation (UVA) (wave length 320 
– 400 nm). Therefore UVB rays can penetrate more deeply into the skin than can UVA (Holick, 
2016). 
The first step of vitamin D synthesis takes place in the epidermis of the skin. First, UVB 
irradiation converts 7 – dehydrocholesterol (7-DHC) to pre-vitamin D3. This previtamin D3 is 
thermodynamically unstable and undergoes spontaneous isomerization into cholecalciferol in 
the plasma membrane of epidermal and dermal cells within 3 days (Holick et al, 1980). Then 
vitamin D3 is transported bound to Vitamin D Binding Protein (DBP) in the circulation and 
hydroxylated to 25-hydroxyvitamin D (25(OH)D) in the liver. This hydroxylation process is 
catalyzed by cytochrome P450 2R1 (encoded by the gene CYP2R1) (Henry, 2011) and the 
produced 25(OH)D circulates in the blood circulation bound to DBP. This 25(OH)D is taken up 
by the kidney by endocytosis via the endocytic receptor megalin in renal proximal tubular cells 
(Dusso, 2011) in preparation for the second hydroxylation step in which  25(OH)D is converted 
to 1,25-dihydroxyvitamin D (1,25(OH)2D). This 1,25(OH)2D is considered as the active form 
of vitamin D which responsible for various function of vitamin D (Nykjaer et al., 2001). This 
2nd hydroxylation process is catalyzed by the mitochondrial P450 enzyme 1α-hydroxylase 
(encoded by the gene CYP27B1) (Prentice et al., 2008) (Figure 1.2). Production of 1,25(OH)2D 
also occurs in other tissues including placenta, breast, colon, prostate, endothelial cells, 
pancreatic islets, parathyroid glands and macrophages for paracrine and autocrine functions in 
these tissues (Norman, 2008). The large majority of 25(OH)D and 1,25(OH)2D (85 – 90%) in 
the blood is bound to DBP, most of the remainder is  bound to albumin and less than 1% is free 
in the circulation (Bikle et al., 1986).  The metabolic fate of 25(OH)D depends on the calcium 
status of the body. When more calcium is required, a greater proportion of 25(OH)D undergoes 
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Figure 1.2 : Process of vitamin D synthesis in the skin (Source : SACN, 2016) 
Vitamin D2 and D3 are absorbed by unsaturable passive diffusion process in the small 
intestine. However at high concentration of vitamin D in the intestinal lumen, vitamin D is 
absorbed by passive diffusion in jejunum and ileum (Reboul et al., 2011). Vitamin D3 
synthesized in the skin enters the extracellular fluid and then diffuses into dermal capillaries 
(Holick, 2011). Various factors such as the form of vitamin D (D2 or D3), dietary fiber content 
of the diet, amount of triglycerides in the diet, presence of other micronutrients (vitamin A, K 
and E), genetic factors, obesity, vitamin D status of the person and age affect the 
bioavailability of vitamin D (Maurya and Aggarwal, 2017) in the diet.  After entering the 
circulation 25(OH)D is transported to the liver bound to DBP, where the active form of 
vitamin D (1,25(OH)2D) is produced. Dietary vitamin D2 and D3 are transported in 
chylomicrons via the lymph and blood plasma to the liver. The vitamin D metabolites are 
transported in blood bound primarily to DBP and albumin. Approximately 85 – 90% of 
vitamin D metabolites are bound to DBP while 12 – 15% of vitamin D metabolites are bound 
to albumin (Bokle, 2017). Adipose tissue is considered as the major storage site for vitamin 
D. However, some evidence says that muscle also is a storage tissue for 25(OH)D (Girgis et 
al., 2014). 
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1.3 Regulation of 25(OH)D and 1,25(OH)2D Production  
Plasma 25(OH)D concentration is not subjected to feedback regulation, but appears to reflect 
vitamin D supply from cutaneous synthesis and the diet. Plasma 25(OH)D concentration 
depends on the amount of vitamin D delivered to the liver, the amount produced by the liver 
and its half-life in the plasma (Prentice et al., 2008). These are affected by a number of factors 
such as the amount of vitamin D entering the body, the amount of body fat and muscle mass, 
rate of 25(OH)D uptake and the rate of conversion to other metabolites (such as 1,25(OH)2D, 
24,25(OH)2D). Other factors affecting plasma 25(OH)D concentration include the volume of 
extracellular fluid and DBP concentration (Bolland et al., 2007). The serum concentration of 
25(OH)D has also been reported to decrease during the acute-phase response to inflammation 
(Silva and Furlanetto, 2015).  
Synthesis of 1,25(OH)2D in the kidney is tightly regulated. Up-regulation is through the 
action of parathyroid hormone (PTH) and down-regulation is through fibroblast growth factor 
23 (FGF23) and direct negative feedback by 1,25(OH)2D itself (Henry, 2011). Calcium-
sensing proteins in the parathyroid gland stimulate PTH secretion in response to a fall in 
serum ionized calcium concentration. PTH stimulates the production of the CYP27B1 enzyme 
in the proximal cells of the kidney (Bajwa et al., 2008) which increases the renal synthesis of 
1,25(OH)2D. Plasma 1,25(OH)2D exerts a direct negative feedback by down-regulating the 
expression of the gene for CYP27B1, the enzyme required for its synthesis (Henry, 2011). It 
also exerts indirect negative feedback by reducing secretion of PTH. Additionally, 
1,25(OH)2D induces its own degradation by stimulating the production of the CYP24A1 
enzyme, a 24-hydroxylase that converts 1,25(OH)2D and 25(OH)D to water soluble 
compounds which are excreted through bile (Holick, 2011). Wat et al., 2007 reported that an 
optimal level of 25(OH)D that suppress serum PTH concentration was 75 nmol/L. PTH began 
to rise when 25(OH)D levels were below 75 nmol/L whereas PTH levels did not change when 
25(OH)D levels were above 75 nmol/L. Lu et al.,  2012 showed that the levels of procollagen 
1 N-terminal peptide (P1NP) and beta C-telopeptide of collagen (β-CTX) started to increase 
when serum 25(OH)D levels were less than 75 nmol/L (Lu et al., 2012).  
1.4 Biological Functions of Vitamin D 
Mechanisms of the biological function of vitamin D can be categorized as genomic and non-
genomic action of 1,25 (OH)2D (Ceglia and Harris, 2013). Mainly it is believed that vitamin 
D metabolites can affect muscle cell metabolism through gene transcription and variation in 
the Vitamin D Receptor (VDR) allele (Barr et al., 2010). VDRs are found in muscle tissues 
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and are involvedin the activation of muscle protein synthesis. Once VDR is transported to the 
nucleus by an intracellular binding protein called, calcitriol, it binds to the nuclear receptor 
which results in gene transcription for de novo protein synthesis. At the nuclear level, the 
activation of VDR induces hetero-dimerization between the active VDR and the retinoic 
receptor. This leads to the activation of the vitamin D response element, a complex of genes 
coding for the “Genomic effects” of vitamin D (Boland, 2011).  
Nongenomic action is occurring via a nonnuclear or membrane-associated VDR. Nonnuclear 
VDR is thought to be associated with proteins which are stimulated by IGF-1 and result in 
activation of mitogenaci-activated protein kinase (MAPK) and phosphoinositol-3 kinase 
(PI3K)/Akt cascades pathways that regulate cell differentiation and growth. Nongenomic 
mechanisms also mediate the actions of 1,25(OH)2D on calcium influx and muscle 
contractility (Ceglia and Harris, 2013). 
Vitamin D shows its genomic effects by activating the gene transcription via intranuclear 
VDR. It results in the synthesis of specific proteins that influence muscle calcium handling, 
phosphate transport across the cell membrane, and muscle cell differentiation and 
proliferation. Vitamin D regulates muscle calcium uptake by modulating the activity of 
calcium pumps in sarcoplasmic reticulum and sarcolemma. Modifications in intracellular 
calcium level controls contraction and relaxation of the muscle. Further, 1,25(OH)2D 
modulates intracellular calcium levels by stimulating the expression of a calcium-binding 
protein called calbindinD9K. One of these 1,25(OH)2D-dependent proteins is a calmodulin-
binding component of the myoblast cytoskeleton. Calmodulin is a calcium binding protein 
(CaBP) that regulates several cellular processes including muscle contraction. Vitamin D 
appears to play a role in the regulation of phosphate metabolism in myoblasts as well. 
Exposure to 1,25(OH)2D stimulates accelerated phosphate uptake and accumulation in cells. 
These effects may occur through the effects on the expression of FGF-23, which is a key 
hormone regulate phosphate homeostasis and effects on phosphate transporters. The study by 
Ceglia and Harris (2013) et al. found that administration of 1,25(OH)2D to myoblasts up-
regulated gene pathways responsible for myogenic differentiation including insulin growth 
factor 2 (IGF-2) expression (Figure 1.3) . 
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Figure 1.3 : Effect of 1,25(OH)2D on muscle cells : Genomic and non genomic pathways 
(Source : Ceglia and Harris, 2013) 
 
(MAPK :  Mitogenaci Activated Protein Kinase, VDR : Vitamin D Receptors, RXR :  Retinoid X receptors, IGF : 
Insulin Like Growth Factors) 
1.5 Biomarkers of Vitamin D Status and Vitamin D Metabolites 
1.5.1 Serum or plasma total 25(OH)D concentration and free 25(OH)D concentration 
The plasma total 25(OH)D concentration which is the summation of 25(OH)D2 and 25(OH)D3 
is a useful vitamin D biomarker. It is widely used to diagnose Vitamin D Deficiency (VDD) 
in both clinical and non-clinical settings. Serum/plasma 25(OH)D has a comparatively long 
half-life of 2-3 weeks and its concentration is not under tight homeostatic regulation. 
Therefore 25(OH)D concentration reflects the vitamin D supply and usage over a period of 
time (Ross et al., 2011). Serum 25(OH)D is commonly bound to DBP and albumin which can 
be converted into hormonally active 1,25(OH)2D in the kidney, colon and several other 
tissues. Most circulating 25(OH)D is bound to either DBP (88%) or albumin (12%) and only a 
small fraction (less than 1%) circulates in a free form. The albumin-bound fraction of 
25(OH)D plus free fraction are therefore called as the bioavailable fraction of 25(OH)D. 
Therefore total plasma/serum 25(OH)D include both free and bound forms of 25(OH)D. The 
total plasma concentration of 25(OH)D depends on many factors, including the amount of 
vitamin D entering the body from the skin and diet, the amount of body fat and muscle, the 
activity of 25-hydroxylase, DBP production in the liver, the volume of the extracellular 
compartment, the expression and affinity of VDR in target tissue, the efficiency of cellular 
uptake of 25(OH)D and its rate of conversion to 1,25(OH)2D or 24,25(OH)2D, the amount of 
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25(OH)D produced by the liver and the half-life of 25(OH)D in the plasma (Prentice et al., 
2008).  
1.5.2 Total serum/plasma 1,25(OH)2D and free 1,25(OH)2D concentrations 
Serum/plasma 1,25(OH)2D is the active form of vitamin D which is responsible for all 
biological functions in the body and it is the summation of both 1,25(OH)2D2 and 
1,25(OH)2D3. The majority of 25(OH)D and 1,25(OH)2D is primarily bound to DBP and 
approximately 10–15% of 25(OH)D and 1,25(OH)2D to albumin. Some of the researchers use 
1,25(OH)2D as one of the functional biomarkers of vitamin D under normal physiological 
conditions. In contrast, 1,25(OH)2D is not considered as a valuable nutritional biomarker for 
vitamin D status as circulating 1,25(OH)2D concentration is under homoeostatic control and it 
has a short half-life of a few hours (Ross et al., 2011). In addition, 1,25(OH)2D concentration 
is not considered as an ideal biomarker of vitamin D, as it is not an accurate predictor of the 
cellular 1,25(OH)2D concentration in all target cells. The free fraction of 1,25(OH)2D in 
plasma may be an index of the amount available for cellular uptake. The half-life of 
1,25(OH)2D in plasma provides information about the balance between supply and 
metabolism at the tissue level (Prentice et al., 2012) 
1.5.3 Plasma PTH concentration  
PTH has been proposed as a functional marker of vitamin D and it is considered as elevated 
plasma PTH concentration is a risk factor for osteoporosis. PTH secretion is stimulated when 
plasma ionized calcium decreases as the result of low dietary calcium intake or poor calcium 
absorption. High dietary phosphorus intake and high plasma phosphate concentration can also 
induce PTH secretion. An inverse relation between plasma concentrations of PTH and 
25(OH)D has been reported (Bates et al., 2003). However, the plasma PTH concentration 
varies widely within and among individuals because the plasma PTH concentration depends 
on many factors other than vitamin D status, such as stage of life, ethnic background, dietary 
calcium and phosphorus intakes, time of day, kidney function, physical inactivity, drug use 
and the laboratory method used to analyse the PTH concentration (Prentice et al., 2008).  
1.5.4 Serum / plasma 24,25(OH)2D concentration  
In addition to the 1,25(OH)2D, in the kidney, 25(OH)D is further hydroxylated to 24,25 
dihydroxyvitamin D. Production of 24,25(OH)2D is usually the first step in the metabolic 
pathway to inactivate 25(OH)D, which prevents vitamin D intoxication (Norman, 2008). 
Plasma concentration of 24,25(OH)2D is directly related to 25(OH)D concentration. Its 
concentration is about 50-fold higher than that of 1,25(OH)2D.The ratio of serum 
24,25(OH)2D to 25(OH)D concentration has also been suggested as an indicator of VDD 
 
    8 
(Cashman et al., 2015). The role of 24,25(OH)2D is not very clear. However, some 
researchers suggest that 24,25(OH)2D plays a role in calcium and phosphorus homeostasis in 
cartilage and bone (Edouard et al., 2012). 
1.6 Dietary Sources of Vitamin D  
Only a small proportion of commonly consumed foods are significant sources of vitamin D 
(Holick 2004).  Oily fish such as salmon, tuna and mackerel, meat, egg yolk, sundried 
mushrooms and fortified foods are the most common vitamin D rich foods (Food Standard 
Agency, 2002). Seamans & Cashman, 2009, reported that for each additional 1 µg (40 IU) of 
vitamin D consumed, serum 25(OH)D concentrations increased approximately by 0.58 
nmol/L. In addition, a recent meta-analysis showed that vitamin D3 is more effective in 
raising serum 25(OH)D concentrations than vitamin D2 (Tripkovic et al., 2012). Since most 
foods are poor sources of vitamin D (see Table 1.1), it is difficult to obtain large amounts of 
vitamin D from the diet (O’Mahony et al., 2011).  
 
Table 1:1 Vitamin D content of dietary sources of vitamin D  
Foods  Mean vitamin D content  
(Per 100g or 100mL) 
 µg IU 
Herring (grilled) 16.1 644 
Salmon (formed, grilled) 7.8 312 
Mackerel  8.5 340 
Sardine (grilled) 5.1 204 
Tuna (cooked) 3.1 124 
Eggs (whole, boiled) 3.2 128 
Fortified bran flakes 4.2 168 
Fortified cornflakes 4.2 168 
Fortified rice cereals 4.2 168 
Fat spread 7.5 300 
Milk (per 100 mL) 1.0 40 
Yogurt 1.2 48 
Liver (lamb, fried) 0.9 36 
Beef 0.7 28 
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1.7 Nutritional Requirements for Vitamin D and Scientific Basis  
Using the risk-assessment framework commonly used to set Upper Levels for nutrients, the 
Institute of Medicine (IOM) in their recent Dietary Reference Intake (DRI) report (Ross et al., 
2010) set a 25(OH)D concentration of 30 nmol/L as indicative of vitamin D deficiency based 
on integrating a number of key bone health outcomes, including rickets, osteomalacia, 
impaired calcium absorption and lower BMD.  The nature of the relationship between 
25(OH)D concentration and bone health outcomes will be discussed in detail later in this 
review. It is noteworthy that the IOM committee concluded that there was insufficient 
evidence to define vitamin D deficiency based on non-skeletal outcomes. Based on the 
relationship between 25(OH)D status and those aforementioned bone health outcomes, and 
using both data from epidemiological and intervention studies, the IOM established a 
population 25(OH)D concentration of 40 nmol/L and 50 nmol/L as the basis for setting an 
Estimated Average Requirement (EAR) of 10 µg/day and a Recommended Daily Allowance 
(RDA) of 15 µg/day, respectively in people aged 1-70 years. The IOM set an RDA of 20 
µg/day for individuals aged >70 years, while it could only establish an Adequate Intake (AI) 
of 5µg/day for infants < 1 year (Ross et al., 2010).  The EAR is the amount of a nutrient 
which meets the needs of half (50%) the population while the RDA is the amount of a nutrient 
which will meet the needs of practically all (97.5%) healthy persons in a population. The AI is 
an estimation of the observed dietary intake of an asymptomatic population. The approach 
and conclusions of the recent IOM report (Ross et al., 2010) was a significant deviation from 
those of the previous IOM DRI report of 1997 (Institute of medicine, 1997) in that for the first 
time an EAR and RDA was established for children and adults. In the past only an AI of 5 
µg/day could be derived for persons up to 70 years (Institute of Medicine, 1997).  Two of the 
caveats of the IOM report are that the vitamin D recommendations (1) assume an adequate 
dietary calcium intake and (2) assume a negligible contribution from sunlight to 25(OH)D 
concentrations. It is also noteworthy that in terms of adverse effects, the Tolerable Upper 
Intake Level (UL) for vitamin D which is the highest level of daily consumption that current 
data have shown to cause no side effects is 100 µg/day (Ross et al., 2010) while in the older 
DRI report (Institute of Medicine, 1997) it was set at 50 µg/day.  In 1998, the UK Committee 
on Medical Aspects of Food and Nutrition Policy (COMA) concluded that a prudent public 
health approach to safeguard against vitamin D deficiency and its adverse effect on bone 
health would be to retain the Reference Nutrient Intake set in 1991 (10 µg/day for those aged 
>65 years).   
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The Scientific Advisory Committee for Nutrition (SACN) in the UK re-evaluated nutritional 
requirements for vitamin D for the British population in 2016 (SACN, 2016).  The findings of 
the report suggests a Reference Nutrient Intake (RNI) of 10 µg/d (400 IU/d), throughout the 
year, for everyone in the general UK population aged 4y and above.  The approach used in 
deriving the new RNIs involved determining the dietary input of vitamin D required to keep 
the circulating 25(OH)D above 25 nmol/L (the population protective cut-off to protect 
musculoskeletal health) (SACN, 2016).  The RNI of 10 µg/d (400 IU/d) for the general UK 
population includes pregnant and lactating women and population groups at increased risk of 
VDD.  Since, there were insufficient data to set RNIs for children aged under 4y, Safe Intakes 
were recommended for this age group (8.5-10 µg/340-400 IU per day for all infants aged 
under 1y and 10 µg/400 IU per day for ages 1 up to 4y).  SACN were unable to quantify and 
take account of sunlight exposure in setting the DRVs because of the number of factors that 
affect endogenous vitamin D synthesis.  The EFSA and the Endocrine Society also set targets 
for vitamin D intake and these together with the IOM and SACN recommendations are 














Table : 1.2 : Different criteria of defining vitamin D adequacy in adults  
Organizations 
which set the cut-
off value 
Target population 25(OH)D cut-off (nmol/L)  Basis for the cut-off Reference  
IOM  North Americans >50 :  sufficient 
30 - 50 : insufficient 
< 30 : deficient 
Establishing RDA of 15 µg/day for 
vitamin D based on bone outcomes  
(Presence of rickets and osteomalacia, 
BMD and calcium absorption) 
Ross et al., 2011 
SACN  UK population > 25 : adequate Basis for establishing RNI of 10 µg/day 
based on MSK outcomes  (Presence of 
rickets, osteomalacia, falls, muscle 
strength and function)  
SACN, 2016 
EFSA Europeans  >50 AI of 15 µg/day EFSA et al., 2016 
Endocrine Society  Patients who are at 
risk of VDD 
>50 Patient management  Holick et al., 2011 
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Some previous studies have suggested the required serum 25(OH)D concentration for 
different health outcomes. Heaney and Holick, 2011 suggested that serum concentration of 
25(OH)D higher than 70 – 80 nmol/L is the optimal level for children, adolescents, adults for 
the both skeletal and non-skeletal outcomes. According to a systematic review, serum 
25(OH)D concentrations between 22.5 – 94 nmol/L are associated with higher BMD in all life 
stages. Therefore they concluded that serum 25(OH)D concentrations between 90 and 100 
nmol/L are desirable for the prevention of hip and any non-vertebral fractures in older adults. 
In the same systematic review they reported that for lower-extremity strength, serum 
25(OH)D concentrations  >40 nmol/L is desirable, but a concentration between 90 to 100 
nmol/L would optimal (Bischoff-Ferrari et al., 2006).  
Vitamin D intake is expressed in International Units (IU) or in micrograms (μg). One IU of 
vitamin D is defined by the World Health Organization (WHO) as the activity produced by 
0.025 μg of crystalline vitamin D3 (1 μg = 40 IU). According to the past studies of older 
persons, 25(OH)D concentrations can be increased by 10–40 nmol/L with an intake of 400 IU 
vitamin D/day (Heaney et al., 2003) by 31 nmol/L with the intake of 600 IU/day (Vieth et al., 
2004), and by 50–65 nmol/L, with the intake of 800 IU vitamin D/day (Dawson-Hughes et al., 
1997) Mean concentrations of 75 to 100 nmol/L can be achieved with the intake of 700 to 
1000 IU/day among young and older adults. In young men and women, 4000 IU vitamin 
D/day (100 µg/day) may increase 25(OH)D concentrations by 56 nmol/L (Bischoff-Ferrari et 
al., 2006). However, it is believed that the amount required for children is 8.5 – 10 μg/day 
(SACN, 2015). IOM suggests that individuals over 70 years should have 800 IU/day of 
dietary intake of vitamin D (Ross et al., 2011) which is equivalent to 20 µg/day. 
Recommended Nutrient Intake (RNI) values of vitamin D, according to the SACN, for 
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Table 1.3: Vitamin D requirement for different life stages according to the SACN 
recommendations 
Life stages  UK RNI values (µg) 
0 – 6 months infants*  8.5 
7 – months – 3 years* 7.5 
4+ years** 10 
Pregnant women 10 
Lactating women 10 
     * Safe Intake   Source: SACN, 2016 
     ** Includes all at risk groups in the population 
 
1.8 Dietary Vitamin D Intake of Older Adults 
Though SACN recommends to have 10 µg/day of dietary vitamin D, most research shows that 
the consumption of dietary vitamin D is below this level among older adults. A RCT of 
vitamin D supplementation conducted in Cork, which found the dose related increase in 
serum 25(OH)D in older adult reported that average habitual intake of vitamin D was 4·4 
µg/day among elderly subjects. They further stated that the vitamin D intake that maintained 
serum 25(OH)D concentrations >25 nmol/L in 97.5% of the population was 8.6 μg/day 
(Cashman et al., 2009). In 2014, National Adult Nutrition Survey (NANS) in Ireland 
predicted that the median intake of vitamin D2 ranged from 1.7 to 2.3 µg/day on serum 
25(OH)D concentrations (Cashman et al., 2014). According to a study conducted in 
Newcastle, UK median dietary vitamin D intake of older adults aged above 85 years was 2.9 
μg/day (Granic et al., 2017). Among Korean adults aged above than 20 years the mean 
vitamin D intake was 4.0 ± 0.17 µg/day and 2.6 ± 0.1 µg/day for men and women, 
respectively (Touvier et al., 2015). The National Diet and Nutrition Survey, UK in 2016-17, 
reported that vitamin D intake in all age groups, for both genders and for all income groups 
was below the RNI for vitamin D in the UK (NDNS, 2019).  
1.9 Deficiency Symptoms of Vitamin D 
Rickets and Osteomalaca are the main deficiency disease of VDD. Rickets is the VDD disease 
in children, while Osteomalacia is the deficiency disease in adults.  Serum 25(OH)D 
concentration < 25 nmol/L, is usually defined as VDD rickets among children (SACN, 2015). 
In  rickets , bone formation rate is accelerated and mineralization of growth plates get reduced 
(Parfitt, 2003). This leads to inappropriate shape and low bone strength which lead to low 
BMD and weak weight bearing bones (Bishop, 1999). Metaphyseal bone sites are naturally 
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extended in patients with rickets, therefore they have  difficulty in walking (Agarwal et al., 
2009), suffer comorbidities such as respiratory infections (Karatekin et al., 2009) and muscle 
weakness (Cangussu et al., 2015). Osteomalacia is the adult form of rickets, which results 
from a chronic VDD affecting both bones and muscles. Increased risk of fractures, muscle or 
bone pain, and advanced deformities in bones are some of the common symptoms of 
Osteomalacia (Narchi et al., 2001).  
1.10 Vitamin D Status in the UK and European Population  
In the past few years, prevalence of VDD has increased in nonequatorial locations in the 
world (Cashman et al., 2016). A recent study conducted using a representative sample of the 
European population found that 13.0% of individuals had serum 25(OH)D concentrations <30 
nmol/L on average in a year. Among them, 17.7%  and 8.3% of people had serum 25(OH)D 
concentration below 30 nmol/L during the winter and summer, respectively. In the same 
study, the prevalence of VDD was 40.4% according to the cut-off of < 50 nmol/L (Cashman 
et al., 2016). Another recent study conducted in Mexico recruiting older adults revealed that, 
37.3% of them were vitamin D deficient and majority were women (Contreras-Manzano et 
al., 2017). Another survey conducted recruiting Irish adults showed that the year-round 
prevalence rates for serum 25(OH)D concentration < 30, < 40, < 50 and < 75 nmol/L were 
6.7, 21.9, 40.1 and 75.6 %, respectively (Cahman et al., 2013). During winter, the prevalence 
for the same serum 25(OH)D concentrations were 11.1, 31.1, 55.0 and 84.0 %, respectively. 
A cohort study conducted in England recruiting 711 788 children aged 0-17 years found that 
the crude rate of VDD increased from 3.14 per 100 000 person-years to 261 per 100000 
person-years during the period of 14 years (from 2000 – 2014) (Basatemur et al., 2017).  
According to the National Diet and Nutrition Survey, 2017 – 19, UK, during January-March, 
29% of adults aged 19 to 64 years (28% of women, 30% of men) and 27% of adults aged 65 
years and over (24% of women, 32% of men) had a serum 25(OH)D concentration below 25 
nmol/L. During April-June this prevalence decreased to 19% for adults aged 19 to 64 years 
(16% of women, 22% of men) and 9% for adults aged 65 years and over (9% of women, 9% 
of men). In contrast, during July-September, 4% of adults aged 19 to 64 years (5% of women, 
4% of men) and 4% of adults aged 65 years and over (6% of women, 1% of men) had a 
25(OH)D concentration below 25(OH)D nmol/L. The percentages were increased in October-
December showing 15% of adults aged 19 to 64 years (10% of women, 20% of men) and 15% 
of adults aged 65 years and over (15% of women, 14% of men) had a serum 25(OH)D 
concentration below 25 nmol/L (NDNS, 2019).  
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1.11 Laboratory Assessment of Vitamin D Metabolites and PTH 
Several methodologies have been developed to measure vitamin D metabolites in plasma or 
serum samples such as high Performance Liquid Chromatography (HPLC), 
Radioimmunoassay (RIA), Automated Immunoassays, Enzyme-linked Immunosorbent Assay 
(ELISA) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Currently, 
RIAs and LC-MS/MS are the commonly used methods to assess 1,25(OH)2D and 24, 
25(OH)2D. LC- MS/MS detection method has been established as the gold standard method 
for testing vitamin-D metabolites (Galior et al., 2018).  
1.11.1 Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
This technique is based on the dissociation of 1,25(OH)2D and 25(OH)D from its binding 
sites by ionization and absorption of excess energy. After the separation of interfering 
substances 1,25(OH)2D and 25(OH)D are identified in the chromatographic media. LC-
MS/MS has high specificity, sensitivity and wider dynamic range compared to immunoassay 
methods (El-Khoury et al., 2011). This method provides better accuracy at medical decision 
levels to correctly classify patients as vitamin-D deficient and sufficient. Different LC-
MS/MS methods are available to measure several metabolites of vitamin D including 
25(OH)D, 1,25(OH)2D, 24,25(OH)2D and vitamin D3 epimer separately (Ketha et al., 2016). 
Although LC-MS/MS is considered the gold standard method for 25(OH)D testing, initial 
capital investment, the labor and time intensive nature of development and implementation, 
slower turnaround time, need of high sample volume, the requirement of calibration to 
standardize the measurements are the some of the limitations of this method. Because of the 
high cost, this method is not commonly used (Grebe and Singh, 2011).  
1.11.2 High Performance Liquid Chromatography (HPLC)  
This technique is based on the isolation of serum or plasma 25(OH)D in chromatographic 
media of spectral characteristics of the compounds. The main strength of this method is that it 
can be used to measure both 25(OH)D and 1,25(OH)2D with good recoveries, convenience 
and high throughput. Potential interfering substances such as proteins and lipid are removed 
before adding into HPLC which is also considered as one of the advantages of this method. 
Further, reliability, low batch to batch variation and low limit of detection is considered as the 
other advantages. However, there is a lack of consistency in standardization procedures. 
Therefore most HPLC extraction and procedural losses are corrected by the inclusion of 
internal standard. Poor specificity, matrix interference and lack of common standard, highly 
skilled operation requirements, expensive nature, large sample volume and slow sample 
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throughput are the main disadvantages of this method. Therefore this method is not suitable 
for routine use (Martin and Newton 1998).  
1.11.3 Enzyme-linked Immunosorbent Assay (ELISA) 
The assay utilizes a competitive ELISA technique with a selected monoclonal antibody 
recognizing 25(OH)D. For a reliable determination of 25(OH)D, it is necessary to release 
25(OH)D from the 25(OH)D-VDBP-complex. Standards, controls and test samples which 
needed to be assayed for 25(OH)D are prediluted with the releasing reagent and transferred to 
the microplate coated with 25(OH)D. After an incubation an anti-25(OH)D antibody is added 
to release 25(OH)D. During an incubation step, 25(OH)D in the sample and a fixed amount of 
25(OH)D bound to the microtiter well compete for the binding of the antibody. Then a 
peroxidase-conjugated antibody is added into each microplate well. A complex of 25(OH)D – 
anti-25(OH)D antibody – peroxidase conjugate is formed. Tetramethylbenzidine  is used as a 
peroxidase substrate. Finally, an acidic solution is added to terminate the reaction, whereby 
the color changes from blue to yellow. The intensity of the yellow color is inversely 
proportional to the concentration of 25(OH)D. A dose response curve of the absorbance unit 
(optical density, at 450 nm) vs. concentration is generated and the standard 25(OH)D in the 
samples can be determined from this curve. Long laboratory procedures, necessity of 
centralized laboratory equipment and large sample volume requirements are the limitations of 
this method (Arneson and Arneson, 2013).  
1.11.4 Radioimmunoassay (RIA) 
RIA method is based on a competitive principle with a goat antibody against 25(OH)D, an 
iodinated (125I) 25(OH)D3 tracer, and donkey anti-goat precipitating complex as the 
secondary antibody. The first part of the assay involves a rapid extraction of 25(OH)D and 
other hydroxylated metabolites from serum or plasma with acetonitrile. Following extraction, 
the sample, antibody, and tracer are incubated for 90 min at 20–25°C. Separation is 
accomplished after a 20 minutes incubation at 20–25°C with the secondary antibody. A buffer 
is then added prior to centrifugation to reduce non-specific binding. Radioactivity is measured 
by a gamma counter and is inversely proportional to the concentration of 25(OH)D in the 
sample (Wagner et al., 2009). This method is suitable for the laboratories with large testing 
volume. Also it is reliable, accurate, convenience and  fast. However, 1,25(OH)2D and 
25(OH)D cannot be measured separately by this method. Multiple phase separation steps and 
requirement special instruments are the main limitations of this method (Wagner et al., 2009).  
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1.11.5 Chemiluminescence Immunoassays 
This assay uses magnetic particles (solid phase) coated with antibody against 25(OH)D and 
25(OH)D conjugated to an isoluminol derivative (tracer). During the first incubation phase, 
25(OH)D is dissociated from binding protein by buffer containing 10% ethanol and then binds 
to the anti 25(OH)D antibody on the solid phase. After a second incubation with the tracer, 
the unbound material is washed off and starter reagents are added to generate a flash 
chemiluminescent signal which is measured by a photomultiplier and is inversely related to 
25(OH)D concentration. This method is more practical and an easier method compared to 
other methods. High throughput capacity and lower sample volume requirement are also the 
advantage of this method. However, the concentrations of 1,25(OH)2D and 25(OH)D cannot 
be measured separately by this method (Wagner et al., 2009). 
1.11.6 Roche Electrochemiluminescence Immunoassay (ECLIA) 
Roche modular 25(OH)D ECLIA assay is a direct competitive electrochemiluminescence 
immunoassay for human serum or plasma. The assay employs microparticles coated with 
streptavidin and a polyclonal sheep antibody against 25(OH)D, which is labelled with 
ruthenium. In the first incubation, 25(OH)D3 in the sample competes with biotin labelled 
25(OH)D for binding with the anti-25(OH)D antibody. In the second incubation, the biotin 
25(OH)D/anti-25(OH)D antibody immunocomplex becomes bound to the microparticles via 
interaction of biotin and streptavidin. The microparticles are then magnetically captured onto 
the surface of an electrode. A voltage is applied to the electrode to produce a 
chemiluminescent emission, which is measured by a photomultiplier and is inversely 
proportional to 25(OH)D concentration (Wagner et al., 2009). 
1.11.7 Electrochemiluminesence assay of PTH analysis  
PTH was analyzed using the sandwich test principle of electrochemiluminescence technology. 
The analysis was carried-out at Newcastle Laboratories, Freeman Hospital, Newcastle upon 
Tyne. In this assay a biotinylated monoclonal antibody reacts with the N-terminal fragment 
and a monoclonal antibody labelled with a ruthenium complex reacts with the C-terminal 
fragment. In the second incubation, after addition of streptavidin-coated microparticles, the 
complex becomes bound to the solid phase via interaction of biotin and streptavidin. The 
reaction mixture is aspirated into the measuring cell where the micro-particles are 
magnetically captured onto the surface of the electrode. Unbound substances are then 
removed with ProCell molecular. Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier. Results are determined 
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via a calibration curve generated by 2-point calibration and a master curve provided via the 
reagent barcode. 
1.12 Quality Assurence of Vitamin D Analysis in Laboratories  
The College of American Pathologists (CAP) and Vitamin-D External Quality Assessment 
Scheme (DEQAS) surveys are used to monitor the performance of laboratories using various 
methods for testing vitamin D metabolite (Burdette et al., 2017). Lack of standardization has 
been recognized as a challenge in steroid hormone testing. The Center for Disease Control 
and Prevention has established a Vitamin-D Standardization Certification Program (VDSCP) 
focused on providing reference measurements for 25(OH)D, to assess the accuracy and 
precision of vitamin D tests, to monitor their performance over time and provide technical 
support to external quality assurance programs, proficiency testing programs and research 
studies. A recent study by VDSCP established core performance criteria, namely CV ≤ 10% 
and mean bias ≤ 5% for 25(OH)D testing. Inter-laboratory performance of 25(OH)D 
measurement was compared by providing a set of 50 individual donor samples to 15 
laboratories representing national nutrition survey laboratories, assay manufacturers, and 
clinical or research laboratories. Samples were analyzed using immunoassays and LC-
MS/MS. All LC-MS/MS results achieved VDSCP criteria, whereas only 50% of 
immunoassays met the criterion for  ≤ 10% CV and only three of eight immunoassays 
achieved the ≤ 5% bias (Wise et al., 2017).  
1.13 Determinants of Vitamin D Status  
Sun exposure related variables, dietary intake and supplemental vitamin D are mainly 
associated with vitamin D status of a person. In addition some personal factors such as age, 
gender, BMI, alcohol intake and smoking status, are also associated with a person’s vitamin D 
status.  
1.13.1 Sunlight exposure factors  
It is believed that about 90% of total serum 25(OH)D concentration is accounted by cutaneous 
synthesis (Fraser and Milan 2013). Several studies also confirmed that the UVB exposure is 
the main determinant of the serum 25(OH)D concentration in the skin (Hedlund et al., 2013, 
Freedman et al., 2013, Berger et al., 2012). Time spent outside during sunny weather, 
frequent outdoor activities, time of the day of sunlight exposure, clothing habits, use of 
sunblock and skin exposure area are some of the sunlight exposure related factors that 
determine the 25(OH)D concentration (Touvier et al., 2015, Voipio et al., 2015). Blinkley et 
al., (2009) reported that the efficacy of the vitamin D synthesis in the skin is inversely related 
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to vitamin D status of the individual (Nair and Maseeh, 2012).  Liver 25-hydroxylase enzyme 
is inhibited by 25(OH)D, which result in hindering the hydroxylation of vitamin D3 to 
25(OH)D (Binkley et al., 2009). Various personal and environmental factors are associated 
with vitamin D synthesis in the skin upon UVB exposure.   
Zenith angle, season and latitudes 
Zenith angle is the angle between the vertical local line and line of straight to the sun. The 
intensity of UV radiation reduces with increasing zenith angle. This is caused by two effects. 
First, the intensity of down-welling solar irradiance is proportional to the cosine of the solar 
zenith angle. Second, the length of the atmosphere that irradiance has to pass through 
increases with increasing zenith angle, which causes a high level of absorption of irradiance 
by atmospheric gases and aerosols. For a particular site at the earth’s surface, the solar zenith 
angle depends on latitude, time of day and the season (Fioletov et al., 2010). 
The seasonal variation in serum 25(OH)D concentration is documented in many studies 
(Brembeck et al., 2016, Jolloffe et al., 2015, Touvier et al., 2015). According to a study 
conducted among older adults live in care homes in the East London found that, there was 
10.3 nmol/L increase in serum 25(OH)D concentration during summer compared to winter 
(Jolliffe et al., 2015). The seasonal difference in serum 25(OH)D concentration has also been 
reported in UK dwelling South Asian women. It is reported that the prevalence of VDD in 
older adults was 2% higher during winter season compared to autumn season (Darling et al., 
2013). People with large seasonal changes in 25(OH)D concentration may have suboptimal 
vitamin D concentration for most of the time of the year (Christensen et al., 2010). In addition 
to the variation in UVB exposure, seasonal changes in 25(OH)D concentration is also caused 
by the disparity in the activity of the hydroxylase enzyme which controls vitamin D 
metabolism. These enzymes include 1-hydroxylase (CYP 27B1) and 24-hydroxylase 
(CYP24A1) (Christensen et al., 2010). 
Latitude is a well-known factor affecting sun exposure of the population. The conversion of 7-
DHC to previtamin D does not occur in the winter months among the people who live in the 
areas located in the latitudes above 400N. Also when altitude rises, even summer synthesis of 
vitamin D is reduced. Due to the lower solar zenith angle, the intensity of UV rays is higher at 
the countries of low latitudes than that of the countries in the high latitudes. However, the 
effect of latitudes may vary depending on the cloud cover and the level of air pollution 
(Fioletov et al., 2010). In contrast, it is believed that the people who live in higher latitudes 
evolved to synthesize a high amount of vitamin D effectively (Mei et al., 2007). 
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UV index and solar spectrum  
UV index (UVI) gives an indication of the amount of UV rays that reach to the earth at solar 
noon time to produce erythema, which reflects as a single number. Erythema is a condition 
that skin turns to light pink in color upon sunlight exposure. It is the main sunlight exposure 
related factor that affects vitamin D synthesis. The UVI can be computed by multiplying the 
erythemal irradiance, in watts per m-2, by 40. This index was introduced in Canada in 1992 in 
response to growing concern about the increased availability of UV radiation due to the 
reduction of the ozone layer. The World Meteorological Organization and the World Health 
Organization in 1994 adopted UVI as a standard indicator of UV levels (Fioletov et al., 2010).   
Atmospheric gases, particles and clouds  
The wide varieties of aerosol types are available in the atmosphere  can be categorized as 
man-made and natural. Volcanoes, forest fires (Fioletov et al., 2001) and deserts (Sarra et al., 
2003) are some of the natural sources of aerosols while power plants, factories, biomass 
burning  automobiles and aircraft are some of the artificial sources. Absorption of UV by 
aerosols in urban areas reduces UV rays that reach the earth by 10%-15%. As a result of the 
ozone layer, only less than 3% of radiation reaches the earth’s surface (Fioletov et al., 2003). 
Sulphur dioxide (SO2) and nitrogen dioxide (NO2) also can absorb UVB radiation. SO2 causes 
significant absorption up to 50% of erythemal UV. Clouds can reduce UV and visible solar 
radiation reaching the earth surface but not by the process of absorption by the process of 
scattering (Fioletov et al., 2010). A study that was conducted in Boston to compare 
previtamin D3 production on a cloudless day and cloudy day, found that vitamin D3 
production efficiency was reduced by ∼20% on a cloudy day compared to cloudless day 
(Holick et al., 2007).  
Altitude 
Surface UV radiation increases with increasing altitude. UVI increases with decreasing 
pressure and as a result, areas in higher elevation receive more UV radiation compared atsea 
level. In addition, the UV absorbing aerosols are located at low elevation and reduce the UV 
level at the ground level. Data showed that erythemal UV increases between 7% - 15% per 
km of altitude (Zaratti et al., 2003).  A study conducted in Australia using young and middle 
aged adults in three locations proved that VDD decrease with increasing altitudes (Engelsen, 
2010). In addition another study reported that the chance of synthesising vitamin D on the 
mountain Everest at 5350 m height was 400% compared to the sea level (Holick et al., 2007). 
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Time of the day 
Early morning and late afternoon sunlight is inefficient to synthesise vitamin D as a result of 
increasing solar angle (Holick 2007). To identify the effect of time of the day on vitamin D 
synthesis Mei et al.,2017 carried out a research in Australia. A sealed 7-dehydrocholesterol in 
ethanol under argon in borosilicate ampoules was exposed to sunlight for one hour, in the 
early morning, noon and late afternoon. Samples were then analysed by  HPLC for the 
conversion of 7-DHC to previtamin D3. Amount of previtamin D3 was high in the samples 
placed under the noon sunlight. Production of vitamin D between the hours 8 – 10 am and 4-6 
pm was 20% less than that produced at mid-day. Also they examined the vitamin D synthesis 
at noon time in June and October. About 0.8% of 7-DHC was converted to previtamin D3 
after 5 minutes exposure in June, at 35 minutes exposure, 3.3% of 7-DHC was converted to 
previtamin D3 in October. The efficiency of converting 7-DHC to previtamin D3 was linear as 
a function of time over a period of 30 minutes.  At early morning and late afternoon the zenith 
angle is more oblique resulting in a long distance for the solar UVB photons to pass through, 
which increase the possibility of absorbing UVB by the ozone layer and reduce the UVB 
reach to the earth surface (Fioletov, 2010).  
Skin exposure area and duration of sun exposure 
Several studies have indicated that serum 25(OH)D concentration is positively associated with 
the time duration of sunlight exposure (Patwardhan et al., 2015, Touvier et al., 2015, Wakayo 
et al., 2015). High duration of sun exposure might be associated with a high physical activity 
which itself have a positive effect on vitamin D status (Brock et al., 2010). Patwardhan et al., 
(2015) stated that the association between serum 25(OH)D concentration and sun exposure 
depends on the HDL concentration of the person.. A research conducted using Muslim 
students who had traditional clothing which covers the most parts of the body showed lower 
serum 25(OH)D concentration than in the students who had normal clothing style (Wakayo et 
al., 2015).  
1.13.2 Diet and vitamin D supplements 
Dietary sources of vitamin D comes from plant sources, D2 called ergocalciferol or animal 
sources, D3 called cholecalciferol. It is believed that the increase in serum 25(OH)D 
concentration upon dietary intake of vitamin D rich food is low compared to sun exposure 
(Fraser and Milan, 2013).  It is reported that D3 is more effective than D2 in increasing serum 
25(OH)D concentration (Tripkovic et al., 2012).  It was suggested that efficient absorption of 
vitamin D is dependent upon the presence of fat in the intestinal lumen (Maurya and 
Aggarwal, 2017). Some physiological factors may also affect the response of dietary vitamin 
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D intake to the serum 25(OH)D concentration. For example, the larger the BMI, the smaller 
the rise in serum 25(OH)D concentration. Further, the higher the baseline serum 25(OH)D 
concentration, the smaller the reached concentration of 25(OH)D in response to a dietary 
vitamin D (Maurya and Aggarwal, 2017).  
Vitamin D supplementation is a safe and inexpensive method to overcome VDD (Hathcock et 
al., 2008).  Both D2 and D3 are available as dietary supplements. The relative efficacy of D2 
vs D3 in humans is not well understood. However, it is believed that both appear to be 
effective in preventing and treating VDD. A single dose of 50,000 IU of D2 or D3 produced a 
similar increase in the total 25(OH)D concentration, but the obvious longer half-life of D3 
suggests that less frequent dosing is needed for D3 (Armas et al., 2004). A daily dosing study 
of 1000 IU of D2 vs D3 showed no difference in concentration of 25(OH)D2, 25(OH)D3, or 
total 25(OH)D concentration after the supplementation (Holick et al., 2008). Another study 
which compared 1600 IU of D2 once daily vs 1600 IU of D3 once daily vs 50,000 IU of D2 
once monthly vs 50,000 IU of D3 once monthly suggested that D3 is more effective as it 
showed higher levels of 25(OH)D3 at the end of 1 year supplementation period (Binkley et al., 
2009). It is recommended that both D2 and D3 be taken with a meal containing fat, ensure the 
maximum absorption of vitamin D2 and D3. Since 1997, the Food and Nutrition Board has 
advised an Adequate Intake (AI) of vitamin D of 200 to 600 IU/day to treat vitamin D 
deficiency (IOM, 1997).  
How much vitamin D is needed to correct severe VDD (25(OH)D nmol/L) is questionable.  
Although it is not validated by clinical trials, a commonly applied strategy is to prescribe a 
“loading dose” (eg, 50,000 IU of vitamin D orally once weekly for 2-3 months, or 3 times 
weekly for 1 month) to correct severe VDD. A review paper suggested that a minimum total 
dose of 600,000 IU is the best dose to achieve endpoint serum 25(OH)D concentration greater 
than 75 nmol/L (Pepper et al., 2009).  Although many different strategies may be used in 
treating VDD, a common mistake is to stop treatment or provide inadequate vitamin D 
maintenance dosing once the 25(OH)D level reaches the optimal range. Regardless of initial 
vitamin D therapy, and assuming no change in lifestyle or diet, a maintenance  daily dose of 
800 to 2000 IU or more is needed to avoid recurrent deficiency (Heaney, 2005).  A 
maintenance   average dose of 2000 IU/day meets the current safe upper limit guidelines and 
is below the safe upper limits reported by Hathcock et al., 2008.  
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1.13.3 Personal factors  
 Age and gender  
It is well-known fact that the ability of vitamin D synthesis in the skin is reduced with aging. 
Among older people whose age is higher than 65 years, the skin 7-dehydrocholesterol 
concentrations are  about 25 % those for a person of 20–30 years old (McLaughlin et al., 
1985). Low levels of 7-DHC, poor function in liver and kidney function, exposure to sunlight, 
low physical activity and increased use of medication are the possible reasons for low vitamin 
D synthesis in older people (Cashman et al., 2014, Freedman et al., 2013, Berger et al., 2012). 
On the other hand, there is  evidence of low serum 25(OH)D concentration among females 
compared to males (Chailurkit et al., 2011, Lu et al., 2009). Females have more Fat Mass 
(FM) compared to males, therefore more vitamin D is trapped inside the FM and may not 
present in the serum to be detected by the laboratory method of assessing vitamin D status. In 
addition, a survey conducted in China revealed that females use more clothe cover and sun 
cream than males, which leads to low vitamin D status compared to males. Further they 
reported that a higher percentage of women did not like to go out compared to men, which 
may also cause  lower vitamin D status compared to men (Kotta et al., 2015).  
Use of sun protection cream and clothing 
Sun protection cream with Sun Protection Factors (SPF) of 8 absorb 92 – 95% of UVB 
photons and reduce the cutaneous vitamin D synthesis to the same degree (Matsuoka et al., 
1987). The use of sun protection cream is the major factor that reduces vitamin D synthesis in 
the skin in the people who live in the countries located near the equator (Nimitphong and 
Holick, 2013). However, the different practices of sun cream application may have different 
impacts on vitamin D synthesis (Engelsen, 2010). Use of sunblock is recommended for the 
prevention of sunburn and skin cancer, which has raised concerns that its application may 
inhibit or prevent vitamin D synthesis (Springbett et al., 2010). A review of studies reported 
that the majority of people did not use sunblock at the recommended concentration and 
therefore, use of sunblock did not significantly reduce the production of vitamin D (Norval 
and Wulf, 2009). Overall, the data suggested that vitamin D synthesis is still possible even 
when sunscreens are used at the application density used for SPF testing (SACN, 2016).  
During winter time people wear more clothes to cover most parts of the body which inhibit 
the penetration of UV radiation through to the skin (Parisi et al., 2003). A study done in 
Istanbul recruiting female undergraduate students found that the Islamic dressing style 
considerably associated with low level of serum 25(OH)D concentration. They stated that 
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VDD was 55% in those with covered dressing style whilst it was 20% in those with 
uncovered dressing style among the school children (Buyuruslu et al., 2014).  
Skin color 
Skin color also plays a role in vitamin D status in a population. Dark-skinned ethnic 
subgroups had 3 to 71 fold prevalence of serum 25(OH)D <30 nmol/L compared to white 
populations (Cashman et al., 2016). Vitamin D synthesis is highly dependent on the 
concentration of melanin in the skin as melanin absorbs and scatters UVB radiation, resulting 
in less efficient conversion of 7-dehydrocholesterol to previtamin D3 (Jablonski et al., 2004). 
Therefore, dark-skinned individuals experience slower vitamin D synthesis than light-skinned 
ones. This is especially important at higher latitudes where the intensity and duration of 
sunlight are low. However, although individuals with light skin are more efficient in 
producing vitamin D, they are affected by an high level of sunburn, a lower tanning ability 
(Wagner et al., 2002) and a greater susceptibility to skin cancers (Sturm et al., 2002). 
Physical activity  
Some studies reported that vitamin D status is high among the people who are more 
physically active (Touveir et al., 2015, Freeman et al., 2013, Berger et al., 2012) independent 
of time spent for outdoor activities (Scott et al., 2010). However, indoor exercises also result 
in improved 25(OH)D concentration as physical activity has the direct effect on serum 
25(OH)D concentration by changing the calciotropic hormones and increase the concentration 
of IGF (Maiimoun and Sultan, 2009, Gomez et al., 2004). High-intensity physical activity 
may also contribute to higher vitamin D status in older adults through  increasing and 
maintaining  muscle mass. Increased muscle mass can uptake and store 25(OH)D in muscles. 
The magnitude of the relationship between physical activity and vitamin D status depends on 
sex and the intensity of the physical activity (Scott et al., 2010). 
Body composition and BMI 
A systematic review with meta analysis of 34 cross sectional studies of adults reported a 
significant inverse, but weak, association between BMI and serum 25(OH)D levels. This 
inverse associations were significant in both genders (Saneei et al., 2013). There are studies 
that investigated the association between BMI and vitamin D status in older adults. A recent 
cross sectional study of older adults >65 years (n=1842) found that BMI was inversely 
associated with serum 25(OH)D levels after adjustment for confounders. They reported that 
this association was most prominent in individuals with a BMI in the ‘overweight’ and 
‘obesity’ range and fat percentage in the last two upper quartiles (Araghi et al., 2015). 
Another cross sectional study of large number of older adults in Mexico found that 
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overweight/obesity was significantly associated with low concentrations of serum 25(OH)D 
concentration (Rontoyanni et al., 2017).  
Smoking and alcohol intake 
Smoking and drinking alcohol are associated with a lower concentration of 25(OH)D in the 
serum (Voipio et al., 2015, Jungert and Neuhauser – Berthold, 2015). Smoking may interfere 
with the synthesis of 25(OH)D by inhibiting the expression of cytochorome P450 2RI in the 
liver. The benzopyrene produced by cigarette smoke may increase the degradation of 
25(OH)D3 and 1,25 (OH)2D3 by stimulating the 1,25(OH)2D3-dependent induction of 
cytochrome p450 (Matsunawa et al., 2009).  According to a recent review paper, alcohol 
intake had a positive association with 25(OH)D concentration. However the authors 
elaborated that further research is needed to identify the association between alcohol intake 
and serum 25(OH)D concentration, considering the health status of alcohol users and with a 
more standardized methodology to confirm this finding.  
1.14 Quantifying Cutaneous Vitamin D Synthesis and Recommendations for Sun 
Exposure 
Human exposure to UVR can be measured by Standard Erythema Dose (SED) and Medium 
Erythema Dose (MED).  The SED refers to erythemal effective radiant exposure from natural 
and artificial sources of UVR. One SED is equal to an erythemal effective radiant exposure of 
100 J/m2. One MED is the dose of UVR required to cause sunburn or slight pinkness in the 
skin (SACN 2016). Thus, it is a measure of the variable nature of individual sensitivity to 
UVR (Diffey, 2002). Full body UV exposure causing slight pinkness in skin is similar to the 
oral intake of 250 – 625 µg (10,000IU – 25,000 IU) of vitamin D. It is considered that 1000 
IU vitamin D is generated by exposing 25% of the body area to sunlight which is equivalent 
to 0.25 MED. Therefore, exposure of 6% of the body to 1 MED is equivalent to taking about 
600 – 1000 IU of vitamin D. The “Holick Rule” says the  exposure of face, arms and legs for 
a period equal to 25% of the time of one 1 MED for 2-3  times a week  can satisfy the body’s 
vitamin D requirement. It is estimated that for elderly people exposure of hands, face and arm 
to sub-erythemal dose of radiation, 10-15 min between 11.00 am - 2.00 pm for 2-3 times a 
week in the summer can satisfy the requirement of 400 IU/day of vitamin D (Holick, 2004). 
Therefore,  it is said that, exposure of arms and legs for 5 to 30 minutes (depending on the 
time of day, season, latitude, and skin pigmentation) between the hours of 10 am - 3 pm twice 
a week is often adequate for optimum vitamin D status (Holick, 2004). Dark-skinned 
individuals require a greater duration of sunlight exposure than light-skinned individuals to 
synthesize the same amount of vitamin D3 with the same amount of MED (Webb and 
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Engelsen, 2006). Webb et al., 2010, carried out a study using artificial UVB and they 
concluded that when wearing knee -length shorts and T-shirt with sleeves to mid upper arms 
at latitude of 300N – 600N,  midsummer noontime sun exposure for approximately 30 minutes 
for 3 times a week could be enough for archiving 25(OH)D levels above ~ 63 nmol/L. 
Similarly, Barger – Lux and Heaney, 2002 reported that to optimize dermal production of 
vitamin D, staying in the direct sunlight only for 15 minutes, while maximizing the skin 
exposure area might be sufficient without prolonging sun exposure.   
However, many research scientists advise getting 1000–4000 IU of vitamin D per day. These 
amounts are usually not available from usual daily sun exposure. However, for normal 
summer clothing, the exposed skin (at least 25% of the body area) needs to be sunburnt in 
order to produce 4 000 IU. The skin would then receive a UV dose associated with clearly 
elevated skin cancer risk (Webb and Engelesenl, 2008). Cancer Research UK has established 
the following guidelines to advise people on safe sun exposure, which is called Sun SMART. 
This concept says 5 facts about safe sun exposure, i) Spend time in the shade between 11.00 
am and 3.00 pm ii) Make sure you never burn iii) Aim to cover up with a T-shirt, hat and 
sunglasses iv) Remember to take extra care with children v) Then use UPF 15+ sunscreen e 
(Cancer Research UK, 2003).  
1.15 Methods of Assessing Sun Exposure 
Factors associated with UV exposure can be categorized into environmental and personal 
factors. Latitude, season, time of the day, ground reflectivity, and cloud or tree cover are some 
of the environmental factors, while sun-protection behaviors, amount of time spent outdoors, 
clothing pattern, duration of sun exposure and holiday visits are some of the personal factors. 
The anatomical distribution of UV also depends on standing or sitting postures and body site 
(McCarty, 2008). Assessing sun exposure is often used as a proxy indicator to serum 
25(OH)D concentrations in most vitamin D studies based on large populations. Several tools 
have been identified to assess sun exposure that is categorized as direct and indirect methods 
(McCarty, 2008).   
1.15.1 Self-reported questionnaire and diaries 
Self-reported questionnaires are the most widely used indirect method of assessing sun 
exposure.  However, no standard questionnaire has yet been developed, which may be used in 
all circumstances. Typical questions included in such questionnaires are sunlight exposure, 
time of the day, skin exposure area, sun protection practices, season, latitudes/place of living, 
cloud cover/tree cover, occupational behaviours and details of sunny holidays (Detert et al., 
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2015). In some studies, each question was given a score to calculate composite scores for the 
sun exposure questionnaires (Humayun et al., 2012). Sun exposure questionnaires and diaries 
have some limitations. The main limitation is the large individual variation in serum 25(OH)D 
concentration cannot be explained by self-reported sun exposure. In addition, recall bias may 
be a source of confounding when using such questionnaires and they may be a burden to the 
participants, as they need at least 30 minutes to complete the questionnaire. Some 
questionnaires need further improvements and tools to validate, while others are suitable only 
for specific durations such as during the summer (Yu et al., 2009).  
1.15.2 Dosimeters / Daysimeter 
Use of Dosimeters is a direct method of determining UVR that measured using either 
physical, chemical or biological methods. Physical dosimeters comprise a small UV detector 
electrically connected to a data logger, which is worn on a belt, in a pocket or the outer 
surface of the garments. Chemical dosimeters measure a chemical change in response to UV 
exposure, mostly using a thermoplastic polysulfone film, while a biological dosimeter 
measures the biological effects of UV exposure on the body, typically reflected by changes in 
biomarkers such as scoring of chromosomes abnormalities or circulating lymphocytes. The 
use of a Daysimeter is also similar to dosimeter. It measures circadian light exposure and 
incorporates an activity meter to estimate the circadian light/dark exposure and activity/rest 
patterns. It consists of two optical sensors. The first sensor detects optical radiation and a 
second sensor has an intrinsic long-wavelength response cut-off at approximately 580 nm 
together with a UV blocking filter creating a spectral response peaking at approximately 460 
nm. An accelerometer within the Daysimeter is used to detect the subject's activity. Measures 
obtained from the Daysimeters can be summarized by calculating hourly averages of the 30 
seconds data points of light exposure for each day (Bajaj et al., 2011).  
 1.15.3 Weather stations and equations  
UVR can be estimated using the data from satellite, spectrophotometers and computers 
located in weather stations.  The estimate of UVR is mainly based on the measurements of 
total ozone, ground albedo (reflection) and cloud transmittance. These techniques have some 
limitations including short-term variation in the cloud cover changes can have a large effect 
on UV radiance. Also UVR measurements may vary with the frequency of the measurements. 
UV data from satellites provide UVR measurement for a large geographical area, thus the 
actual UV value at the ground level may vary from the obtained value. Further, there are lots 
of other factors affecting the ground level UVR, which are not easy to estimate, such as water 
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vapor, temperature, albedo, zenith angle and snow cover. Despite these limitations, such 
weather parameters may help to estimate long-term sun exposure (Fioletov et al., 2010). 
There is a body of literature on the derivation of equations to calculate UVI, using the 
measurements obtained by spectrophotometers and satellite from weather stations. Most of 
these equations consider solar zenith angle and total ozone. However, equations do not 
account for many factors that can affect UVI, especially the cloud cover, haze, other gases, 
surface elevation and surface albedo, which are main limitations of this method (O'Sullivan et 
al., 2017).  
1.16 Role of Vitamin D in Bone Health: Mechanism of Action  
The definition of the optimal 25(OH)D concentration has been the concentration that 
maximally suppresses PTH concentration. This 25(OH)D is related to bone metabolism, 
because elevated PTH is associated with increased bone loss (Bischoff-Ferrari et al., 2006). 
The active form of vitamin D (1,25(OH)2D) plays a role in bone by increasing the absorption 
of calcium in the small intestine. In addition, vitamin D increases the absorption of other 
essential minerals, such as P, Mg, Zn and Mn and enhances the renal reabsorption of calcium 
and phosphorus. Thus, 1,25(OH)2D is the major regulator of calcium homoeostasis, which 
helps in bone mineralization (Wintermeyer et al., 2016). Furthermore, 1,25(OH)2D regulates 
the phosphate and calcium balance by supporting the intestinal absorption via epithelial 
calcium channels and CaBP. To obtain its biological activity, 1,25(OH)2D needs to be bound 
to the VDR whose property it is to form heterodimers with related receptors (e.g., the retinoid 
X receptor, (RXR))and bind to vitamin D response elements to initiate intracellular signaling 
cascades (Wacker et al., 2013). As one possible response, 1, 25(OH)D enhances the 
expression of the receptor activator of NFKB ligand (RANKL) in osteoblasts. RANKL 
associates with the receptor activator of NFKB (RANK) on immune cells to induce 
differentiation into osteoclasts to release calcium and phosphorus from the skeleton into the 
blood. This role of vitamin D on bones is illustrated in figure 1.4 (Takahashi et al., 2014).  
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Figure 1:4 Role of vitamin D in bone health (Source : Wintermeyer et al., 2016) 
(VitD : Vitamin D, 7DHC : 7-Dehydrocholesterol, DBP : Vitamin D Binding Proteins,  
PTH : Parathyroid Hormones) 
 
1.17 Evidence of Vitamin D on Bone Health From RCT and Epidemiological Studies 
Recent cross sectional studies (Meng et al., 2017, Molsele et al., 2013), a longitudinal study 
(Kuchuk et al., 2009), a systematic review (Zhao et al., 2017) and a RCT (Jackson et al., 
2006) have reported the positive association of serum 25(OH)D and bone health. There is 
epidemiological evidence that higher serum 25(OH)D levels are associated with a greater 
BMD in both young and old populations, with a linear relationship maintained up to a serum 
25(OH)D concentration of approximately 75 nmol/L. However, it is reported that this 
association differs according to  ethnic group (Bischoff-Ferrari et al., 2004).  
A number of placebo-controlled intervention trials have examined the effect of vitamin D 
supplementation on BMD, factures and falls. Doses of vitamin D supplement used in those 
studies ranged from 300 IU/day to 7,000 IU/day (Aspray et al., 2018, Reid et al., 2014, 
Macdonald et al., 2013, Sanders et al., 2010). According to the above studies consistent 
relationship between vitamin D supplementation and BMD was not reported across all 
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anatomical sites. As an example Reid et al, (2014) reported the improvement in BMD in the 
femoral neck, while Macdonald et al., 2017 reported the improvement in hip BMD in older 
adults.  Conversely a recent meta-analysis of 33 randomized clinical trials which included 
51 145 older participants (Zhao et al., 2017), concluded that the use of calcium, vitamin D, or 
combined calcium and vitamin D supplements was not associated with a lower risk of 
fractures among community-dwelling older adults.  Hip fracture was defined as the primary 
outcome while secondary outcomes were nonvertebral fractures, vertebral fractures, and total 
fractures (Zhao et al., 2017). 
It has been suggested that vitamin D supplementation in daily dose of at least 800–1000 IU  is 
required to decrease the incidence of both falls and fractures in older adults (Bischoff-Ferrari 
et al., 2012) while a Cochrane review reported that no evidence that vitamin D 
supplementation on fracture prevention (Avenell et al., 2014).  Whereas another study using 
300,000 IU of vitamin D2 given intramuscularly to care home residents for 10 months had no 
effect on hip fracture incidence (Low et al., 2016). Another study of the yearly oral dose of 
500,000 IU vitamin D supplementation for the women aged over 70 years was associated with 
an increased risk of both fractures and falls during the first 3 months after the administration. 
(Sanders et al., 2010). Most recently, a study looking at monthly bolus doses of three 
regimens (60,000 IU D3 versus 24,000 IU plus 300 μg calcifediol versus 24,000 IU D3) 
observed significantly more falls in the 60,000 IU and the 24,000 IU plus calcifediol groups 
compared with the 24,000 IU group (Bischoff-Ferrari et al., 2005). It has been suggested that 
the effect of vitamin D supplementation seen in some studies is due to the prevalence of 
hypovitaminosis D and the treatment of mineralization disorder in associated osteomalacia, 
rather than an effect of the supplement on the prevention of osteoporosis (Macdonald et al., 
2013). 
1.18 Methods of Assessing Bone Health 
1.18.1 Dual Energy Extra Absorptiometry (DEXA) 
Dual Energy Extra Absorptiometry (DEXA) is the most widely used gold standard method of 
assessing BMC and BMD (Punda and Grazio, 2014). It uses two energy beams, low and high, 
the low energy beam is attenuated by the soft tissue and the high-energy beam is attenuated 
only by the bone tissue. The degree of attenuation of the two beams is used to estimate BMC 
and BMD (Kanis, 2002). DEXA requires less time for the examination and it is widely used 
to diagnose osteoporosis and to predict the fracture risk. The limitations of DEXA scans are 
the two-dimensional projection images that measure BMD (i.e as grams of bone per unit area) 
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and it does not separate the effects of true bone density (i.e. grams of bone per unit volume) 
(Blake and Fogelman, 2009). 
1.18.2 Heel Ultrasounds Scanning (US) 
Ultra Sound Scanning devices are easy to use, portable, and low in cost. Ultrasound scanners 
are based on the principle that the intensity and Speed Of Sound (SOS) waves that are altered 
when passing through a substance and this change can be measured. In the heel bone 
ultrasound scanner, high frequency sound waves are allowed to send to the heel bone (Os 
Calcis). In this technique, the person’s heel is surrounded by warm water encapsulated 
between two membranes. From one side of the transducer convert an electrical signal into a 
sound wave which passes through the water and person’s heel. Then at the opposite side of 
the machine again converts sound waves back to electrical signals. The machine measures 
SOS and the frequency dependent attenuation called, Broadband Ultrasound Attenuation 
(BUA). The machine provides an index called Stiffness Index (SI) combing BUA and SOS 
(Chin and Ima-nirwana, 2013). 
1.18.3 Quantitative Computer Tomography  
Quantitative Computed Tomography (QCT) is advantageous compared to other techniques as 
it can measure the true volumetric density (expressed in mg/cm3).  Trabecular bone located in 
the lumbar spine can be measured independently of the surrounding cortical bone by QCT. 
This technique has low precision as a result of longer scanning time and high radiation dose 
compared to DXA measurements. Usually, the spine QCT is used as a primary diagnostic 
method in patients with severe degenerative disease of the spine, scoliosis, lumbar 
compression fractures or obesity. Recently, automated scanning and analysis software with 
new CTs have been developed with the high-resolution, high-quality image to assess the 
microstructure of the trabecular bones (Schreiber et al., 2014). 
1.18.4 Fractures  
Beyond changes in BMD, the important clinical outcome is osteoporotic fractures. It is 
considered as an important clinical outcome that reflects the bone quality. A Fracture Risk 
Assessment Tool for evaluating fracture risk has been developed. A tool called FRAX was 
developed to evaluate a person’s 10-year probability of hip fracture and major osteoporotic 
fractures at spine, forearm, hip, or shoulder. This tool is applicable to people aged 30–85 
years (IOM, 2011).  
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1.18.5 Bone resorption and bone formation markers 
Molecular markers of bone metabolism are novel tools which detect the dynamics of bone 
remodeling with respect to bone formation and resorption. This method is wider available, 
reliable, cost-effective and sensitive. Different assays for bone turnover markers would 
complement the measurement of BMD in the management of osteoporosis, especially in the 
follow-up of the patients who are on antiresorptive or bone formation therapies. Propeptides 
of type 1 collagen, Alkaline phosphatase (ALP), Osteocalcin (OC) are the commonly used 
bone formation markers, while Telopeptides of type 1 collagen, Hydroxyproline, Pyridinium 
crosslinks, Bone sialoprotein, Osteoprotegerin, Cathepsin K are some of bone resorption 
markers (Shetty et al., 2016) 
1.19 Role of Vitamin D in Muscle Function in Older Adults : Mechanism of Action  
The loss of muscle strength and muscle mass are  main changes occur during aging process. 
Loss of muscle strength and muscle mass cause an increased risk of falls, mobility disabilities 
and bone fractures (Cangussu et al., 2015). Loss of muscle mass and function in the elderly is 
called  sarcopenia (Fielding et al., 2011) which leads to functional impairments such as falls, 
mobility, disability, fractures and poor Quality Of Life (QOL) (Yu et al., 2014). Reasons for 
sarcopenia is multifactorial. Genetics, environmental and hormonal factors play a role in the 
occurrence of sarcopenia (Fielding et al., 2011). Older people naturally have low vitamin D 
status as a results of low dietary intake, less sunlight exposure, low skin thickness, low 
amount of 7-DHCavailability in the skin, poor absorption of vitamin D in the intestine, 
reduction in expressions of VDR gene in muscles, excessive use of multiple drugs and poor 
function of kidney and liver cause for this situation (Bruyere et al., 2014, Holick, 2006, 
Bischoff-Ferrari et al., 2004). Therefore vitamin D is a very important critical nutrient for 
older adults. 
There is also strong evidence for the direct effect on muscle function with the localization of 
the VDR in skeletal muscle cells (Ceglia and Harris 2013). Effect of vitamin D 
(1,25(OH)2Dthe active form of  vitamin D) on muscle is by increasing calcium accumulation 
in the sarcoplasmic reticulum by increasing the number of calcium-binding sites or altering 
the efficiency of these sites for calcium uptake (Ceglia and Harris, 2013). Based on a vitamin 
D supplementation study conducted in rats, it was suggested that vitamin D can increase ATP 
and leucine in skeletal muscles (Endo et al., 2003). Another concern is brought up by a study 
conducted using rats which showed the increase in serum phosphorus level (Schubert and 
DeLuca, 2010). In addition to calcium, vitamin D handles phosphorus in muscle cells. 
Furthermore vitamin D involves in preventing sarcopenia by expression of the gene for 
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muscle contractile protein synthesis, muscle fiber differentiation and increase the oxidative 
capacity of mitochondria (Ceglia, 2008).  
1.20 Role of Vitamin D in Muscle Function : Evidence from RCT and Epidemiological 
Studies  
Several recent cross-sectional studies (Berners et al., 2018, Brech et al., 2017, Bischoff-
Ferrari, 2004), a longitudinal study (Granic et al., 2017) and RCTs (Cangussu et al., 2015, 
Broe et al., 2007, Sato et al., 2005) have demonstrated the positive associations between 
vitamin D and muscle function in older adults. In a study conducted, with nursing homes 
residents, with an average age of 89 years, who were randomized to receive one of four oral 
dose of vitamin D3 supplements (200 IU, 400 IU, 600 IU and 800 IU) or placebo daily for 5 
months it was shown showed that the highest dose receivers had the lowest number of falls 
compared to the other groups (Broe et al., 2007). Positive effects of oral vitamin D3 
supplements on Grip Strength (GS) and chair rise test were reported in a study of 
postmenopausal women aged 50 – 65 years who received 1000 IU of oral vitamin D3 daily for 
9 months period (Cangussu et al., 2015). A study of ambulatory older adults with the history 
of falls and serum 25(OH)D < 30 nmol/L who received a single intramuscular injection of 
60000 IU of ergocalciferol reported the beneficial effect on functional performance, reaction 
time and balance but not muscle strength (Dhesi et al., 2004). Another RCT of ambulatory 
older adults living in a nursing home with  serum 25OHD concentration < 75 nmol/L,  
randomized to receive the oral or intramuscular injection of 600000 IU of cholecalciferol for 
12 weeks demonstrated an improvement in muscle strength which was assessed using 
quadriceps and physical performance battery (Tellioglu et al., 2012). According to Zhu et al., 
2010, among community-dwelling older adults aged 70 – 90 years with serum  25(OH)D 
concentration < 60 nmol/L (24 ng/mL) supplemented with 1000 IU of vitamin D2 daily for 1 
year period, improved TUG test only among the older adults who were the slowest and 
weakest at the baseline.  
There are several epidemiological studies that showed the positive association of vitamin D 
status and muscle function. A large study of community dwelling older men and women in 
which was the muscle function was assessed by tandem test, 5 timed chair stands gait speed, 
6-minute walking distance, GS, and quadriceps strength, showed that lower 25(OH)D levels 
were associated with worse coordination and weaker strength in women, a slower walking 
time and a lower upper limb strength in men, and a weaker aerobic capacity in both genders 
(Toffanello et al., 2012). A cross sectional study of 127 pre-frail and frail elderly people in 
Netherlands showed 25(OH)D concentration was low among the older adults who had low 
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muscle function which was assessed by appendicular lean mass, leg strength, handgrip 
strength and physical performance (short physical performance battery) (Tieland et al., 2009). 
In the Newcastle 85+ Study (n = 845), which is a longitudinal study of older adults showed 
that, low baseline 25(OH)D concentration contributed to muscle strength decline in the very 
old and particularly in men (Granic et al., 2017). Another cross sectional study performed in 
American and Swedish older adults who were examined for potential participation in a 
combined exercise and nutrition intervention trial showed that higher serum levels of 
25(OH)D associated with better performance on the chair stand test (Berens et al., 2018).  
1.21 Assessment of Muscle Function 
1.21.1 Handgrip Strength Test (GS) 
Grip Strength (GS) is a widely used low-cost method to measure upper body muscle strength. 
It is the simplest method for assessment of muscle function in clinical settings, specially to 
assess sarcopenia (Roberts, 2011). Low values are associated with falls (Sayer et al., 2006), 
disability, impaired health, poor QOL (Syddall et al., 2009), and increased mortality (Gale et 
al., 2007, Cooper et al., 2010). A hand grip dynamometer is the equipment used to measure 
GS (Cruz-Jentoft, 2010). The dominant hand is usually recorded, before taking the 
measurements (Hogrel, 2015). Subjects are advised to sit on an armchair and hold the hand 
grip dynamometer using one hand, while keeping the arm on the chair arm. Study participants 
are asked to squeeze the handle of the dynamometer using his or her maximum strength for a 
few seconds when measurements are taking. The value displayed in the dial is the value needs 
to be recorded. This should be performed for three times for one hand and then the same 
procedure should be repeated with the other hand. Recently published cutoff value for 
predicting sarcopenia is less than 20 kg for females and less than 30 kg for males (Filippin et 
al., 2017).  
1.21.2 Timed-Up and Go test (TUG) 
The ‘Timed-Up and Go’ (TUG) test is a simple and widely used clinical measure of lower 
body muscle strength (Weiss et al., 2010). To perform this test, participants are asked to sit on 
backed-chair. The participant should stand from the chair without any support, walk for a 2 m 
or 3 m distance, turn back, walk back to the chair and sit on the same chair. The total time 
spent on this activity is recorded. Usually, this test is performed three times and the mean 
value is recorded (Herman et al., 2011). A systematic review reported that TUG test value of 
13.5 sec is considered as the cutoff for the risk of falling in older adults (Barry et al., 2014). 
But according to a study conducted in for Brazil recruiting older adults the predicted TUG test 
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value was 12.47 sec for the risk of falls (Alexandre et al., 2012). According to Filippin et al., 
2014, cutoff values for predicting sarcopenia is 7.5 seconds.  
1.21.3 Falls  
Falls are a common event among older adults, and are the leading cause of severe injuries, 
and hip fractures, in older people (Edwards et al., 2013). A study of 2299 residents aged 65 
years or older in Hertfordshire, UK, showed that a history of any type of fall from the age of 
45 years onwards resulted in an unadjusted fracture hazard ratio of 7.31 and 8.56  in men and 
women, respectively (Watanabea et al., 2014). To maintain the balance contributions from 
vision, peripheral sensation, vestibular sense, muscle strength, neuromuscular control and 
reaction time should be coordinated properly. With increased age, there is a progressive loss 
of functioning of these systems and increase a risk of falls and thus details about falls are used 
as an indicator of muscle function. By using simple tests of vision, leg sensation, muscle 
strength, reaction time and standing balance, it is possible to identify accurately older people 
at risk of falls (Lord and Sturnieks, 2005).  
1.21.4 Physical Performance Battery Score (SPPB) 
In clinical practice, gait speed (timed to walk 4 m distance), sit-to-stand time, and standing 
balance are collectively measured within the context of the Short Physical Performance 
Battery (SPPB).  This test has been validated in large-scale epidemiological studies and 
characterized lower extremity functional performance using timed measures of standing 
balance (side-by-side stand, tandem and semi-tandem positions), gait speed (timed 4-metre 
walk), and lower extremity strength (timed test of five chair rises). Score obtained on a 12-
point summary scale indicates a gradient of functional decline that is predictive of mobility-
related disability, institutionalization, and mortality. It is generally accepted that a total SPPB 
score ≤10 indicates functional impairment in older populations (each test is scored from 0 to 
4) (Cooper et al., 2013).  
1.22 Mechanism of Action of Vitamin D in Colorectal Cancer (CRC) 
Some studies have linked polymorphisms of genes of the vitamin D system (VDR, CYP27B1, 
CYP24A1, GC, DHCR7 and CYP2R1) to CRC prognosis or response to therapy (Jiang et al., 
2018).  Calcitriol inhibits proliferation, sensitizes to apoptosis, and promotes differentiation of 
colon carcinoma cells through the regulation of genes and the modulation of signalling 
pathways. (1) Proliferation : Calcitriol reduces cell proliferation by several mechanisms: 
downregulation of cyclin-dependent kinases (CDKs), induction of CDK, inhibiting 
proliferative signaling pathways generated by epidermal growth factor (EGF) and insulin-like 
growth factor II (IGF–II) (Ched et al., 2002). Non-genomic (transcription-independent) 
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effects of calcitriol are mediated by either extranuclear VDR or alternative receptors. In colon 
carcinoma cells, calcitriol induces a transcription-independent signalling pathway that 
involves a rapid increase in the intracellular concentration of Ca2+ and the subsequent 
activation of the small RhoA GTPase (Ordóñez-Morán et al., 2008).  (2) Apoptosis  : 
Calcitriol sensitizes colon carcinoma cells to the initiation of apoptosis by several agents 
through the upregulation of proapoptotic genes, the down-regulation of survival genes 
(survivin and thymidylate synthase) and via interference with IL-1β secretion by macrophages 
(Barbáchano et al., 2017).  (3) Migration, invasiveness and angiogenesis : Calcitriol 
suppresses the expression of DKK-4, which promotes invasion, angiogenesis, and 
chemoresistance in colon carcinoma cells. In addition, calcitriol down regulates the 
angiogenic phenotype of colon carcinoma cells by controlling the expression of several genes 
(Ben-Shoshan et al., 2007).  (4) MicroRNAs :Calcitriol regulates the expression of several 
microRNAs (miRs) in human colon carcinoma cells. One of them is miR-22, which is 
induced by calcitriol which mediates the antiproliferative and antimigratory effects of 
calcitriol in colorectal cancer cells. Further, miR-22 inhibits proliferation, migration, invasion, 
and xenograft tumor growth in several cancer systems including colorectal cancer (Figure 1.5) 
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Figure 1.5 : Effect of Calcitrol on the cell types present in the colon to prevent colon 




    38 
1.23 Evidence of association between vitamin D status and Colorectal Cancer (CRC) 
risk 
 Epidemiologic research showed that incidence and death rates for certain cancers were lower 
among individuals live in southern latitudes, than among those living at northern latitudes 
(Eide et al., 2005). Therefore researchers hypothesized that variation in vitamin D levels 
might account for this association (National Cancer Institute, 2013). Experimental evidence 
has suggested a possible association between vitamin D and cancer risk. The mechanistic 
studies showed that vitamin D has been found to have several activities that might slow or 
prevent the development of cancer, including promoting cellular differentiation, decreasing 
cancer cell growth, stimulating apoptosis, and reducing the tumor blood vessel formation 
(angiogenesis) (Thorne et al., 2008).  A systematic review with meta-analysis of 9 prospective 
cohort studies showed that vitamin D intake and blood 25(OH)D levels were inversely 
associated with the risk of CRC (Ma et al., 2011).  A meta-analysis of five nested case control 
studies showed that maintaining a serum 25(OH)D concentration of 82 nmol/L compared with  
30 nmol/L  resulted in 50% lower risk of CRC (Gorham et al., 2007).In a recent case-control 
study with 1,248 cases of incident of CRC and 1,248 controls found that, those in the highest 
quintile of plasma 25(OH)D concentration had a 40% lower risk of CRC than did those in the 
lowest quintile after adjustment for potential confounders (Jenab et al., 2010).  
1.24 Parathyroid Hormone (PTH), its Functions, Synthesis and Regulation 
PTH is an 84-amino acid peptide hormone that is responsible for maintaining calcium and 
phosphorus homeostasis in the human body. This hormone is secreted by chief cells of the 
parathyroid gland in response to hypocalcemia which is identified by “Calcium Sensing 
Receptors” (CaSR) in the thyroid cell membrane (Fraser, 2009). The signal for an increase in 
PTH production and secretion is a reduced extracellular ionized calcium concentration, while 
the signal for a reduction in PTH production and secretion is an increase in extracellular 
ionized calcium concentration. There is a bifunctionality of PTH - calcium interrelationship, 
which serum calcium concentration control PTH secretion, while PTH regulates the serum 
calcium secretion. When PTH is secreted by parathyroid cells as a result of low Ca2+ 
concentration, it acts on kidney cells to increase renal tubular reabsorption of calcium  and 
conversion of 25(OH)D to 1,25 (OH)2D  by activating of the renal hydroxylase enzyme 
(Taylor et al., 2008). PTH has been proposed as a functional marker of vitamin D status 
largely because an elevated plasma PTH concentration is known as a risk factor for 
osteoporosis. PTH is linked to 25(OH)D through the calcium-phosphate homeostatic system 
(Prentice, 2008).  
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PTH maintains serum calcium concentration through direct action on bone and kidney and 
indirectly, through the action on gastrointestinal tract. In addition, in bones, PTH controls 
Ca2+ release to the extracellular fluids with both the rapid release from the calcium pool and 
the slow mechanism with stimulation of increased bone turnover (Parfitt, 2003).  In addition 
to calcium, PTH regulates phosphorus metabolism. It decreases the serum phosphorus level 
by inhibiting renal phosphate reabsorption. Hence, increased plasma PTH concentration leads 
to increased renal phosphate excretion with decreased plasma phosphate levels. As PTH 
directly influence Ca and phosphorus metabolism, PTH is involved in bone and muscle 
function (Berqwitz et al., 2010).  
The inverse association between PTH and serum 25(OH)D concentration has been identified 
in many studies (Chang et al., 2017, Jungert and Neuhauser-Berthold, 2015). Therefore there 
is a seasonal variation in the PTH concentration of the body (Piak et al., 2010). In addition, 
dietary and plasma calcium level and short-term phosphorus intake and determine PTH 
concentration in the body. Low level of extracellular plasma calcium concentration and lower 
calcium intake elevate PTH levels. Higher plasma phosphate level directly stimulates PTH 
release from parathyroid tissue. Therefore  high phosphorus intake increases the PTH 
concentration in serum. Body Mass Index (BMI), age, vitamin D status, stage of life, time of 
the day, ethnicity, dietary calcium and phosphorus intake, kidney function, physical activity, 
drug use, age and gender are some of the determinants of PTH concentration in the body 
(Fraser et al., 2009, Patel et al., 2007, Vieth et al, 2003). Individuals with a higher BMI had 
higher PTH levels compared to individuals with a lower BMI. This relationship might be due 
to lower serum 25(OH)D levels in obese individuals compared to non-obese individuals 
(Kamycheva et al., 2004). Acute ethanol administration in healthy volunteers (Laitinen et al., 
1991) resulted in lower PTH levels while human studies of chronic alcohol consumption have 
shown elevated PTH levels (Feitelberg et al., 1987).  
Diurnal variation in PTH concentration was identified first in 1960s with the peak 
concentration reported in the early morning. This diurnal variation may have an important 
effect on bone remodeling which showed the increment of several markers of bone resorption 
in the early morning (Fraser et al., 2004).  It is believed that biological fluctuations in 
circulating levels of PTH may have an anabolic effect on bone. Some studies have 
documented a diurnal rhythm for markers of the bone formation such as osteocalcin and the 
propeptide of type I collagen both of which peaked in the early morning hours and, in the case 
of osteocalcin, level increases with the highest PTH concentration (Fuleihan et al., 1997).  
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1.25 Hyperparathyroidism and hypoparathyroidism  
Hyperparathyroidism is a condition with elevated PTH. There are two types of 
hyperparathyroidism, primary hyperparathyroidism (PHPT) or secondary 
hyperparathyroidism. Primary hyperparathyroidism is the excessive release of PTH caused by 
an adenoma of one or more parathyroid glands or hyperplasia of all four glands when there is 
hypercalcemia or normal-high serum calcium levels. PHPT is diagnosed based upon levels of 
blood calcium and PTH. In most people with hyperparathyroidism both calcium and PTH 
levels are higher than the normal. Bone density testing is usually recommended for people 
with hyperparathyroidism. Secondary hyperparathyroidism, is caused by the deficiency in 
vitamin D or uremia (Fraser, 2009).  
Hypoparathyroidism is a disorder of PTH deficiency caused by either autoimmune destruction 
of the parathyroid glands, failure in the connection with other endocrine glands or removal of 
parathyroid tissue. Sometimes hypoparathyroidism can occur as a congenital disorder in 
which the parathyroids and other derivatives of the 3rd and 4th pharyngeal pouches do not 
develop. Very rarely, intracellular processing defects or activating mutations of the calcium 
sensing receptor can also lead to hypoparathyroidism (Brown, 2009).  
For the diagnosis of primary hyperparathyroidism  the blood phosphate level, the vitamin D 
level, urine calcium levels (a urine test of calcium collected over a 24-hour period), and the 
blood creatinine level (a measure of kidney function) needto be tested. Vitamin D levels 
should be checked to diagnose secondary hyperparathyroidism. Patients with elevated calcium 
and/or parathyroid hormone levels should also have their bone density tested, by a DEXA-
scan. Normal blood levels of PTH vary according to the lab that measures the hormone, but 
most laboratories use PTH concentration, 15 - 65 Pg/mL as the normal level (Pallan et al., 
2012). 
1.26 Effect of PTH in Muscle Function  
Previous studies have reported that hypoparathyroidism or hypocalcemia affect muscle 
function (Van et al., 2006, Syriou et al., 2005, Nora et al., 2004) as a result on low Ca2+ 
concentration in serum. But on the other hand, a high level of PTH have been implicated in 
sarcopenia and loss of muscle strength (Visser et al., 2003). Whether the effect of PTH on 
muscle is associated with low vitamin D level or independent is not clear (Houston et al., 
2011). Recent evidence suggests that PTH concentration, independent of vitamin D levels, 
may be important for maintaining muscle integrity and physical function and thereby, 
preventing  falls (Wat et al., 2007).  A longitudinal study showed that a low 25(OH)D 
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concentration and high PTH concentration were the determinants of sarcopenia  and loss of 
muscle strength (Visser et al., 2003).  It is found  that infusion of PTH at high concentration 
increases protein catabolism and decreased the number of type 2 muscle fibres, intracellular 
energy-rich phosphate compounds, and mitochondrial oxygen uptake (Mosekilde et al., 
2005). On the other hand, it has been found that high PTH levels  result in increased skin 
pigmentation and thereby reduction in vitamin D production in the skin (Cosman et al., 2007). 
The presence of FGF-2 in muscle fibers along the muscle - bone interface suggests that PTH 
regulation of FGF-2 maintain coordinately the growth and development of bone and muscle. 
Further it is believed that PTH plays a role in muscle and bone together via the activation of 
IGF-1 (Datta, 2014). It is proposed that PTH enhances the breakdown of DBP-actin complex. 
If the effects of PTH were to both enhance DBP uptake and to facilitate breakdown of DBP-
actin complexes, it would increase binding sites for 25(OH)D3 within the muscle cell. It is 
suggested that  the presence of small elevations in PTH enhance uptake of DBP into muscle, 
and increase the breakdown of DBP-actin complexes, then there are more binding sites for 
25(OH)D3 in muscle, thus protecting 25(OH)D3 from degradation (Abboud et al., 2017). PTH 
stimulates synthesis of interleukin – 6 (IL-6) in the liver and the higher IL-6 concentration was 
associated with faster muscle loss (Schaap et al., 2009). The role of PTH on muscle function 































Figure 1.6 Conceptual diagram of the effect of PTH on muscle function (Adapted from 
Silva and Bilezikian, 2015) 
1.27 Role of PTH in Bone Health 
PTH induced bone resorption is mediated by increased activity of bone-resorbing cells called 
osteoclasts However, some studies indicated that PTH does not directly activate osteoclast, 
but PTH enhances bone resorption through its actions on osteoblasts and osteocytes (Xiong et 
al., 2012). The regulation of the remodeling process of bone is primarily through the 
osteoblasts, which express receptors for both PTH and 1,25(OH)2D.  It is believed that PTH 
mainly has an indirect stimulation on osteoclasts by binding to neighboring osteoblasts. 
Elevated PTH levels induce an increased release of receptor activator of nuclear factor-kb 
ligand (RANKL), which binds to its receptor (RANK) on osteoclast precursor cells and thereby 
activate the formation of osteoclasts.  
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In younger and healthy individuals, increased activation of osteoclasts is normally followed 
by a balanced formation of new bone under the process of bone remodeling. However, this 
increased resorption of bone is seen in both trabecular and cortical bone in 
hyperparathyroidism and causes a temporary bone loss. But it is reversible if the remodeling 
cavities are refilled with new bone (Rolighed et al., 2014). The PTH-induced increase in bone 
turnover is probably the main reason for reduced BMD (Favus et al., 2006). However, if the 
remodelling process is not balanced, the increased bone resorption leads to a catabolic state 
with a subsequent loss of bone mass (Heaney et al., 2009). Apart from that, PTH acts on bone 
cells to increase expression of FGF- 23 (Silver et al., 2013). Thought it is believed that 
catabolic effect of PTH on the bone can be seen in hyperparathyroidism, PTH stimulates both 
bone resorption and bone formation, and the final outcome on bone mass, either catabolic or 
anabolic. This outcome is depending on the dose and periodicity of the PTH signals on bone 
tissues. Rolighed et al., 2014 mentioned that, continuous exposure to PTH resulted in 
catabolic effects on the skeleton, while intermitted low dose of PTH results in osteoanabolic 
effects (Silva and Bilezikian, 2015). Therefore treatment with PTH, in low dose has 
osteoanabolic effect and therefore used as a treatment for osteoporosis (Greenspan et al., 








































Figure 1.7 : Conceptual model illustrating the functional role of PTH concentration on 
bone health (Figure adapted from Silva and Bilezikian, 2015) 
 
1.28 Hypotheses, Aims and Objectives  
The association between serum 25(OH)D concentration and muscle function in older adults 
has been reported in previous studies with no agreement on what constitutes optimal vitamin 
D status for muscle health. The inconsistent findings between studies might be attributed to 
the different cut-off values used to define VDD and the insufficient control of potential 
confounders such as seasonality, dietary and/or supplemental intake of vitamin D, subject 
numbers, laboratory assay for assessing vitamin D status, age, body weight, body composition 
and PTH concentration. In this PhD study, I will explore the association between serum 
25(OH)D concentration and MSK function in older adults living in the North East of England 
(an area with a high prevalence of VDD) in two different study designs whilst adjusting for 
several notable confounders.  In terms of randomized trial evidence of vitamin D 
supplementation and muscle health there are conflicting findings in the literature regarding 
the efficacy of supplementation in improving outcomes.   One of the major limitations of 
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many RCTs of vitamin D supplementation on MSK health is the general ‘adequacy’ of the 
recruited sample in terms of vitamin D status at baseline.  Most trials to date have also 
focused on daily vitamin D supplementation where compliance has been problematic.  In this 
PhD study, I aim to determine the effect of monthly oral supplemental vitamin D3 (12,000 IU, 
24,000 IU or 48,000 IU of vitamin D3) for 12 months on muscle function in a large sample of 
70+ years old adults (n = 379) from the North East of England.   
Understanding the nature of the impact of sunshine exposure on vitamin D status is important 
not only because it influences dietary vitamin D requirements (Cashman et al. 2008; 2009) 
but also because achieved serum 25(OH)D concentrations in RCTs of vitamin D 
supplementation will be influenced by sunshine exposure  as well as the vitamin D 
administered as part of trials.   However, assessing personal sunshine exposure in studies is 
notoriously challenging due to the many factors influencing personal UV exposure.  In this 
PhD I will attempt to estimate the influence of sunshine exposure on vitamin D status in both 
the cross sectional and RCT studies using sunshine exposure questionnaires adapted from 
previously published literature.   
Whilst the role of PTH (as a biomarker of vitamin D status) in bone metabolism is well 
known, PTH might also influence pathways in muscle metabolism (as outlined in Figure 1.6 
above) and may therefore influence muscle function outcomes including strength and 
function.   Whether the putative relationship between PTH and MSK health is independent of 
vitamin D status remains unclear.  Therefore, in this PhD I will attempt to shed some light on 
the relationship between  PTH and muscle function in the two aforementioned studies.  I will 
approach this question using cross sectional and intervention data.    
Finally, given the established link between vitamin D and CRC (IARC, 2008), I will attempt 
to  evaluate the association between vitamin D biomarkers and MSK function in older adults 
who are at moderate risk for CRC as well as examine the impact of sun exposure on vitamin 
D biomarkers in this population.    
The hypotheses of this PhD study are: 
1. Lower serum 25(OH)D concentrations will be associated with poorer  MSK outcomes  
2. Vitamin D supplementation at doses equivalent to 400 IU/day, 800 IU/day and 1600 
IU/day for 12 months will result in improvements in  muscle function in dose 
dependent manner.  
3. Sunshine exposure assessed by newly adapted questionnaires will predict vitamin D 
status in the cross sectional analyses and will modulate the response to vitamin D 
supplementation in the RCT analysis. 
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4. PTH concentration will influence MSK outcomes in both cross sectional and RCT 
analyses.  
 
The two study designs used in this PhD and discussed in more detail in Chapter 2 are: 
 i) A RCT of three doses of supplemental vitamin D in older adults (Vitamin D in Older 
People Study (VDOP) Study). 
 ii) A cross sectional study of older adults who participated in the BORICC Follow-Up 
(BFU) Study. 
Objectives 
The specific objectives of this project were:  
1. to investigate the effects of three doses of supplemental vitamin D3 (12000 IU, 24000 
IU, 48000 IU) monthly for 12 months on markers of muscle function in older adults 
from VDOP study.  
2. to quantify the contribution of cumulative sun exposure to serum 25(OH)D  
concentration among older adults supplemented with vitamin D3 monthly for one year 
from VDOP study. 
3. to investigate relationships between i) sun exposure behaviours and serum 25(OH)D 
concentration and ii) serum 25(OH)D concentration and MSK outcomes in 
participants in the BFU study. 
4. to investigate relationships between PTH concentration, 25(OH)D concentration and 
MSK outcomes of older adults in both the VDOP and BFU studies. 
5. to identify the change in serum 25(OH)D concentration and dietary vitamin D intake 
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Chapter 2 Materials and Methods 
Overview of research studies used in this PhD study and associated statement of my 
personal contribution  
This PhD study, utilizes data collected from two studies 
1) A single centered, double-blind, parallel RCT of three study groups that was designed 
to test the effect of three doses (12000 IU, 24000 IU and 48000 IU) of oral vitamin D3 
supplement on bone health in older adults (The Vitamin D in Older People Study; 
VDOP). 
2) A 12 year follow-up study of people at moderate risk of colon cancer  called the 
Biomarkers of Risk of Colon Cancer Follow-up Study (BFU study).  
Further details of both studies are described in this chapter.   In the VDOP study, I was 
involved in the data cleaning, coding and analysis of all data relating to muscle function.  I led 
on the peer-reviewed publication arising from this thesis (Chapter 3; Ranathunga et al. 2019).  
The chief investigator of the VDOP study was Dr. Terry Aspray.   Prof. Roger M. Francis, 
Prof. Inez Schoenmakers, Dr. Gail Goldberg, Prof. Elaine McColl and Dr. Ann Prentice were 
the co-investigators of the VDOP study.  Christine Harle was the Chief Trial Manager, while 
Jennie Parker was the Assistant Trial Manager of the study. Tom Chadwick played the role of 
the statistician. Planning and implementing the study as well as applying for the ethical 
approval was done by Dr. Terry Aspray with the help of trial management team. The VDOP 
study was supported by Arthritis Research UK (Clinical Studies grant 19544) and also 
supported by the Medical Research Council, UK (MRC program no. U105960371). 
In the BFU study I was centrally involved in participant recruitment, welcoming the 
participants, measuring muscle function, bone health parameters and anthropometric 
measurements, as well as contributed to obtaining ethical approval.  I led on designing the sun 
exposure questionnaire. In addition to data entering and data  analyzing I was also involved in 
conducting awareness events for the participants (called “showcase events”).  Prof. John 
Mathers was the chief investigator of the BFU study. Dr. Mike Bradburn, Dr. Laura Greaves 
were the co-investigators. Post-doctoral fellow Dr. Fiona Malcomson was responsible in day-
to-day management of the study with the help of four PhD students including me.  
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2.1 VDOP (Vitamin D in older People) Study  
2.1.1 Study design 
The VDOP study is a non-commercial, single centered, double-blind, parallel RCT of three 
study groups that was designed to test the effect of three doses (12000 IU, 24000 IU and 
48000 IU) of oral vitamin D3 supplement given each month on Bone Mineral Density (BMD) 
in men and women aged 70 years or older. Study visits took place at baseline and thereafter at 
3-monthly intervals (5 in total) for one year period. Recruitment of participants began in 
November 2012 and was completed in May 2013 in Newcastle upon Tyne (550N). The first 
participant visit was on 8th November 2012 and the last participant visit was on the 6th June 
2014. Findings on the effect of vitamin D supplementation on BMD, which was the primary 
aim of this study was published elsewhere (Aspray et al., 2018).  
2.1.2 Participant recruitment  
A total of 379 community-dwelling men and women aged 70 years or older, resident in 
Newcastle upon Tyne, were recruited. Potential participants were identified through General 
Practice (GP) registers at specific surgeries. At initial check, participants’ age was checked to 
confirm that they were 70 years or older and the other inclusion criteria listed below under 
2.1.3.  The consort diagram of the VDOP study is illustrated in Figure 2.1. Invitation letters 
(total of 7726) were sent to potential participants with the Participants Information Sheet 
(PIS) and the contact details of the research team at the Clinical Aging Research Unit 
(CARU). When potential participants contacted the CARU, they were given an expression of 
interest slip to return to CARU if they interested in taking part in the study. In addition, 
posters were displayed in waiting areas of the North Tyneside General Hospital (NTGH). 
Patients who were interested in taking part in the study were asked to speak to their GP who 
provided them with the PIS and the expression of interest slip if they appeared to be eligible 
to take part in the study. Once the potential participant had returned their expression of 
interest slip, a member of the research team contacted the participant by telephone to inquire 
about the individual’s medical conditions and to further check eligibility for the study. If the 
participant met the inclusion criteria, they were invited to attend the initial screening study 
visit at CARU. Out of 548 participants who expressed the interest in participating in the study, 
522 participants were telephone screened and 433 of them were eligible for the study. Of the 
eligible participants, 392 participants provided the informed consent.  These eligible 
participants were screened further to check the inclusion and exclusion criteria, however, 13 
older adults failed the screening test as they did not meet the inclusion criteria. Therefore 379 
participants were randomized to receive one of three doses of vitamin D3 supplement, 12000 
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IU (n=126), 24000 IU (n=125) and 48000 IU (n=128) vitamin D3, respectively, monthly for a 
12 months period.  
2.1.3 Inclusion criteria  
Ambulatory community-dwelling men and women 70 years or older and the individuals who 
able to give written consent by their own and the individuals who willing to visit to the study 
centre for six times and the individuals who can be contacted by telephone at monthly 
intervals between study visits over twelve months were considered as the inclusion criteria for 
the study. The inclusion criteria were mainly focused on age and the ability to participate in 
the study. If any of the above conditions were not met, the participants were not eligible to 
participate in the study. If any of the participants was not eligible to take part in the study, 
“Participant Withdrawal Form” was completed, mentioning the reason for the exclusion.   
2.1.4 Exclusion criteria 
Exclusion criteria comprised, taking vitamin D supplements at a dose greater than 400 IU/day 
or calcium at a dose greater than 500 mg/day, a fragility fracture within the previous 6 
months, treatment with an anti-resorptive or anabolic treatment for osteoporosis in the 
previous three years, a history of renal stones, previous hip replacement or primary 
hyperparathyroidism, hypercalcaemia (albumin adjusted plasma calcium >2.60 mmol/L), 
hypocalcaemia (albumin-adjusted plasma calcium < 2.15 mmol/L) or an estimated glomerular 
filtration rate (eGFR) less than 30 ml/min/1.73 m2). Participants who had multivitamin or 
supplement containing vitamin D (<400 IU/day) or calcium (<500 mg/day) were not asked to 












































Figure 2.1 : Consort diagram of the VDOP study 
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2.1.5 Ethical consideration  
The favorable opinion was obtained from Tyne and Wear South Research Ethics Committee 
(REC, 12/NE/0050) and the Research and Development approval was obtained from the 
sponsor, Newcastle upon Tyne Hospitals NHS Foundation Trust. All study procedures were 
carried out according to the recommendation which was adopted by 18th World Medical 
Assembly, Helsinki 1964 and later revisions. Prior to the enrolment into the study, informed 
consent was obtained from  each participant from their legally acceptable representative with 
the date of receiving the consent. For the participants who could not consent for themselves, 
an appropriate independent witness provided the written consent. Favorable ethical opinion 
and Clinical Trial Authorization from relevant Competent Authorities were taken prior to the 
commencement of the study. Local approval was taken before recruitment of the study 
participants. A written copy of local approval documentation was provided to the Newcastle 
Clinical Trials Unit before initiating the study. Personal data was regarded as strictly 
confidential. To preserve the anonymity, all data including the biological samples were 
identified by a unique study identification number. The study complied with the Data 
Protection Act, 1998. All study records and Investigator Site Files were kept at the site in a 
locked filing cabinet with restricted access.  
2.1.6 Consent procedures and confidentially  
A discussion about the informed consent took place with the trained staff member with the 
participants. The participants were given an opportunity to ask questions about the study. 
After providing the information about the study, participants were given a minimum of 24 
hours to decide whether or not to participate in the study. Those wishing to take part in the 
study were provided a written signed and dated informed consent, which was witnessed and 
dated by a member of the research team. Written informed consent was obtained from the 
participant prior to the randomization and the study procedures. The original signed consent 
form was retained in the Investigator Site File, with a copy in the clinical notes and another 
copy provided to the participants. The participants provided the consent to their GP being 
informed of their participation in the study. The right to refuse to participate in the study 
without giving reasons was respected and the health care that they received was not altered for 
not being participated in the study.  
2.1.7 Vitamin D supplementation 
Three doses of vitamin D supplementations were 12000 IU once monthly (equivalent to 400 
IU/day), 24000 IU once monthly (equivalent to 800 IU/day) and 48000 IU once monthly 
(equivalent to 1600 IU/day) for one year period. The lowest dose was chosen to be equivalent 
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to the Recommended Nutrient Intake (RNI) defined by the Scientific Advisory Committee on 
Nutrition (SACN), 400 IU (10µg) per day (SACN, 2015), the second dose corresponds to the 
North American RDA for adults aged 70+ years, defined by Institute of Medicine (IOM), 
800IU/day and the highest dose was twice the RDA defined by IOM (and four times the UK 
RNI), which was below the tolerable upper intake of 4000IU/day, declared by IOM (IOM, 
2011). These monthly doses of the supplement were given for a 12 month period. Vitamin D 
supplementation was administered orally under the direct supervision of the nurse at baseline, 
second (after 3 months of supplementation), third (after 6 months of supplementation) and 
fourth (after 9 months supplementation) study visits at the study center. At the end of each 
study visit, 2 bottles of the vitamin D liquid for the next two months to take at home were 
given along with written instructions. The administration of vitamin D at home was 
unsupervised, but the participants were contacted by telephone each month to remind them to 
take the vitamin D supplements, as well as to check whether the participants had missed any 
vitamin D supplements and to know the date of the supplements taken and to report any 
adverse events.  
All vitamin D doses were filled in 10 mL amber glass bottles (target fill volume of 3 mL 
including 0.6 mL overage). The formulation, manufacture and release of the vitamin D were 
undertaken by Swedish clinical supplies company licensed by for the manufacture and release 
of vitamin D for clinical trial use in the EU (MODE Pharma, UK). The vitamin D3 preparation 
was a liquid, containing an appropriate dose of vitamin D3 (Vigantol) solution in a 
concentration of 20,000 IU/mL mixed with Miglyol oil to a total volume of 3.0 mL, Miglyol 
oil contains no vitamin D and is indistinguishable from Vigantol. Both Vigantol and Miglyol 
were provided by MODE Pharma, UK, a clinical trials supply company, who sourced the 
product and provided from the third party. Randomization group 1 received 0.6 mL Vigantol 
and 1.8 mL Miglyol oil, group 2 received a mixture of 1.2 mL Vigantol and 1.2 mL Miglyol 
oil, group 3 received 2.4 mL Vigantol oil. Side effects were documented by the participant 
throughout the course of the trial and assessed by the clinical team at each telephone 
conversation and at the study center. Patients returned all vitamin D bottles in their original 
packaging to the research team once they come to the study center. Documentation of 
prescribing, dispensing and return of vitamin D3 was maintained for study records. Case 
Report Forms (CRFs) (Appendix A) were checked for missing data and the reason for the 
missing data was recorded. Concomitant medication and therapies were updated in CRFs 
including the medication, dosage and the reason for the use. When the individuals were 
withdrawn from the study, “Participants withdrawal form” was completed with the reason for 
withdrawal stated as “screen failure”, “withdrawn by the investigator”, “participant decided to 
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withdrawn” with the signature of chief investigator.   First date and the last date of the 
treatment were recorded in the CRF.  Once the trail is finished, “trial completion form” was 
completed, with the first and the last date of the treatment, whether the person completed the 
trial or not and the reason for the discontinuation of the trial or date of death. 
2.1.8 Study safety and quality control 
Adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse 
reactions (SUSAR) were recorded throughout the study. Those adverse events were recorded 
with the severity that indicated by a code (1 mild, 2 moderate, 3 severe), the relationship to 
the treatment, start date, end date of the adverse event and the action taken for the adverse 
event. In addition, the safety of the supplementation was assessed by performing full blood 
count, plasma calcium, serum creatinine and liver function tests at each study visit. 
Information on clinical fractures during the study also was recorded as a safety measure.  The 
doses used in this study had not previously been reported to be associated with the adverse 
events and even the highest dose of vitamin D3 used in this study was less than half the 
tolerable upper limit of intake advised by the United States Institute of Medicine (Ross, 
2011). As vitamin D was given without additional calcium supplementation, a significant risk 
to participants was even less likely. Quality control was maintained through adherence to the 
Newcastle upon Tyne Hospitals NHS Foundation Trust Standard Operating Procedures 
(SOPs), study protocol, the principles of Good Clinical Practice (GCP), research governance 
and clinical trial regulations. An independent data monitoring and ethics committee  which 
consisted of 2 physicians (not connected to the trial) and one statistician undertook the 
independent review to monitor the efficacy and safety endpoints of the trial. Only the DMEC 
had access to un-blinded study data. A Trial Steering Committee (TSC) was established to 
provide overall supervision of the trial. The TSC consisted of the principal investigator, study 
collaborators, a lay member from the advisory group of National Osteoporosis Society, a 
clinician with the expertise of vitamin D therapy who acted as independent chair of the TSC. 
This committee provided the overall supervision of the study on behalf of the study sponsor 
and study funder to ensure that the study was rigorously conducted in accordance with the 
principles of GCP. 
2.1.9 Randomization  
Randomization was done at the baseline visit and the randomization number was recorded in 
the CRF. Patients were randomized in a 1:1:1 ratio to receive vitamin D3 12000 IU, 24000 IU 
or 48000 IU. A statistician who was not involved in the study, produced a computer-generated 
allocation list that included a sequential study number that linked to a randomly allocated 
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treatment arm of the study. This number was kept blind from both the participants and 
investigators. Each bottle of vitamin D supplements had a unique identification number, and 
each patient was assigned one of these study numbers. Once a person enrolled in the study, a 
study number was allocated sequentially.  
2.1.10  Screening study visit 
A screening study visit was conducted within 7-28 days after the recruitment and 2 weeks 
prior to the baseline study visit. All the study visits were conducted at CARU at the CAV, 
Newcastle University. At the screening study visit, participants were instructed to provide 
informed consent and to provide a “screening safety blood samples” to confirm the eligibility 
and the safety to take part in the study. In addition to collecting fasted blood samples and 
urine samples, demographic information, details about QOL were collected. Further, physical 
examination that measured Waist Circumference (WC), Hip Circumference (HC), TUG, GS 
test and the body composition was carried-out. At the screening visit, inclusion criteria and 
exclusion criteria were further checked and all details were recorded. Individuals who did not 
meet the inclusion criteria for the study, were excluded and the reason for not recruiting was 
recorded in a separate form. Potential participants were allocated a screening number and they 
were identified using this number throughout the study.  
2.1.11  Baseline study visit (study visit 1)  
A baseline study visit was conducted approximately within 2 weeks after the screening visit. 
At this visit, sun exposure details of the last three months, demographic information, food 
consumption data and use of vitamin D supplements were gathered using questionnaires. 
Food Consumption data was gathered using CalQuest Food Frequency Questionnaire (FFQ) 
which was designed to assess habitual vitamin D and calcium intake only. The validity of this 
questionnaire was tested using two commonly used standards of dietary assessment methods, 
five‐day duplicate diets and seven‐day weighed dietary inventories (Nelson et al., 1988).This 
questionnaire consisted of 28 food groups including questions on the type of foods consumed 
eg milks, yoghurts, cheeses, breads, spreading fats and sources of water consumed.  In 
addition to the weight and height measurements, TUG and GS were also measured the study 
visit. Further, fasted study blood samples and urine samples were collected from the 
participants at the study center in the baseline study visit (Figure 2.2). Administration of the 
first dose of vitamin D supplement was done at the study center with the direct supervision of 
the nurse. 
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2.1.12 Study visits 2, 3, 4 and 5 
Details relating to study visits are presented in Figure 2. After three months of vitamin D 
supplementation, all participants were invited for the second study visit to gather information 
about sun exposure, dietary intake, to perform muscle function tests, to collect blood samples 
and check the medical condition along with the Adverse Events (AE) of vitamin D 
supplementation. After 6 months of vitamin D supplementation, all participants were invited 
for the third study visit to gather the above information including the body weight, Fat Mass 
(FM) and Fat Free-Mass (FFM). Similarly, after 9 months and 12 months of 1st vitamin D 
supplementation, participants were asked to visit the study center for the 4th and 5th study visit 














































Figure 2.2 : Outcome measures at all five study visits in the VDOP study 
 
2.1.13 Funding and sponsorship 
This trial was supported by a Clinical Studies Grant (MP/ID19544) from Arthritis Research 
UK. This work was partly supported by Newcastle University and funding from the core 
programme of the MRC Nutrition and Bone Health Group at MRC Human Nutrition Research 
funded by the UK MRC, grant code U10596037. Arthritis Research UK was not involved in 
the analyses or in the decision to publish these results from the trial. The Newcastle upon 
Tyne Hospitals NHS Foundation Trust was the sponsor for this study. The sponsor was 
Group 1 : Oral vitamin D3 
12000 IU per month  for 12 
months (n=126) 
Group 2 : Oral vitamin D3 
24000 IU per month  for 12 
months (n=125) 
Group 3 : Oral vitamin 
D3 48000 IU per month 
for 12 months (n=128) 
Baseline measurements (visit 1) : Sun exposure, Serum 25(OH)D,  
PTH, dietary vitamin D & Ca intake, muscle function test 
Measurement after 3 months (visit 2) : Sun exposure, muscle 
function tests, body weight, FM, FFM 
Measurements after 6 months (visit 3) : Sun exposure, serum 
25(OH)D, dietary vitamin D & Ca  intake, muscle function tests, 
body weight, FM,FFM 
Measurement after 9 months (visit4) : Sun exposure, muscle function tests 
Measurements after 12 months (visit 5) : Sun exposure, Serum 25(OH)D, 
PTH, dietary vitamin D & Ca intake, muscle function tests 
Screening visit : Consent, blood samples, demographic information, muscle 
function tests, body composition, height, body weight, FM, FFM, skin type, 
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responsible for the conduct of the trial according to guidelines declared by GCP, Global 
Research Partnership (GRP), the Data Protection Act and the Declaration of Helsinki. The 
sponsor was also responsible for Pharmacovigilance. These responsibilities were delegated to 
the Principal Investigator Dr T. Aspray and Newcastle Clinical Trial  Unit (CTU). The 
sponsor did not play any role in the design, implementation, analysis or interpretation of the 
data of the study. 
2.2 The Biomarkers of Risk of Colon Cancer (BORICC) Study  
2.2.1 Study design  
The Biomarkers of Risk of Colon Cancer (BORICC) study was a cross-sectional study 
conducted in 2006 with the objective of developing and validating novel biomarkers of bowel 
cancer risk and to determine their relationships with habitual diet and nutritional status.  
2.2.2 Participant recruitment  
Ethical approval for the BORICC study was obtained from the Northumberland Local 
Research Ethics Committee in 2005 (Project reference 04/Q0902/6). Community-dwelling 
men and women aged 17 – 78 years were recruited to this study in 2006 via the 
gastroenterology outpatient clinics at Wansbeck General Hospital, Ashington, 
Northumberland.  All participants had been referred to the hospital for investigation of 
gastrointestinal symptoms and underwent screening by flexible sigmoidoscopy. Those in 
whom no gastrointestinal pathology including colorectal neoplasia, colonic inflammation, 
diverticulae or familial predisposition to colorectal CRC was found, were discharged as 
“nothing found” and were recruited to the BORICC 1 Study (healthy participants, n-268). In 
addition, a further group of participants with adenomatous polyps (premalignant lesion 
associated with increased CRC risk were recruited to the BORICC 2 Study (polyp patients, 
n=95). For both BORICC 1 and BORICC 2 studies, invitation letters were sent to patients in 
advance of their outpatients’ visit for a flexible sigmoidoscopy and written informed consent 
was obtained before recruitment to the study.  
2.3   The BORICC Follow-Up (BFU) Study 
2.3.1 Participant recruitment  
After approximately 12 years, participants in the original BORICC were invited to participate 
in the BORICC Follow-Up (BFU) Study. The primary objective of the BFU study was to 
identify the effect of aging on biomarkers of bowel cancer risk.  The secondary objectives 
were to investigate the associations between lifestyle factors, particularly the diet, physical 
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activity and obesity, and a panel of mucosal molecular biomarkers linked with colorectal 
cancer risk. In addition, The BFU Study investigated i) relationships between vitamin D status 
and musculoskeletal function of older adults and ii) the effect of sun exposure on vitamin D 
status of older adults. Participant recruitment to the BFU study was undertaken between May 
2017 and May 2018 at NTGH, North Shields, Northumberland. Potential participants from 
original BORICC Study 1 and 2 were identified by screening for inclusion using the Single 
View patient information database available via the NTGH. Invitation letters, including the 
study information sheet (Appendix B) were sent in batches of 20 letters, approximately 6 
weeks prior to the proposed study visit. Invitation letters were re-sent to those BORICC Study 
participants who did not respond. Individuals who interested in taking part in the study were 
asked to contact the research team by telephone calls or by email. During the telephone calls, 
participants were given the opportunity to discuss the study and raise their queries if they had. 
Then one member of the research team completed the “BFU Participant Interest Form” 
(Appendix C), which included the date of calling, participant’s name, contact details, 
dominant hand, along with the checklist of participants understanding about the study, 
presence or absence of dementia, use of medications (warfarin, rivaroxaban, apixaban, 
clopidogrel, dipyridamole) and participants ability of visiting the study center.  If possible, the 
hospital study visit was arranged at least two weeks after the date of the telephone call or 
email, allowing time to send the study pack (Figure 2.3). Alternatively, a possible date was 
arranged and the participants were contacted later to inform the study visit day. If the 
participant requested further information about the study, they were invited to participate for 
the “show-case” event which was a one-hour session that described the all aspects of the 
study.  After the “show-case event”, subjects were given a date for the study visit, if they 
expressed their willingness to take part in the study at the “show-case” event. Otherwise, they 



























Figure 2.3: Participant recruitment procedure for the BFU Study 
 
Out of  total BORICC study participants (363), 48 the participants diet during 12 years 
follow-up period. In addition, 4 participants were excluded as they met the execution criteria 
of having Dementia. Therefore the total number of potential participants for the BFU study 
was 311. Invitation letters were sent to all potential participants. A total of 55 participants 
replied for the invitation letters expressing the interest to take part in the study, while 10 
letters were not delivered because of wrong address. From the 55 who expressed interest, 47 
participants were recruited to the BFU Study and all of them completed the study (Figure 2.4). 
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patient information sheet 
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information sheet 
 
Call to discuss study and answer 
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Figure 2.4 : Participant recruitment for the BFU Study 
 
If the member of the research team was not available to answer the telephone call, “BFU 
potential participate call log” (Appendix D) form was filled, with the date, name of the caller, 
telephone number and the best time to contact them by a member of the research team. During 
the call, if the participant expressed  willingness to take part in the study, they were asked to 
send the signed consent form to study center in the given stamped envelope. Once recruited, 
participants were given an identification number and all data were recorded under this 
number. Study data were stored anonymously in password-protected computer in a locked 
cabinet with the security pass-protected building in the Medical School, Newcastle 
University. The study pack consisted of study instructions, three copies of consent forms, 
hospital study visit instruction, direction to the study center, FFQ, lifestyle questionnaire, 
sunlight exposure questionnaire, accelerometer instructions, accelerometer record sheet, sleep 
log, stool collection instruction, urine collection instruction, Home Samples and 
Questionnaire Collection Record Sheet (checklist for all samples and questionnaire 
completion), accelerometer in bubble wrap bag, stool collection Fecotainer, cool bag for stool 
BORICC study 
participants (n=363) 










Deceased – 48 
Dementia - 4 
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collection, cool block for stool collection, two urine collection pots, urine collection tubes that 
separated into two sets of four. Before participants visit the study center they were asked to 
fill “at home sample and questionnaire collection record sheet” (Appendix E) to ensure that 
they have collected all samples and fill all the questionnaires.  
Study packs were posted through the first class post in brown envelope.  However, procedures 
of urine samples and stool samples collection and processing were not described in this 
particular PhD thesis as those details are out of the scope of this PhD study.  
2.3.2 Ethical consideration 
Ethical approval for the BFU Study was granted by the West Midlands - Coventry & 
Warwickshire Research Ethics Committee on 29th November 2016 (REC No. 16/WM/0424). 
Two amendments were made to the study; the first to include a response card and invite 
potential participants to Showcase events described below (approved May 2017) and the 
second to call any participants not returning their response cards to check whether they had 
received the study invitation letter (approved December 2017). Approval for the storage of 
data was provided by the Northumbria NHS Foundation Trust.  All study procedures were 
conducted according to the guidelines laid down in the declaration of Helsinki. 
2.3.3 Inclusion and Exclusion criteria 
All individuals who participated in the original BORICC study 1 and BORICC study 2 were 
potentially eligible to participate in the BFU Study. Exclusion criteria included, actively 
undergoing chemotherapy or radiotherapy treatment, being unable to provide informed 
consent or being unable to attend the study center at NTGH.  
2.3.4 Funds and sponsorships  
The BFU Study (recruitment and sample collection) was funded by the MRC as part of the 
Centre for Ageing & Vitality (Ref: MR/M501700). Sponsorship for the BFU Study was 
provided by the Northumbria NHS Foundation Trust.  
2.3.5 Study visits  
Each participant was asked to visit the study centre only once at ward 1, NTGH.  Two rooms 
were allocated to get body measurements and clinical measurements from the participants, 
separately. One member of the research team welcomed the participants at the entrance of the 
first room and introduced all members of the research team. At the first room all 
questionnaires that filled by the participants were checked for missing or incomplete details. 
If there were any incomplete or missing data, the member of the research team corrected those 
after having a discussion with the participant. Out of three copies of the consent form, one 
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copy was given to the participant after further confirming the willingness to take part in the 
study. Other two copies were kept in the file with participants’ details and their 
questionnaires. In addition the cool bag with a stool sample, urine samples and accelerometer 
were collected from the participant in the first room. Then body weight, height, WC, HC, 
body fat percentage, muscle function tests were measured in the same room. After that a 
medical doctor asked the medical conditions and medication history from the participant and 
filled the “Patient Health History Questionnaire” (Appendix F). After giving the forms to 
claim the travelling expenses, the participant was sent to the second room. The second room 
was a room with a clinical bed that facilitate the venipuncture and rigid sigmoidoscopy 
procedure. Collection of 30 mL of blood samples, Buccal cells sample and ten biopsy samples 
were done by the practiced medical practitioner in the second room. Participants were given 
aftercare advice sheet after the whole procedures. All information and samples were collected 
during one study visit which lasted for approximately 1 hour. Participants were not given any 
payment for participating in the study except the travelling expenses.  
2.4 Data collection  
2.4.1 Demographic information  
VDOP study : Date of birth, gender, ethnicity (white British, white other, black African, 
black other, other), smoking history including the average number of cigarettes and the age 
that they started the smoking and the alcohol consumption with the average number of units 
were recorded in a questionnaire (Appendix A).  
BFU study : Data on age, gender, ethnicity and the date of birth were obtained using the 
questionnaires sent to participants in their study pack. Index of Multiple Deprivation (IMD) 
was used to identify the socioeconomic status.  
2.4.2 Medical history 
VDOP study : At the screening visit and at each study visit the physical examination was 
done. Details about the medication use, and the usage of vitamin D supplements were also 
identified monthly by telephone calls or by face to face discussion at the study center. During 
the intervention period, any changes to the participant’s medication were recorded including 
the type of the medication, total dosage, frequency, route of administration, start date and the 
end date.  
BFU study : Past medical history of the participants were collected by face to face discussion 
with the participants using a short “Patient Health History Questionnaire”  (Appendix F) by 
the medical practitioner at the study center. Presence or absence of selected disease 
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conditions, especially the non-communicable diseases listed in this questionnaire (diabetes, 
heart diseases, osteoporosis, diabetes, blood pressure, cancer) was checked and recorded after 
discussing with the participant. 
2.4.3  Sunlight Exposure  
VDOP study : Interviewer administrated sunlight exposure questionnaire was used to gather 
the information about habitual sun exposure of previous three months (Appendix G). Sun 
exposure questionnaire was adopted from Macdonald et al., 2013. According to Macdonald 
study, sun exposure was measured using sun exposure questionnaire and they obtained a 
significant correlation between sun exposure score and serum 25(OH)D concentration. 
Further, they have used multiplicative sun exposure score to assess the sun exposure which 
was adapted from Macdonald et al., 2008. However, the sun exposure questionnaire used in 
the present study was not validated. These details were gathered at all study visits (at baseline, 
at 3rd month, at 6th month, at 9th month and at 12th month). The questionnaire consisted of 
questions about the frequency of sun exposure, parts of the body exposed to sunlight, use of 
sunblock, part of the body that applied sunblock, use of sunbed, details about the holiday 
visits. Participants were asked these details separately for last month, the last 2 months and for 
last 3 months.  Fitzpatrick skin type (Fitzpatrick, 1988) of the participants was recorded at the 
screening visit based on the following five skin types (Table 2.1).  
 














BFU Study: A Sun Exposure Questionnaire based on that developed by Macdonald, 2013 
was used to gather the information about sun exposure habits during last year. This 
Skin types 
Description 
Type I Burns easily, never tans, white, very fair, red or blond hair, blue eyes, 
freckles 
Type II Burns easily, tans minimally, white, fair, red or blond hair, blue, hazel, 
or green eyes. 
Type III Burns moderately, tans gradually, cream white, fair with any eye or 
hair color, very common.   
Type IV Burns minimally, tans well, brown, typical Mediterranean Caucasian 
skin. 
Type V Rarely burns, tans profusely, dark brown, mid-eastern skin types 
Source : Fitzpatrick, 1998 
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questionnaire included the details Fitzpatrick skin type (I to VI),  frequency of sun exposure, 
duration of sun exposure, sun avoidance habits, clothing style, frequency of wearing less 
clothes, use of sunblock, use of sunbeds, details about mountain climbing and skiing and 
details about holiday visits (Appendix H). This questionnaire was pre-tested using 10 
university students and relevant amendments were done before sending it to the participants.  
2.4.4 Dietary intake 
VDOP study : CalQuest Food Frequency Questionnaire (FFQ) which was designed to assess 
only vitamin D and calcium intake was used to gather information on food intake over the 
previous year. The  validity of this questionnaire have been tested using two commonly used 
standards of dietary assessment methods, five‐day duplicate diets and seven‐day weighed 
dietary inventories (Nelson et al., 1988). This questionnaire consisted of 28 food groups and 
the questions on the type of milk, fat spread and sources of water consumed (Appendix I). 
Food and drinks belongs to several food groups such as beverages, milk and milk products, 
cereals and cereal products, nuts and seeds, beans and pulses, vegetables, eggs, meat and meat 
products, fruits and drinking water are the listed foods and drinks were listed in the 
questionnaires. Participants were asked to record the consumption frequency of listed foods in 
the questionnaire that were commonly consumed calcium and vitamin D rich foods in the UK. 
This FFQ was used to gather the information about dietary intake at the screening visit and 
subsequently during 3rd and 5th visits. Participants were given the questionnaires at screening 
visit to complete on their own at home and bring to the study centre. Incomplete data were 
filled at the study centre by a member of the research team.  
BFU Study:  Details about habitual diet were collected using a slight modification of the 
validated FFQ employed by the EPIC Study (Bingham et al., 1997). The same questionnaire 
was used to assess dietary intake of participants in the BORICC Study at the baseline (12 
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2.4.5 Muscle function tests  
Hand Grip Strength Test (GS) 
GS was used to measure upper body strength using a portable hydraulic hand dynamometer 
(Jamar, 12-0240, SN 04201084, USA) in both the BFU study and the VDOP study. At first, a 
member of the research team explained the procedure for assessing the hand grip strength to 
the study participants including the purpose of the measurement. Then the dominant hand of 
the participants was recorded in the “Physical Capability Record Sheet” (Appendix K). 
Further, details about any physical and clinical problems in hands that the participants 
reported were recorded in the record sheet before performing the test. Next participants were 
instructed to sit on an armchair resting forearm with the elbow bent at a 90-degree angle on 
the arm of the chair, holding the dynamometer (Figure 2.5). 
 
 
Figure 2.5 : Use of portable hydraulic hand dynamometer during measuring the GS  
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Finally, the participant was asked to squeeze the handle of the dynamometer using his/her 
maximum strength following the command  “3, 2,1 and squeeze”.  When the red needle of the 
dynamometer stopped moving, the participant was asked to stop squeezing. The value 
displayed on the dial was recorded to the nearest round number. This test was performed three 
times for each hand alternatively. Participants were given the opportunity to have a practice 
turn before taking the actual measurements. For most participants, the grip handle in the 
handgrip dynamometer was set to level 2 but if the participants had wide hands, the handle 
was set to the level 3.   
Timed-Up-and-Go test (TUG) 
TUG is a widely used measure of mobility in older people. Lower the total time to complete 
the TUG is associated with poor motor function and the variety of adverse health outcomes 
associated with ageing (Weiss et al., 2010). In both the VDOP and BFU studies TUG test was 
used to measure the lower body muscle strength. For this test, a chair with the standing height 
of 40-50 cm from the ground and a stopwatch were used. A line was marked on the cement 
floor with 3 m distance apart from the chair (Figure 2.6).  First, the member of the research 
team explained the procedure of the test to the study participants including the purpose of the 
measurement. Then the participants were asked to sit on the chair with both feet on the ground 
and placing the arms on the thighs. After that, the participants were asked to stand from the 
chair without helping his/herself with the arms, jumping or leaping.  Next the participants 
were asked to walk to the mark on the floor in normal day to day speed once the command 
was given as 3.2,1 and go. They were asked to stand once the researcher said “go”.  Then they 
were asked to turn around the mark and walk back to the chair and sit on the same chair 
without helping themselves (Figure 2.7). The stopwatch was started as soon as the person left 
the chair and stopped as soon as the person sitting on the chair. The total time spent on this 
activity in seconds was measured and recorded. This test was performed for three times and 
the mean value was calculated. At least 10-second reset was given in between each attempt. 
Any medical problems related to the walking was recorded. All measurements were recorded 
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Figure 2.6 : Overview of Timed-Up and Go set-up 
 
 
Figure 2.7 : Illustration of performance of Timed-Up and Go test (TUG) 
 
2.4.6 Body weight and body composition 
In both VDOP study and BFU study body weight and body composition (fat % in BFU study) 
were measured using TANITA TBF-300MA bio-impedance scale to nearest 0.1 kg (Figure 
2.8). At first, the foot plate was cleaned using wet wipes for surface disinfection before 
getting the measurements. Participants’ height, age, sex, type of body (Standard Male/ Female 
/Athletic Male and Female) were fed into the machine. The weight of 0.5 kg was reduced 
from each participant for the weight of the clothes. Then the participant was asked to empty 
their pockets, remove shoes, wrist watches, extra clothing such as jackets before getting the 
measurements. Next, participants were asked to step on the weighing scale when the “step on” 
symbol was flashed, placing feet wholly on both anterior and posterior electrodes and remain 
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still until the measurement was completed. The participant was asked to get down from the 
scale once the measurement was finished. A print of the weight and body composition was 
obtained and it was given to participants after recording the measurement in the 
anthropometry and body fat recording sheet. Weight measurement was obtained only once. In 
the VDOP study, body weight and body composition were measured at the screening visit, the 
visits at 3rd month, 6th month, 9th month and after 12th months of intervention at the study 
center. In addition to the weight measurement, BMR, BMI, impedance, fat percentage, FM, 
FFM and Total Body Water (TBW) were recorded in VDOP study by the research nurse.  
 
 
Figure 2.8 : TANITA TBF-300MA bio-impedance scale 
 
2.4.7 Height 
In both VDOP study and BFU study the height was measured at the study center. A 
Stadiometer (Seca) was used to measure the height in VDOP study while Leicester 
stadiometer was used in the BFU study. Before getting the measurements the stadiometer was 
kept on the firm cement floor and stabilizers rested against the vertical wall surface. All 
participants were given a short description of the way of measuring the height. Foot plate, 
head plate and skeletal scale were cleaned before getting the measurements using the wet 
tissues. Participants were asked to remove their socks and shoes and step onto the 
stadiometer, stand as straight as possible with feet together on the foot-plate, arms by their 
side hanging loosely, palms facing the thighs, both heels placed together touching the base of 
the vertical board of the stadiometer, buttocks and upper back contacted the back of the 
stadiometer, without leaning. Jawline was adjusted to 90° of the trunk. The participant’s head 
was positioned so that the Frankfurt Plane was horizontal. It was checked whether the ear hole 
aligned with the bottom of the eye socket (Figure 2.9). Participants were asked to maintain 
normal breathing and gently lower the horizontal headboard to the most superior point of the 
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head, compressing the hair. Then height measurement was recorded on the anthropometry and 
body fat percentage recording sheet to nearest 0.1 centimetre (cm). The measurement was 
taken two times and the mean value was recorded. If the 2nd measurement was not within 1 
cm of the previous recording, another measurement was taken and the closest two values were 




Figure 2.9 : Positioning the head (A), legs and back (B) against the stadiometer while 
taking the height measurement 
 
2.4.8 Waist Circumference (WC)  
WC was measured from all participants in both VDOP and BORICC studies using a 
stretchable tape. Participants were asked to remove heavy upper garments and then the lowest 
rib and suprailiac crest were identified. If the person had high adiposity, they were asked to 
identify those two points by themselves. The measurement was made at the approximate 
midpoint between the lower margin of the last palpable rib and the top of the iliac crest 
(Figure 2.10) (WHO, 2008). Participants were asked to exhale during the measurements. 
Member of the research ensured that the tape was lying flat on the skin and horizontal. The 
measurement was recorded to the nearest 0.1 cm. The procedure was repeated and the mean 
value was recorded. If the second measurement was not within 1 cm of the first, the third 
measurement was measured. 
A B B 
 




Figure 2.10: Measuring point at the waist to measure the Waist Circumference  
(Source :WHO, 2008) 
 
2.4.9 Hip Circumference (HC)  
 HC was measured in both BORICC and VDOP studies using the stretchable measuring tape. 
The measure was taken at the widest portion of the buttocks with light clothing (Figure 2.11). 
A member of the research team had to make sure that the tape was lying flat on the skin and 
horizontal. Measurement was obtained to the nearest 0.1 cm and two measurements were 
obtained. If the second measurement was not within 1 cm of the first measurement, the third 
measurement was taken and the closest two measurements were considered to measure the 
mean value. Measurements from all participants were taken by the same investigator 
throughout the study to avoid the investigator’s bias. 
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Figure 2.11 : Way of measuring Hip Circumference (Source : WHO, 2008) 
 
2.4.10 Body composition  
In VDOP study, FM and FFM were measured using Body Composition Analyzer (TANITA 
Corp, Tokyo, Japhan). The person was asked to step on the analyzer with bare foot. FM, 
FFM, fat percentage, impedance, BMI, Total Body Water (TBW) and Basal Metabolic Rate 
(BMR) that displayed on the scale were recorded. Body weight, height, BMI, body fat, waist 
and hip circumferences were recorded in the “Anthropometric and body fat percentage record 
sheet” (Appendix L) with the date, time participants ID and any problem related to 
measurements were recorded.   
2.4.11 Bone QUS measures  
Heel bone ultra-sound scanner (Achilles, UK) (Figure 2.12) was the equipment used to 
measure the bone mass of the heel bone of the participants. The Achilles EXPII is a bone 
ultra-sound scanner, that use high-frequency sound waves (ultrasounds) to examine the bone 
status in the heel. During the measurement procedure the heel is surrounded by warm water 
encapsulated between inflated membranes, which is the optimum medium for the 
transmission of the ultrasound. A transducer of the one side of the heel transmits an electrical 
signal into a sound wave, which passes through the water and person’s heel. Transducer at a 
fixed distance on the opposite side of the heel receives the sound wave and converts it to an 
electrical signal that is analyzed. The machine measures the Speed Of Sound (SOS) and the 
frequency dependent attenuation of the sound waves and combines them to form a clinical 
measure called a “Stiffness Index” (SI). This value indicates the risk of osteoporosis fractures 
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and comparable to BMD, which expresses as t–score. The measurement is taken in Os Calcis 
bone at the heel, which is highly trabecular and weight bearing bone with high metabolic rate 
and turn over as hip and spin bones.  
In the BFU study, this test was performed in the first room of the study center by the same 
investigator throughout the study.  As the first step, the surface of the machine including the 
“calf support” and “footplate” were cleaned using wipes for surface disinfection tissues. The 
second step was to perform the quality assurance test. To perform this test, both membranes 
of the machine and both side of the QA cylinder were spared 70% ethanol and then QA 
cylinder was placed between deflated membranes.  Next, the command was given to the 
machine to perform the test. If the test was not passed, membranes were filled with battery 
water or membranes were changed (if required) and the test was performed again. This quality 
assurance was performed each day before getting the measurement. As the thirds step, the 
reference population was set to “Europeans”.  Participants were given a short description of 
the measurement mentioning that this test was about the bone strength and the way of getting 
the measurement. Participants’ age, ID number were fed to the machine and the gender and 
the foot (left or right) were selected in the LED screen before getting the measurements. 
Participants were asked to remove the socks and shoes and sit in front of the machine on a 
chair. Then ethyl alcohol was sprayed two times into both sides of the heel and the 
membranes of the machine. Next, participants were asked to lay the foot flatly on the 
“footplate” of the machine and the rest the calf slightly on the “calf support” (Figure 2.13 and 
2.14). Percipients were asked to position the foot so that the white rib on the “footplate” was 
between the first two toes. Then the command was given to the machine to perform the test. 
Participants were asked to keep the foot still until the measurement was completed. All values 
displayed on the digital screen were printed off by the machine. Those values were recorded 
including the SI, T-score and Z-score in the “Bone Densitometry Record Sheet” (Appendix 
M). Two measurements from each foot were recorded and the mean value of each foot was 
calculated.  
 
    73 
 
 





Figure 2.13 The working position and the components of the ultrasonometer device 
(Wishvanath et al., 2011) 
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Figure 2.14 : Positioning the foot on the “footplate” of the bone scanner 
 
2.4.12 Blood samples collection 
VDOP study  : Venous blood samples were collected from the over-night fasted participants 
at the initial screening visit and at last study visit after 12-month supplementation by 
venipuncture procedure. The time and date of the sample collection were recorded. Blood 
drawing of all study participants was done by a practiced medical practitioner. Vacutainers 
were used to centrifuge and store the samples in -80oC freezer until shipped to central labs for 
analysis. All samples were collected at 8.30 – 11.30 am at the study center. Plasma samples 
were used to analyze the total 25(OH)D concentration.  All samples were labelled with the 
study identification number, initials and date of birth of the participants. After venipuncture, 
breakfast was offered at the study center. Time of the samples stored in the freezer and the 
freezer temperature were recorded in record forms.  
 
BFU study : A total of 30 mL of random non-fasted venous blood samples were collected by 
venipuncture procedure. A medical practitioner collected the blood samples from all study 
participants.  A aliquot of 500 µL serum samples were allocated to Eppendorf tube for the 
analysis of total serum 25(OH)D while EDTA added 500 µL of plasma sample was allocated 
for the analysis of PTH. As soon as the blood was collected to vacutainers, it was gently 
inverted to mix well and then the samples were centrifuged in the NTH at room temperature 
7000 rpm for 10 minutes. The serum samples were aliquetted into two 1.5 mL tubes (approx. 
500µl per tube) and stored at -80 oC in the freezer in NTGH until transport to the laboratory in 
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Newcastle University for analysis.  All blood samples were collected from all study 
participants from May 2017 to April 2018. Dates and time of the samples collected were 
recorded.  
2.5 Laboratory analysis  
2.5.1 Total serum 25(OH)D 
VDOP study : Overnight fasting venous blood samples were collected from participants at 
each visit. Blood collection and processing protocols, biochemical measurement, methods and 
quality control of assay performance were strictly standardized, as previously described 
(Schoenmakers  et al., 2003). The 25(OH)D2 and 25(OH)D3 concentrations in plasma were 
measured by Liquid Chromatography Tandem Mass Spectrometry (LC-MSMS) in duplicate 
samples as described in Schleicher et al., 2011. Lithium Heparin added plasma samples were 
used for the 25(OH)D analysis. Total 25(OH)D concentration was calculated by summing up 
the values for 25(OH)D2 and 25(OH)D3. The test was done in Immulite, Siemens Healthcare 
Diagnostics Ltd, Camberley, UK. Assay performance was monitored using a kit and in-house 
control and under strict standardization according to ISO 9001 : 2000. Quality assurance of 
25(OH)D assay was performed as a part of the Vitamin D External Quality Assurance 
Scheme (DEQAS) (www. deqas.org) and National External Quality Assurance Scheme 
(www.ukneqas.org.uk). The Analysis was repeated if the coefficient of variation was more 
than 10%. Assay performance was monitored using chrome systems and in-house controls, 
and is traceable to NIST standards. The inter-assay variation was less than 10% for 25(OH)D2 
and less than 7% for 25(OH)D3 and the limit of quantification was 6 nmol/L. 
BFU study : Total serum 25(OH)D concentration was analyzed in the Newcastle 
Laboratories, Freeman Hospital, Newcastle upon Tyne, using the Roche method. EDTA 
added serum samples were used for the total serum 25(OH)D analysis in duplicate samples. 
Considering the time limitation, ease of sample analysis and transport as well as the restricted 
budget for the laboratory analysis, serum samples were sent to our local biochemistry hospital 
laboratory at the Freeman hospital which uses the Roche assay with DEQAS certification.  
2.5.2 Parathyroid Hormones (PTH)  
VDOP study : EDTA plasma was used for the analysis of PTH by immunoassay. The 
analysis of PTH was carried-out at Immulite, Siemens Healthcare Diagnostics Ltd, 
Camberley, UK. Similar to 25(OH)D, quality assurance of PTH analysis was also performed 
as a part of DEQAS and National External Quality Assurance Scheme. Inter and intra-assay 
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CV were consistently below 4% in this laboratory. For the PTH analysis, between-assay CV 
was 3.1%. 
BFU study : PTH was analyzed using the sandwich test principle of 
electrochemiluminescence technology. The analysis was carried-out at Newcastle 
Laboratories, Freeman Hospital, Newcastle upon Tyne. Inter-assay CV was 1.4% while intra-
assay CV was 2.9%”. 
2.6 Statistical analysis  
Data were analyzed using SPSS statistical package for Windows version 24.0. Specific details 
of the statistical methods used in each study are provided in each of the experimental chapters 
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Chapter 3 :  The Effect of Vitamin D3 Supplementation for One Year on 
Muscle Function in Older Adults  
3.1 Introduction  
Loss of muscle mass and decreased muscle strength are features of ageing, with an annual 
loss of 0.5 – 1.0 % of muscle mass per year after 70 years of age (Mitchell et al., 2012) and a 
10 - 15% decline in muscle strength per decade in older people of aged 70-79 years 
(Goodpaster et al., 2006). Decreased muscle mass and strength results in sarcopenia, which is 
associated with poorer Quality Of Life (QOL), loss of independence and increased health care 
costs (Yu et al., 2014). Assessment of GS and TUG are the widely used methods to test the 
muscle strength and to identify the presence of sarcopenia (Dodds et. al., 2014).   
Links between vitamin D status and muscle function have been reported based on mechanistic 
in vitro studies (Bischoff –Ferrari et al., 2014), human observational studies (Berners et al., 
2018, Brech et al., 2017, Ceglia and Harris., 2013, Giris et al., 2013), longitudinal studies 
(Granic et al., 2017) and intervention studies (Muir and Montero-Odasso, 2011). Some 
observational (Tieland et al., 2013, Toffanello et al., 2012, Muir and Montero-Odasso, 2011) 
and longitudinal (Granic et al. 2017) studies have reported positive associations between 
serum 25(OH)D concentration and muscle function in older adults, whereas other studies did 
not find such association (Berners et al., 2018). These conflicting findings may be due to the 
differences in the characteristics of the population and differences in the vitamin D status of 
the participants. Current evidence suggests that vitamin D status is associated with muscle 
strength, function and physical performance in older adults (over 60 years of age) only when 
serum 25(OH)D concentration falls below 50 nmol/L (Rajnmark, 2011). The National 
Osteoporosis Society (NOS) (https://nos.org.uk/media/2073/vitamin-d-and-bone-health-
adults.pdf) also suggests, that serum 25(OH)D concentration < 25 nmol/L is considered as 
deficient, 30 – 50 nmol/L might adequate for some people while > 50 nmol/L is adequate for 
almost all in the population based on optimum bone and muscle health outcomes (Francis et 
al., 2013).   
The findings from RCTs of vitamin D are inconsistent, reflecting the variation in 
characteristics of the study population (e.g. age, gender, baseline vitamin D status), study 
design and the nature of the intervention (route, dose, frequency and form of vitamin D 
supplementation). Some studies showed the positive effect of vitamin D supplementation on 
muscle function only in older adults whose baseline serum 25(OH)D concentrations <30 
nmol/L (Beaudart et al., 2014) or <50 nmol/L (Rajnmark, 2011). However, less number of 
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studies have been conducted recruiting large number of free-living older adults. In addition 
the effect of vitamin D supplementation doses correspondent to RNI for vitamin D (400 IU) 
defined by SACN, North American RDA for vitamin D (800 IU/day) defined by IOM and the 
tolerable upper intake level (TUIL) (4000 IU/day) of vitamin D have not been studied. Further 
the plasma concentration and vitamin D supply required for optimal muscle function in older 
adults is not well understood. 
Therefore this study attempted to address the issues of past studies recruiting large number 
(379) of free living older adults and giving three different doses correspondent to the UK RNI 
for vitamin D, US RDA for vitamin D and the tolerable upper intake of vitamin D. We 
undertook a secondary analysis of a 1-year dose-ranging randomized vitamin D3 
supplementation trial evaluating its effects on muscle function (Aspray et al., 2018). 
Therefore aims of this chapter were to; 
i) determine the association between common vitamin D biomarkers (25(OH)D) on 
muscle function in older adults  
determine the effect of vitamin D supplementation on muscle function in older adults. The 
objectives of this chapter were to;  
i) investigate relationships between serum 25(OH)D concentration and muscle 
function in older adults from VDOP study 
ii) investigate the effects of three doses of supplemental vitamin D3 (12000 IU, 24000 
IU, 48000 IU) monthly for 12 months on muscle function in older adults from 
VDOP study 
3.2 Materials and Methods  
Data from the Vitamin D in Older People (VDOP) study which was a randomized double-
blind interventional trial of 379 male and female older adults aged 70 years or older, was used 
for the present study. In the original VDOP study to compare the absolute change in BMD at 
the hip, giving a 2-sided significance level of 0.05 and a power of 90%, 125 participants per 
arm were required. This resulted in a planned sample size of 375 participants to allow for 20% 
attrition by 12 months. This estimation was based on the variance in change in BMD over 12 
months from a previous study (Macdonald et al., 2013) and enabling detection of a 
0.006g/cm2 difference between 2 arms. However in a retrospective power calculation 
considering GS, giving a 2-sided significance level of 0.05 and a power of 80% the detectable 
changes in GS over one year as  2.8 kg (Frederiksen et al., 2006) with an SD for that 
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difference of 11.6 kg  the required sample size was 137 per arm. Allowing 20% attrition, the 
required sample size was 164 per arm.  
3.2.1 Sunshine exposure, dietary intake, anthropometry and demographic variables  
Data on GS, TUG test, anthropometry, including,  height, weight, FM and FFM, dietary 
intake of vitamin D, serum 25(OH)D and PTH concentration at baseline and after the total 
supplementation was gathered for the present analysis. Further details about participants’ 
recruitment, inclusion and exclusion criteria, vitamin D supplementation, outcome measures, 
and analysis of biological samples are described in subsection 2.1, 2.4 and 2.5, respectively in 
Chapter 2.  
3.2.2 Data and statistical analysis  
Baseline data were available for 379 older adults, while 343 older adults completed the 
intervention study. Thus, the total sample of 379 was used for the baseline data analysis, 
while the data from 343 older adults were used to investigate the intervention effects after 12 
months. Older adults who used vitamin D supplements were omitted in this analysis. Older 
adults were sub-divided into two groups based on baseline plasma 25(OH)D concentration < 
25 nmol/L, which is the cut-off of value of vitamin D inadequacy used in the UK (SACN, 
2016) and plasma 25(OH)D concentration < 50 nmol/L, which is the cut-off for vitamin D 
inadequacy used in North America (Ross et al., 2011).  Statistical analysis of the data was 
conducted using SPSS for Windows version 24.0. Kolmogorov-Smirnov test was used to 
evaluate the distribution of the variables and those that were not normally distributed were log 
transformed prior to the analysis and were near normally distributed after the conversion. 
Primary outcomes for the study were GS and TUG in response to supplementation with    
12000 IU, 24000 IU and 48000 IU vitamin D3 per month.  
Baseline 25(OH)D, baseline muscle function variables, age, weight, height, FM, FFM and 
vitamin D intake were predetermined as potential confounders.  Multinomial logistic 
regression analysis was used to investigate the association between plasma 25(OH)D 
concentration (based on two cut-offs, < 25 nmol/L and < 50 nmol/L) and muscle function at 
baseline, adjusting for confounders. The ANOVA test was used to test the effect of vitamin D 
supplementation on muscle function, plasma 25(OH)D and PTH concentration. The 
ANCOVA was used to test for the effect of the treatment on post-intervention variables after 
controlling for potential confounders (age, weight, height, FM, FFM and vitamin D intake). 
The Bonferroni test was used for post hoc comparisons. Stepwise linear regression analysis 
was used to identify the predictors of GS and TUG test before and after supplementation. 
Paired t test was used to identify changes in serum 25(OH)D, PTH, GS and TUG test within 
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each dose groups during the supplementation period. A P value <0.05 was considered as 
significant.  
3.3 Results  
Vitamin D was administered orally under direct supervision of a research nurse at baseline 
and at the third, sixth and ninth month study visits. At the end of each study visit, participants 
are given two bottles of vitamin D for the two subsequent months before their next scheduled 
study visit together with written instructions on how to take the supplement. On months when 
the participant was not attending the clinic, they were contacted by telephone, to remind them 
to take the supplement. Participants were directed to return all supplement bottles in their 
original packaging to the research team.  Dropout rates of the participants in 12000 IU, 24000 
IU and 48000 IU dose groups were 10.3%, 8.8% and 9.3%, respectively. Twelve (12) 
participants showed an Adverse Event (AEs) and withdrew from the study. The withdrawal 
was related to the vitamin D intervention only for one person. There was no evidence of a 
dose effect and no overall difference in the AEs were found between the vitamin D doses 
(Aspray et al., 2018). Table 3.1 presents the participants’ characteristics at baseline, stratified 
by vitamin D3 supplementation dose. Baseline values for the main outcome measures, GS, 
TUG and plasma 25(OH)D concentration were similar across the intervention groups as were 
mean values for the main confounders including weight, height, BMI and age indicating that 
randomization was successful. The initial characteristics of the baseline sample (379 
participants) and the sample of older adults who completed the intervention study (343 












Table 3.1 : Participants’ characteristics at baseline by the dose of vitamin D supplementation 
Characteristics  12000 IU (n=126) 24000 IU (n=125) 48000 IU (n=128) P 
value1 
 n (%) Mean SD n (%) Mean SD n (%) Mean SD  
Age (years)  74.6 4.0  75.0 4.2  75.4 4.4  
   Age (n, % >70 <71.5) 33 (26.2) 31 (24.8) 33 (25.8) 0.793 
   Age (n,% > 71.5 < 74) 36 (28.6) 30 (24.6) 28 (21.9)  
   Age (n,% > 74 < 77) 29 (23.0) 33 (26.4) 29 (22.7)  
   Age (n,% > 77) 28 (22.2) 31 (24.8) 38 (29.7)  
Gender (n, % males) 126 (54.8) 125 (52.8) 128 (49.2) 0.669 
Weight (kg) 126 73.9 11.8 125 77.1 14.0 128 76.1 14.2 0.150 
Height (cm) 126 167.4 8.1 125 167.0 9.8 128 167.4 10.0 0.925 
Waist (cm) 125 94.5 11.4 125 97.7 14.0 127 97.5 14.3 0.102 
Hip (cm) 125 103.9 8.2 125 105.8 9.5 127 105.3 10.5 0.256 
Body Mass Index (BMI) (kgm-2) 126 26.3 3.6 124 27.5 4.1 127 27.2 4.0 0.047 













   18.5 – 24.9  
   25.0 – 29.9  
   >30.0  
Body fat % 124 31.9 8.6 125 32.9 7.7 127 32.5 7.8 0.633 
Grip Strength (GS) (kg) 
(Reference range for sarcopenia; 
<20kg for female, < 30kg for male) 




          






Table 3.1 continue            
TUG3 (s) (Reference range for 
sarcopenia: 10.85 s) 
125 10.8 2.5 124 11.6 2.9 127 11.9 3.6 0.016 
Plasma 25(OH)D4 (nmol/L) 126 41.3 19.9 124 39.5 20.6 128 38.9 19.7 0.518 
     < 25 nmol/L 33 (26.2)   34 (27.4)   .35 (27.3)   0.745 
     25 – 50 nmol/L 52 (41.3)   56 (45.2)   61 (47.1)    
     50 – 75 nmol/L 35 (27.8)   26 (21.0)   24 (18.8)    
     > 75  nmol/L  6 (4.8)   7 (6.5)   8 (6.3)    
PTH (Pg/ml) (Ref range : 10.4 – 
60.4 Pg/mL) 
126 48.6 25.7 123 47.4 23.3 128 49.9 21.3 0.688 
Dietary vitamin D intake 
(µg/day) 
119 3.6 2.0 121 3.6 2.5 123 4.0 3.0 0.520 


















Table 3.2 : Multinomial logistic regression analysis1 of relationships between plasma 25(OH)D concentration, categorized according to 
SACN and IOM cut-offs and muscle function at baseline 
 Total population (n=379) Males (n=198) Females (n=181) 
Classification of 25(OH)D OR CI p value2 OR CI p value3 OR CI p value3 
Grip Strength (kg)          
     25(OH)D < 25 nmol/L2 0.339 0.166 – 0.691 0.003 0.333 0.137 – 0.810 0.015 0.251 0.063 – 1.001 0.050 
     25(OH)D >25 nmol/L Reference   Reference   Reference   
     25(OH)D <50 nmol/L3 0.990 0.510 – 1.922 0.976 0.588 0.216 – 1.443 0.229 1.870 0.520 – 6.719 0.338 
     25(OH)D  >50 nmol/L Reference   Reference   Reference   
Timed-Up and Go test (s)          
    25(OH)D < 25 nmol/L 0.645 0.388 – 1.070 0.090 0.501 0.229 – 1.093 0.084 0.720 0.358 – 1.446 0.355 
   25(OH)D >25 nmol/L Reference   Reference   Reference   
25(OH)DD < 50 nmol/L 0.697 0.424 – 1.147 0.155 0.775 0.386 – 1.543 0.468 0.584 0.273 – 1.250 0.166 
    25(OH)D  > 50 nmol/L Reference   Reference   Reference   
1To be in the category of higher muscle function based on dichotomisation at the median value   2 SACN  cut-off   3IOM cut-off  
2  Adjusted for gender, age, body weight, height, season of blood collection, Fat Mass (FM) and Fat Free Mass (FFM)  







Figure 3.1 : Relationship between Grip Strength (GS) and serum 25(OH)D 
concentration at baseline in males 
 
 
Figure 3.2 : Relationship between Timed-Up and Go test (TUG) and serum 25(OH)D 






















































Serum 25(OH)D concentration (nmol/L)
R = 0.084 
P = 0.243 
R= -0.083 







Figure 3.3 : Relationship between Grip Strength (GS) and serum 25(OH)D 
concentration at baseline in females 
 
Figure 3.4: Relationship between Timed-Up and Go (TUG) test and serum 25(OH)D 
























































Serum 25(OH)D concentration (nmol/L)
R = -0.002 
P = 0.975 
R = 0.184 
P = 0.013 
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Table 3.2 shows the multinomial logistic regression analysis of the relationships between 
baseline plasma 25(OH)D concentration and muscle function variables according to the cut-
offs values of plasma 25(OH)D concentrations from SACN, 2016 (25 nmol/L) and IOM, 2011 
(50 nmol/L). After adjusting for age, body weight, height, FM, FFM, vitamin D intake and 
season blood collected, older adults who had plasma 25(OH)D concentration < 25 nmol/L at 
baseline were significantly (p=0.003) less likely to have GS above the median compared with 
individuals with plasma 25(OH)D concentration >25 nmol/L. This relationship was evident 
for GS for both males (p= 0.015) and females (p= 0.050). When using the cut-off value of 50 
nmol/L, there were no relationships between vitamin D status and either GS or TUG for all 
participants and for both gender groups. Figures 3.1, 3.2, 3.3 and 3.4 further illustrate the 
association between serum 25(OH)D and TUG test and GS in males and females.  
Table 3.3 shows the effect of vitamin D supplementation on post-interventional and change 
(Δ) in muscle function variables, plasma 25(OH)D concentration and PTH concentration by 
the dose of vitamin D supplementation. After one year of vitamin D supplementation, there 
were no differences between treatment doses for post-intervention GS or TUG. In addition, 
there were no significant changes in GS and TUG from between intervention arms, with and 
without adjustment for baseline values, age, gender, weight, height, FM, FFM and vitamin D 
intake. Further, subgroup analysis of those with a baseline 25(OH)D concentration < 50 and 
<25 nmol/L, did not show any effect differences between intervention arms in post-
intervention GS and TUG, or for change in GS and TUG. As expected, there were significant 
differences between treatment arms in post-interventional plasma 25(OH)D and change in 
25(OH)D concentration. This relation was the same for the sub-group analysis those with 
baseline plasma 25(OH)D concentration < 50 nmol/L and < 25 nmol/L. After the 
supplementation, the change in plasma 25(OH)D concentrations were 14.3 (SD 12.6), 25.3 
(SD 18.0) and 40.9 (SD 19.8) nmol/L for the 12000 IU, 24000 IU and 48000 IU dose group, 
respectively. There was no significant difference in uncorrected post-interventional PTH in 
the total sample, although after correction for confounders this was significant. Subgroup 
analysis of those with a baseline 25(OH)D concentration < 50 nmol/L, change in PTH 
significantly differed between intervention arms before and after adjusting for confounders. 
Serum 25(OH)D concentration increased significantly after 12 month supplementation in all 
dose groups (p<0.001). PTH concentration decreased only in the high dose group (p<0.001) 
while GS was significantly decreased for all dose groups within 12 month period. TUG test 
values did not change significantly over time in any of the treatment groups.  
 
87 
Table 3.3 : Effect of vitamin D supplementation on post-interventional and change (Δ) in 
muscle function variables, plasma 25(OH)D concentration and PTH concentration by 
the dose of vitamin D supplementation 
Parameters 12000 IU/month 24000 IU/month 48000IU/month p1 p2 
Total sample (n=343) 
Plasma 25(OH)D (nmol/L) (n=113) (n=114) (n=116)   
   Pre-intervention  41.2 (20.3) 39.4 (20.8) 38.5 (19.4) 0.495  
   Post-intervention 55.9 (15.6) 64.6 (15.3) 79.0 (15.1)* <0.001 <0.001 
        P value3  <0.001 <0.001 <0.001   
   Change (Δ) in 25(OH)D 14.3 (12.6) 25.3 (18.0) 40.9 (19.8)* <0.001 <0.001 
PTH4 (pg/mL)      
   Pre-intervention  46.8 (23.5) 47.1 (23.9) 50.6 (21.6) 0.443  
   Post-intervention 44.0 (21.3) 44.6 (24.5) 40.1 (18.4) 0.244 0.016 
        P value3  0.095 0.076 <0.001   
   Change (Δ) in PTH -2.9 (18.4) -3.1 (18.2) -10.6 (15.4)* <0.001 <0.001 
GS5 (kg)      
   Pre-intervention  27.5 (12.7) 29.4 (13.2) 28.1 (12.2) 0.641  
   Post-intervention 24.7 (10.1) 26.2 (10.6) 25.7 (9.4) 0.692 0.449 
       P value3 0.012 <0.001 <0.001   
   Change (Δ) in GS -2.8 (11.6) -3.2 (8.1) -2.4 (7.7) 0.820 0.426 
TUG6 (s)      
   Pre-intervention  10.9 (2.5) 11.5 (2.9) 11.8 (3.5) 0.187  
   Post-intervention 11.5 (2.6) 12.0 (3.7) 11.9 (3.2) 0.437 0.713 
        P value3 0.656 0.084 0.519   
   Change (Δ) in TUG 0.56 (2.32) 0.46 (2.77) 0.15 (2.5) 0.773 0.680 
Older adults with baseline 25OHD < 50 nmol/L (n=242) 
Plasma 25(OH)D (nmol/L) (n=75) (n=83) (n=84)   
   Pre-intervention  30.2 (10.9) 29.1 (10.3) 29.6 (10.6) 0.862  
   Post-intervention 49.7 (11.8) 60.5 (14.8) 76.8 (14.3)* <0.001 <0.001 
   Change (Δ) in 25(OH)D 19.3 (10.0) 31.3 (15.0) 47.4 (15.3)* <0.001 <0.001 
PTH (pg/mL)       
   Pre-intervention  49.9 (24.9) 52.9 (24.4) 54.2 (22.0) 0.210  
   Post-intervention 45.7 (21.5) 48.9 (24.5) 41.0 (19.7) 0.137 0.101 
   Change (Δ) in PTH -4.2 (21.1) -4.0 (19.5) -13.4 (15.3)* <0.001 0.002 
GS (kg)      
   Pre-intervention  26.5 (11.8) 29.1 (13.6) 28.3 (12.8) 0.457  
   Post-intervention 23.8 (10.3) 25.5 (10.3) 25.1 (9.3) 0.801 0.403 
   Change (Δ) in GS -2.7 (12.5) -3.6 (8.5) -3.1 (8.4) 0.486 0.889 
TUG (s)      
   Pre-intervention  10.9 (2.3) 11.8 (2.9) 11.8 (3.2) 0.094  
   Post-intervention 11.7 (2.8) 12.3 (3.9) 12.0 (3.5) 0.560 0.630 
   Change (Δ) in TUG 0.74 (2.4) 0.45 (2.8) 0.29 (2.3) 0.512 0.823 
Older adults with baseline 25OHD < 25 nmol/L (n=93) 
Plasma 25(OH)D (nmol/L) (n=31) (n=30) (n=32)   
   Pre-intervention 19.3 (4.1) 18.2 (4.5) 18.8 (3.9) 0.582  
   Post-intervention 41.9 (10.7) 55.5 (14.7) 73.7 (12.8)* <0.001 <0.001 
   Change (Δ) in 25(OH)D 22.6 (9.3) 37.3 (14.0) 54.9 (12.7)* <0.001 <0.001 
PTH (pg/mL)      
   Pre-intervention  61.9 (27.8) 59.5 (19.3) 58.8 (23.2) 0.930  
   Post-intervention 50.4 (20.6 ) 47.7 (16.6) 41.5 (24.1) 0.102 0.143 
   Change (Δ) in PTH -12.2 (25.9) -11.9 (17.4) -17.4 (14.7) 0.470 0.563 
GS (kg)      
   Pre-intervention  25.6 (13.8) 24.1 (9.1) 25.8 (14.2) 0.895  
   Post-intervention 22.3 (11.2) 22.5 (9.0) 22.8 (7.9) 0.903 0.860 
   Change (Δ) in GS -3.3 (16.1) -1.6 (4.8) -3.0 (9.1) 0.814 0.714 
TUG (s)      
   Pre-intervention  11.0 (2.4) 12.8 (3.7) 12.5 (4.1) 0.938  
   Post-intervention 11.9 (2.8) 13.7 (4.1) 12.9 (4.1) 0.798 0.379 
   Change (Δ) in TUG 0.91 (2.6) 0.88 (2.7) 0.38 (2.5) 0.806 0.823 
* 
Significantly different from 12000 IU and 24000 IU groups
 1
One-way ANOVA followed by Bonferroni test 
2 ANCOVA controlled for baseline values of the variables, age, gender, weight, height, Fat Mass (FM), Fat Free Mass (FFM) 
and vitamin D intake 






Figure 3.5 depicts the proportion of older adults above and below various vitamin D cut-offs 
at baseline and after vitamin D supplementation. At baseline, the percentage of older adults 
with serum 25(OH)D concentration < 25 nmol/L were 26.2%, 27.2% and 27.3% for the 
12000IU, 24000IU and 48000IU dose groups, respectively (p>0.05). The percentage of older 
adults with serum 25(OH)D <25 nmol/L after vitamin D supplementation, was 0.9% in the 
12000IU dose group, whilst none of the participants who took the 24000 IU and 48000 IU 
dose of vitamin D had serum 25(OH)D < 25 nmol/L.  The proportion of older adults with 
serum 25(OH)D > 75 nmol/L increased with increasing dose of vitamin D supplementation. 
Only those participants who took the 48000IU dose of vitamin D maintained 25(OH)D 
concentrations above 50 nmol/L after 12 months.  So in summary, 12000IU monthly for 1 
year was sufficient to keep nearly all participants above a 25(OH)D concentration of 25 
nmol/L, whilst the 48000IU monthly dose was required to keep all participants above the 50 
nmol/L threshold.  
 
 
Figure 3.5 Vitamin D status of older adult before and after the supplementation 
 
Table 3.4 shows the changes in dietary, anthropometric and demographic variables in all dose 
groups during 12 months supplementation period. Changes in dietary, anthropometric and 
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Table 3.4 : Changes of dietary, anthropometric and demographic characteristic during 
supplementation period by the dose of vitamin D supplementation  
Characteristics Total sample 12000 IU 24000 IU 48000 IU 
Fat Mass (kg)     
   Before supplementation 24.9 (8.3) 23.8 (8.3) 26.0 (8.3) 24.7 (8.2) 
   After supplementation  24.8 (8.2) 23.8 (7.9) 26.0 (8.1) 24.7 (8.4) 
     P value  0.902 0.973 0.931 0.893 
Fat Free Mass (kg)     
   Before supplementation 50.8 (10.4) 49.5 (8.9) 51.9 (10.9) 50.9 (10.9) 
   After supplementation  50.6 (10.3) 49.4 (9.0) 51.9 (10.6) 51.0 (11.0) 
     P value  0.348 0.622 0.125 0.893 
Body fat %     
   Before supplementation 32.5 (8.0) 32.2 (8.5) 33.2 (7.8) 32.2 (7.6) 
   After supplementation  32.5 (8.1) 32.3 (8.2) 33.5 (7.9) 32.3 (7.7) 
     P value  0.631 0.619 0.239 0.773 
Weight      
   Before supplementation 75.9 (13.7) 73.3 (11.5) 77.9 (14.7) 76.4 (14.3) 
   After supplementation  75.5 (13.7) 73.1 (11.5) 77.3 (14.1) 76.1 (14.9) 
     P value  0.700 0.466 0.018 0.203 
Body Mass index (kgm-2)     
   Before supplementation 27.0 (3.9) 26.3 (3.6) 27.7 (4.20) 27.1 (3.4) 
   After supplementation  26.8 (3.9) 26.2 (3.55) 27.1 (4.08) 26.9 (4.1) 
     P value 0.088 0.409 0.022 0.196 
Dietary vitamin D intake 
(µh/day) 
    
   Before supplementation 3.8 (2.5) 3.6 (1.9) 3.7 (2.4) 4.0 (3.0) 
   After supplementation  3.9 (2.9) 3.6 (2.2) 3.8 (2.9) 4.3 (3.5) 
     P value  0.418 0.816 0.972 0.358 
Dietary calcium intake 
(mg/day) 
    
   Before supplementation 835.9 (390.5) 824.6 (358.0) 814.4 (400.2) 866.2 (412.4) 
   After supplementation  792.4 (377.9) 783.1 (343.6) 758.2 (358.1) 832.0 (423.6) 






 Table 3.5 shows the predictors of GS and TUG test before and after vitamin D 
supplementation. Significant determinants of GS before supplementation were FFM, age, 
gender and height, while age, gender and height were the predictors of GS after the vitamin D 
supplementation. Similarly, age and fat percentage were the determinants of TUG test before 
supplementation while age, BMI and height were the determinants of the TUG test after the 
supplementation. The single biggest predictor of GS before and after supplementation was the 
gender while the single biggest predictor of TUG test before and after supplementation was 
age.  
Table 3.5 : Multivariate models of predictors of Grip Strength and Timed-Up and Go 
test before and after the supplementation. 
Predictors Constant B D β p CI 
 Before supplementation 
Grip Strength       
R2 0.363      
Constant 6.081      
Fat Free Mass (kg)  0.356 0.102 0.285 0.001 0.156 – 0.556 
Age (years)  -0.458 0.133 -0.136 0.002 -0.687 – (-0.163) 
Gender   -4.876 1.736 -0.190 0.005 -8.289 – (-1.462) 
Height (cm)  0.230 0.102 0.166 0.025 0.029 – 0.431 
       
Timed-Up and Go test       
R2 0.130      
Constant -7.839      
Age (years)  0.236 0.037 0.322 <0.001 0.164 – 0.308 
Body fat %  0.073 0.019 0.193 <0.001 0.036 – 0.110 
       
 After supplementation 
Grip strength       
R2 0.564      
Constant -13.02      
Gender  -9.27 1.052 -0.465 <0.001 -11.34 – (-7.201) 
Height (cm)  0.358 0.055 0.341 <0.001 0.249 - 0.467 
Age (years)  -0.223 0.085 -0.099 <0.001 -0.930 -0.056 
       
Timed-Up and Go test       
R2 0.159      
Content  3.141      
Age (years)  0.192 0.035 0.227 <0.001 0.123 – 0.261 
Body Mass Index (kgm-2)  0.166 0.041 0.202 <0.001 0.084 – 0.247 
Height (cm)  -0.061 0.017 -0.179 <0.001 -0.095 – (-0.027) 





3.4 Discussion  
3.4.1 Main findings  
This double-blind, randomized controlled study found that monthly vitamin D3 
supplementation with 12000 IU, 24000 IU and 48000 IU (which corresponds to 400 µg, 600 
µg and 1200 µg of dietary vitamin D per day) for one year produced significant dose-related 
increases in plasma 25(OH)D concentration but had no effect on muscle function in older 
adults. However, at baseline, there was a negative association between plasma 25(OH)D 
concentration and GS for those with baseline plasma 25(OH)D concentration <25 nmol/L. 
After supplementation, there were no associations between plasma 25(OH)D concentration 
and muscle function. To our knowledge, this is the first dose-ranging RCT conducted in the 
UK, with a large number of free-living older adults, evaluating the effect of vitamin D 
supplementation on muscle function. 
3.4.2 Comparison with other studies  
Following table (Table 3.6) summarises the findings of past RCTs and systematic reviews 
(SR). According to all these studies, inconsistent findings are attributed to the differences in 
study design including the differences in cohort characteristics, duration, dosage, 
formulations, route of vitamin D supplementation and the functional outcomes measured. 
However in summary the improvement in muscle function can be seen only in older adults 
whose baseline vitamin D status < 60 nmol/L or older adults whose muscle functions were 









Table 3.6: Summary of the previous studies of vitamin D supplementation and muscle function in older adults 
Study  Target group Sample 
size  





al., 2017.  
Female adults of long 
term care residence ; 65 
+ years 
137 800 IU daily for 24 months Gait speed and physical 
performance test 
No effect of supplementation  
RCT, Bischoff-
Ferrari et al., 
2016 
Home dwelling men and 
women : 70 + years  
200 24 000, 60 000 or 24 000 D3 
with 300 µg of calciferol 
monthly for 12 months  
Short physical performance 
battery 
No improved in lower extremity 
muscle function  
RCT, Hansen 
et al., 2015 
Postmenopausal women 
aged 75 years or 
younger with baseline 
25(OH)D 35 – 67 
nmol/L  
230 800 IU and 50 000 vitamin D 
twice monthly for one year 
Five sit - stand test and TUG test No effect on muscle function  
RCT; Broe et 
al., 2007.  
Nursing home residents, 
average age of 89 years 
124 One of 200 IU, 400 IU, 600 IU 
and 800 IU; daily for 5 months  
Rate of falls  Reduced falls in high dose group 
RCT, Cangussu 
et al., 2015 
Postmenopausal women 
aged 50 – 65 years  
160 Oral D3 supplements; 1000 IU 
for 9 months   
GS and chair rise test  Improvement in muscle strength in 
vitamin D supplemented people  
RCT, Dhesi et 
al., 2004  
Older adults with serum 
25(OH)D  
< 30 nmol/L  
139 Single dose of 60,000 IU 
ergocalciferol  
Aggregate functional performance 
time, Choice reaction time, 
quadriceps strength,   
Improvement in balance, reaction 
time, functional performance, not 
the muscle strength   
RCT, Tellioglu 
et al., 2012 
Older adults (65 
+) in nursing homes with 
serum 25(OH)D 
concentration < 30 
nmol/L  
116 60,000 IU for 12 weeks  Quadriceps an physical 
performance battery  
Improved the muscle strength.  
RCT, Zhu et 
al., 2010 
Community dwelling 
older adults, 70 – 90 
years with serum 
25(OH)D < 60 nmol/L 
302 1000 IU daily D2 for 1 year TUG Improved the TUG only in the older 
adults who were slowest and 










Table 3.6 continue 
Study  Target group Sample 
size  
Dose and duration  Method of assessing muscle 
function 
Conclusion  
SR, Stockton et 
al., 2011 
Adults whose baseline 




All forms and doses of vitamin 
D supplementation  
Evaluation of muscle strength  Positive effect on muscle function 
in older adults whose baseline 
serum 25(OH)D less than 25 
nmol/L 
SR, Rosendahl-
Riise et al., 
2017 
Community dwelling 




Bolus injection or oral vitamin 
D dose ranging from 1000 IU – 
600000 IU  given daily or 
weekly for 16 weeks – 20 
months 







To support the finding of negative association between GS and plasma 25(OH)D 
concentration below 25 nmol/L at baseline, Wu et al., 2017, reported that the serum 25(OH)D 
concentration of 29 – 33 nmol/L may optimise MSK health in middle-aged women (36 - 
57 years). Similar to our study Grimaldi et al., 2013, also reported a positive association 
between serum 25(OH)D concentration and GS, but not with other tests of muscle function 
and suggested that this might be related to anatomical site differences in the androgenic effect 
of vitamin D or to differences in vitamin D receptor expression between upper and lower 
body muscle and consequently muscle function.  
GS loss in our study was much higher than the reported values in previous studies. The annual 
loss of GS among the older people aged 65 - 75 years reported in the previous studies ranged 
from 0.3 to 1.3 kg (Turusheva et al., 2017, Xue et al., 2010, Frederiksen et al., 2006). The 
higher decline in muscle function in our study might be due to the fact that the mean age of 
our participants was on average 75 years and they were in a phase of the rapid ageing process 
with rapid muscle degradation. Though the GS is the standard method to assess sarcopenia, 
differences in the equipment and methods used in various studies may have caused variation 
in the measurements, making it difficult to compare between studies (Roberts et al., 2011).  
According to this study, plasma 25(OH)D concentration < 25 nmol/L was negatively 
associated with GS. This finding supports the recommendation of SACN, UK that for the 
protection of MSK health, serum 25(OH)D concentration should not fall below 25 nmol/L 
throughout the year (SACN, 2016). The US Institute of Medicine (IOM) defines the desired 
range of 25(OH)D as 30 - 50 nmol/L and ESFA (EFSA et al., 2016) advises a target value of 
50 nmol/L for the general population. The US Endocrine Society advises a target range of > 
50 nmol/L for patient management who are at risk of VDD (Holick et al., 2011). In addition, 
Kotlarczyk et. al., 2017 suggested that at least a concentration between 30-40 ng/ml (~ 75 – 
100 nmol/L) is required for older adults for optimum muscle function (Kotlarczyk et al., 
2017). With regards to vitamin D supplementation, the American Geriatrics Society (Broe et 
al., 2007) and the Endocrine Society (Holicket et al., 2011) recommend vitamin D 
supplementation of 600–1000 IU/day in older adults who are at risk of falling. A SR of 
vitamin D supplementation trials also reported a daily dose of 700–1000 IU for physical 
performance and to prevent falls (Bischoff-Ferrari et al., 2009). SACN, 2016 suggests that for 
the adults > 50 years, the beneficial effect of vitamin D supplementation on muscle strength 
and function can be seen among the adults at the mean baseline serum 25(OH)D 
concentrations ranging between 25 and 66 nmol/L. In this study, except the highest dose 
group, none of the other intervention groups reached a mean post-intervention plasma 
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25(OH)D concentration above this range. Accordingly, it can be speculated that the dosage 
used in this study may not have been high enough to reduce the negative effects of the ageing 
process. The absence of a detectable effect of supplementation in this study may also be 
attributed to the fact that only 30% of our participants were vitamin D deficient (<25 nmol/L) 
at baseline. However, as a result of lack of a placebo group, data on “natural decline” of 
muscle function of this group was not available. Thus the effect of vitamin D supplementation 
cannot be compared with that of non-supplemented individuals.  
For tissues other than the kidney, total 25(OH)D may not fully reflect its availability for, local 
hydroxylation into 1,25(OH)2D which is the active metabolite of vitamin D. Although 
1,25(OH)2D  is responsible for the biological action of vitamin D, its systemic concentration 
does not reflect function at the target tissue level (Bike et al., 2017, Prentice et al., 2008). 
Many vitamin D target tissues, including the muscle tissue, are known to express the 
1,25(OH)2D producing enzyme CYP27A1 for auto- and paracrine functions. Some reports 
suggest that muscle tissue may be capable of internalising vitamin D binding protein bound 
25(OH)D, although it remains to be determined whether this is a significant route of cellular 
supply of 25(OH)D (Girigis et al., 2013). To date, no data are available to identify whether 
free 25(OH)D provides a better prediction of muscle function compared to total 25(OH)D.  
3.4.3 Strengths and limitations  
The lowest intervention dose (which corresponds to the current UK dietary recommendation) 
group was used as the reference group but did not include a placebo group in our study design 
as directed by the approving authorities. As a result, we could not establish the effect of three 
doses of vitamin D supplements compared to a placebo group. Further, plasma 25(OH)D 
concentration was measured at baseline and after 1-year supplementation, for both of which 
blood samples were collected early winter to late spring, during which in non-supplemented 
individuals, vitamin D status is lower than the year-round average. Therefore, vitamin D 
status of individuals at baseline and post-intervention may have been misclassified and not 
fully reflect the trajectory of vitamin D status throughout the year. Further, this population 
was not selected randomly from the community. They were invited on the basis of screening 
of pre-specified criteria in their electronic health record. Also, there may have been self-
selection bias as those that expressed an interest to participate in the study may be more health 
conscious. In addition, the response to vitamin D supplementation and status may have been 
influenced by factors not measured in this study, such as the distribution of type I and type II 
of muscle fibres, genetic factors, habitual physical activity or exercise habits and hormonal 
factors. This study had several strengths. The large sample size  compared to previous studies 
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and the number of available measurements that could potentially influence muscle force, i.e. 
those related to body composition and size. The use of three different vitamin D doses 
corresponding to the UK RNI (SACN, 2016) the US RDA (Ross, 2011) and the value below 
the Tolerable Upper Intake Level (TUIL) was a strength to this study.  
3.4.4 Conclusions  
At baseline, plasma 25(OH)D concentration < 25 nmol/L was negatively associated with GS 
for both male and females. Vitamin D supplementation significantly increased the plasma 
25(OH)D concentration of older adults in all doses of supplementation. Vitamin D 
supplementation with 12000 IU, 24000 IU and 48000 IU for 12 months had no effect on 


















Chapter 4 :Relationship Between Sunlight Exposure and Serum 25(OH)D 
Concentration During a 12 Month Randomized Control Trial With High 
Dose Vitamin D3 Supplementation: Results from the Vitamin D in Older 
People (VDOP) Study 
4.1 Introduction 
Cutaneous synthesis of vitamin D upon UVB radiation from sunlight is the main source of 
vitamin D for most humans (Holick, 1994). It has been assumed that 80 – 90% of the vitamin 
D requirement is provided by skin synthesis (Fraser and Milan, 2013), while diet makes a 
relatively small contribution (SACN, 2015). There is evidence that the prevalence of VDD 
has increased during the past decade in most countries (Bishoff-Ferrari et al., 2006) which is 
attributed to insufficient cutaneous synthesis of vitamin D as a result of low sunlight 
exposure. Skin synthesis of vitamin D is affected by both personal and environmental factors.  
Age, clothing habits, skin color, frequency of outdoor activities, holiday visits and the use of 
sunblock  are the important personal factors (Touvier et al., 2015, Darling et al., 2014, Tsiaras  
and Weinstock 2011) while, season, altitude, attitude, pollution and time of the day are 
important environmental factors (Touvier et al., 2015, Brembeck et al., 2015) that influence 
the cutaneous synthesis of vitamin D. To optimize vitamin D status, vitamin D 
supplementation is recommended for individuals with low sunlight exposure or low cutaneous 
synthesis (O'Sullivan et al., 2019). However, excess exposure to sunlight increases the risk of 
skin cancer, cataract and skin aging (Health and Safety Environment, 2012). Therefore 
vitamin D synthesis upon UVB exposure has become an important concern in the area of 
vitamin D research.  
Limited data are available about the relative contribution of sun exposure and vitamin D 
supplementation to plasma 25(OH)D which is the biomarker of vitamin D status (Ross et al, 
2010). Current recommendations for the prevention of VDD focus on vitamin D   
supplementation and thus physicians are insecure about what advice to offer regarding sun 
exposure recommendations (Holick et al., 2011). It is believed that the effectiveness of 
vitamin D supplementation on plasma 25(OH)D concentration is altered by the dermal 
production of vitamin D (O’Sullivan et al., 2019). The contribution of cumulative sun 
exposure behaviors over a period of time on plasma  25(OH)D concentration in free-living 
older adults in the UK has not been investigated. Furthermore, the relative contribution of 
cumulative sun exposure to plasma 25(OH)D concentration among older adults supplemented 
with vitamin D has not been studied. Therefore, the aim of the present study was to quantify 
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the impact of sun exposure on vitamin D status in older adults supplemented with twelve 
monthly doses of vitamin D3 supplements  (12000 IU, 24000 IU and 48000 IU) in the UK. 
The objectives of this study were to,  
1) investigate the relationships between sun exposure behaviours and serum 25(OH)D 
concentration in older adults.  
2) quantify the contribution of cumulative sun exposure to serum 25(OH)D  concentration 
among older adults supplemented with vitamin D3 monthly for one year. 
4.2 Methods  
Data from VDOP (Vitamin D in Older Adults) study was used for the present study. The 
primary aim of the VDOP study was to test the effect of three doses of monthly vitamin D3 
supplements (12000 IU, 24000 IU and 48000 IU) on BMD in men and women aged 70 years 
or older. The aim of this chapter of the PhD thesis was to identify the relationship between the 
cumulative sun exposure and total plasma 25(OH)D concentration in older adults of the 
VDOP study.  
4.2.1 Study design and participant recruitment 
VDOP study is a randomized double-blind interventional trial of 379 male and female older 
adults aged 70 years or older, living in the North-East of England (550N), which conducted 
from November 2012 to May 2013. Details about the recruitment of participants, inclusion 
criteria and exclusion criteria are described in chapter 2 in this PhD thesis. Total of 379 older 
adults enrolled for the study and seven (7) older adults were excluded from the baseline data 
analysis due to the missing measurements of plasma 25(OH)D concentration and/or sun 
exposure. In addition, older adults who used dietary supplements of multivitamins, calcium, 
vitamin D and fish oil (n=33) were excluded from data analysis. Hence, total baseline sample 
consisted of 339 older adults. Further details about study design and participant recruitment 
and ethical approval are described in section 2.1 in Chapter 2.  
4.2.2 Study visits and vitamin D supplementation  
Participants were randomized to receive one of three doses of vitamin D3, 12000 IU, 24000 
IU or 48000 IU, monthly for one year. Study visits took place at baseline and thereafter at 3-
monthly intervals (5 in total) for a one year period. Vitamin D3 supplements were given at 
each study visit and the two bottles of vitamin D supplements were given to all participants to 
take at home for the next two months. Of the total participants, 62% of participants began the 
12 months supplementation during the time of the year where there is no UVB radiation at the 
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study location (550N), defined as October to March. The rest of the participants began the 12 
months supplementation during summer months defined as April to September. 
 
4.2.3 Sunshine exposure, dietary intake, anthropometry and demographic variables 
Assessment of sunlight exposure  
Sun exposure questionnaire which was adopted from Macdonald et al., 2013 was used to 
gather the information about habitual sun exposure behaviors during the last three months 
(each month separately). However this questionnaire was not previously validated. The 
frequency of sun exposure, use of sunbed, skin exposure area, sunblock usage, details about 
holiday visits and the Fitzpatrick skin types (Fitzpatrick, 1988) were collected using this 
questionnaire (Appendix G). Except for the skin types, all other information was collected at 
all five study visits (at baseline, after 3 months, 6 months, 9 months and after 12 months).  
Analysis of sun exposure data 
The following factors were considered when analyzing the sun exposure data. 
1. Sun exposure details of each month were approximately similar, therefore, sun 
exposure detail of the previous month was considered in the analysis.  
2. Skin exposure area was calculated according to Petersen et al., 2013 which accounted 
for 6%, 2.5%, 12.5%, 38.5% and 28% for the head, both hands, both arms, both legs 
and stomach and back skin areas of the whole body, respectively.  
3. Skin type I and II and skin type IV and V were combined in the data analyses due to 
the low number of participants in each skin type.  
4. If the participants’ previous month’s sun exposure of each data collection point fell 
during April to September, it was considered as ‘summer sun exposure’ while 
previous month’s sun exposure fell during October to March it was considered as 
‘winter sun exposure’. 
5. Only about 6% of participants answered the question about skin area that applied 
sunblock at the baseline study visit. Therefore information about skin area of 
sunblock used was not considered in the data analysis.  
6. Sun exposure questionnaire did not include a direct question about the sunblock use, 
therefore individuals who answered the question about the skin area of sunblock use, 
were considered as the sunblock uses.  
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Calculation of cumulative Sun Exposure Score (SES) 
SES of each time point was calculated according to the scoring system described by Pilz et 
al., 2012. Following equation was used to calculate the sun exposure score.  
 
SES = [Score for the frequency of outdoor activity + score for the skin exposure area + score 
for the sunblock use + score for holiday visits + score for the season of holiday visit]   
 
Questionnaires which were answered coving the sun exposure details only during the summer 
months (April to September) at each study visit were considered in the analysis.  Each study 
participants had 2 or 3 study visits that covered the sun exposure details during summer 
months of the previous year. The mean SES of 3 or 2 study visits was used to get the SES of 
the whole year. Scores for the responses of each question in the questionnaire are displayed in 
Table 4.1.  
 
Table 4.1 : Scoring system used in the analyses of sun exposure questionnaire  
Question in the questionnaire   Responses  Score 
Frequency of outdoor activities  Often  3 
      Occasionally 2 
      Seldom/never 1 
        
Skin exposure area Bathing suit 4 
 Face, hand, arms and legs 3 
 Face, hand and arms 2 
 Face and hand 1 
Sunblock use  No 1 
  Yes 0 
Holiday visits  Yes 1 
      No 0 
Duration of holiday visits < 7 days 1 
 5.– 14 days 2 
 14– 21 days 3 
 >21 days 4 
Skin types I 5 
 II 4 
 III 3 
 IV 2 
 V 1 
Season of the holiday visits  During summer months 1 





The CalQuest dietary questionnaire, which was adapted from Calquest (Nelson et al., 1998) 
was used to gather the information about dietary intake at the screening visit and subsequently 
during 3rd and 5th study visits.  Dietary intake of calcium and vitamin D were calculated. The 
mean values for dietary calcium and vitamin D intake across these 3 time points were used in 
subsequent data analysis.  
Anthropometry and sociodemographic information 
Height and weight were measured at 3 months intervals at the study center, WC and HC were 
also measured at the first study visit. BMI was calculated by dividing the weight in kg by 
square of height in meters. A questionnaire was used to collect information on medical 
history, vitamin D supplement use, lifestyle information and sociodemographic information.   
Blood samples   
Overnight fasting venous blood samples were collected from participants at each study visit. 
Concentrations of 25(OH)D2 and 25(OH)D3 concentrations in plasma were measured by LC-
MSMS, before and after the intervention.  Total plasma 25(OH)D concentration was 
calculated by summing-up 25(OH)D2 and 25(OH)D3 values. EDTA plasma was used for the 
analysis of PTH by immunoassay (Immulite, Siemens Healthcare Diagnostics Ltd, 
Camberley, UK). 
4.2.4 Statistical analysis  
Statistical analysis was done using Statistical Package for the Social Sciences (SPSS 24.0, 
Chicago). Older adults who used vitamin D supplements were omitted in the present analysis.  
Baseline characteristics of the study population were presented as mean + SD and 
percentages. Data were checked for normality using the Kolmogorov-Smirnov statistic. 
Plasma 25(OH)D concentration at baseline was not normally distributed and, therefore was 
converted to natural logs values, prior to the analysis. Baseline and endpoint plasma 25(OH)D 
concentration that was stratified based on demographic, biochemical, sun exposure and 
anthropometric variables were compared using one-way ANOVA and Student’s t-test.  For 
the variables that had more than two categories, one-way ANOVA was used, while for the 
variables that had two categories Student’s t-test was used. The Bonferroni test was used for 
post hoc comparisons between means.  Stepwise linear regression analysis was executed to 
identify the predictors of baseline and endpoint plasma 25(OH)D concentration for each 
vitamin D dose group separately and for the total sample. SES was added to the models to 
represent the sun exposure behaviors of older adults. The dose of supplementation, baseline 
plasma 25(OH)D concentration, BMI, age, gender, dietary vitamin D intake, dietary calcium 
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intake, FFM and FM were the other predictor variables added into the regression models. 
These variables were selected on the basis of prior knowledge of the factors associated with 
plasma 25(OH)D concentration. Baseline 25(OH)D concentration, dietary vitamin D intake, 
calcium intake, BMI age and SES were the continuous variables. Gender and dose of 
supplementation (12000 IU, 24000 IU and 48000 IU) were the categorical variables. Sun 
exposure related variables were compiled to get the SES, described by Pilz et al., 2012. 
Variables that had more than two categories were entered into the model as dummy coded 
variables. Scatter plots were used to show the relationship between PTH and plasma 25(OH)D 
concentration for both males and females and for  both before and after vitamin D 
supplementation. Simple linear regression analysis was performed to identify the relationship 
between PTH and 25(OH)D concentration for males and females and for  both before and 
after the supplementation. A p value less than 0.05 was considered statistically significant. 
 
4.3 Results 
4.3.1 Basic characteristics and vitamin D intake  
Table 4.2 shows the characteristics of the study participants at baseline. Mean plasma 
25(OH)D and PTH concentrations were 38.2 (SD 19.2) nmol/L and 48.9 (23.4) Pg/mL, 
respectively. Mean age and BMI were 75.0 (SD 4.2) years and 27.0 (SD 4.0) kgm-2, 
respectively. The percentage of males and females was approximately similar. Twenty four 
percent (24%) of males and 36.7% of females had plasma 25(OH)D concentration less than 
25 nmol/L. Vitamin D status of males and females at baseline is depicted in Figure 4.1.  
Majority of males (98.1%) and females (98.7%) did not meet the RNI for vitamin D (10 











Table 4.2: Characteristics of the study population at baseline (n=339) 
Characteristics  Mean (SD) 
     Age (years) 75.1 (4.2) 
     Body Mass Index (kgm-2) 27.1 (4.0) 
     Serum 25(OH)D conc. (nmol/L) 
       < 25 nmol/L (n (%)) 




     Parathyroid Hormones conc (Pg/ml) 48.9 (23.4) 
     Mean dietary vitamin D intake  (µg/day)  3.8 (2.6) 
     Mean dietary calcium  intake  (mg/day)   838.3 (392.5) 
          % who did not meet the RNI for vitamin D (n(%))   
               Males 332 (98.1%) 
               Females  334 (98.7 %) 
     Gender (n (%)) 
 
        Males  175 (51.6) 





Figure 4.1 Vitamin D status of males and females at baseline 
4.3.2 Relationships between plasma 25(OH)D concentration and sun exposure, 
demographic, dietary, and anthropometric variables at baseline  
Table 4.3 summarizes the plasma 25(OH)D concentration by sun exposure, demographic, 
dietary and anthropometric variables at baseline. Participants who sampled during summer, 
had significantly high plasma 25(OH)D concentration compared to the participants sampled 
during winter (p=0.035). Similarly, participants who had holiday visits at the baseline study 
visit had significantly higher plasma 25(OH)D concentration compared to the older adults 









































significantly associated with plasma 25(OH)D concentration (p = 0.003, p = 0.033, p = 0.046, 
respectively). Participants who had a normal BMI range and the overweight BMI range had 
significantly higher serum 25(OH)D concentration compared to obese individuals (p < 0.001). 
 
Table 4.3 Plasma 25(OH)D, concentration by sun exposure, demographic, dietary  and 
anthropometric variables at baseline (n=339) 
 





Sun exposure variables     
     Frequency of sun exposure     
        Often 240 35.0 (18.8) 0.185 
        Occasionally 67 30.7 (16.9)  
        Seldom/never 27 30.2 (19.2)  
     Use of sunblock    
         No 319 33.2 (16.2) 0.756 
         Yes 20 34.9 (18.3)  
     Sun exposure  season2     
        Winter (Oct – Mar) 235 32.5 (15.3) 0.043 
        Summer (Apr – Sep) 104 36.6 (17.6)  
     Season of blood sampling     
       Winter (Oct – Mar) 238 36.7 (19.1) 0.035 
        Summer (Apr – Sep) 101 41.5 (19.4)  
     Holiday visits     
        No 244 32.0 (19.7) 0.003 
        Yes 95 38.5 (18.6)  
     Length of holiday visits    
        < 2 weeks  58 35.8 (16.7) 0.147 
        > 2 weeks  37 42.3 (19.9)  
     Fitzpatrick skin type    
        Type I & II 113 30.1 (15.9) 0.002 
        Type III 164 40.82 (19.4)  
        Type IV & V 57 40.92 (22.9)  
     Skin exposure area    
        < Median (6% of total body area) 196 33.6 (15.6) 0.782 
        > Median  143 34.0 (16.3)  
    
Demographic, dietary  and     
anthropometric variables 
   
     Gender    
        Male 175 36.5 (18.6) 0.003 















Table 4.3 continue  





     Age categories    
        1 st quartile (< 71.5 yrs) 84 34.3 (15.3) 0.033 
        2nd quartile (71.5 – 74.0 yrs) 86 36.2 (16.9)  
        3rd quartile (74.1 – 77.1 yrs) 86 35.3 (16.3)  
        4th quartile (>77.1 yrs) 83 29.33(15.2)  
     Body Mass Index (kgm-2)    
        Normal (18.50 – 24.99) 110 40.74 (19.4) <0.001 
        Overweight (25.00 – 29.99) 165 40.54 (20.0)  
        Obese (> 30.00) 64 27.7 (12.2)  
     Dietary vitamin D intake (µg/day)    
        < Median  (3.22) 165 32.0 (17.9) 0.046 
        > Median   165 35.7 (19.7)  
     Dietary calcium intake (mg/day)    
        < Median  (767.9)   165 34.2 (19.6) 0.762 
        > Median  165 33.5 (20.1)  
1 One way ANOVA for the variables that had more than two categories and  Student’s t-test for the 
variables that had two categories with Bonferroni post-hoc comparison  
2 Significantly different from skin types 1& II   
3 Significantly different from1st, 2nd and 3rd quartiles 
4 Significanly different from obese individuals  
 
 
Table 4.4 presents the total predictors (demographic, dietary and anthropometric variables) 
and sun exposure predictors of plasma 25(OH)D concentration at baseline. Only 59 
individuals completed the sun exposure questionnaire covering the sun exposure details 
during summer months. BMI and gender, explained 6.5% of the variance in baseline plasma 
25(OH)D concentration. Female gender was a negative predictor of baseline plasma 25(OH)D 
while BMI was a positive predictor of baseline plasma 25(OH)D concentration. However, in 
this multivariate model SES, dietary calcium intake, vitamin D intake, age, FFM and FM 








Table 4.4 : Total predictors1 of plasma 25(OH)D concentration in older adults at baseline2 (n=59) 
Total predictors  B SE β p CI 
R2 0.065      
Constant 123.76      
    Body Mass Index (kgm-2)  -1.105 0.701 -0.208 0.030 -2.769 – 0.163 
    Male  Reference      
       Females  -6.790 0.500 -0.179 0.024 18.29 – 251.50 
   Dietary calcium intake (mg/day)  -0.001 0.003 -0.022 0.706 -0.012 – 0.013 
   Dietary vitamin D intake (µg/day)  0.667 0.719 0.129 0.358 -0.777 – 2.111) 
   Age  -0.649 0.679 -0.140 0.344 -2.015 – 0.716 
   Sun Exposure Score   -0.530 1.226 0.066 0.667 -1.933 – 2.993 
   Fat Free Mass (kg)  -0.248 0.526 -0.137 0.639 -1.306 – 0.810 
   Fat Mass (kg)  -0.097 0.826 -0.039 0.907 -1.757 – 1.562 
1 Sun exposure, dietary, sociodemographics and anthropometric variables,  
2Stepwise multiple linear regression.  
Independent variables were Body Mass Index,, Fat Mass Index,, Fat Free Mass, gender, age, dietary calcium intake, dietary vitamin D intake, Sun Exposure Score
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4.3.3 Relationship between plasma 25(OH)D concentration, sun exposure, demographic, 
dietary and anthropometric variables after supplementation  
Table 4.5 illustrates the mean plasma 25(OH)D concentration by cumulative SES, 
demographic, dietary and anthropometric variables by the dose of vitamin D supplementation 
at the end of total supplementation. Older adults who had high BMI value had significantly 
lower plasma 25(OH)D concentration than the other counterpart, irrespective to the dose of 
vitamin D supplementation. Older adults who had the highest vitamin D intake was associated 
with high serum 25(OH)D only in high dose group. SES was not associated with serum 
25(OH)D concentration in any of the dose groups.  
Figure 4.2 shows percentage of  participants with serum 25(OH)D concentration below 
threshold of vitamin D status according to vitamin D supplementation groups. Plasma 
25(OH)D concentration was significantly associated with the dose of supplementation 
(p<0.001), which showed the highest value for the high dose group. After the supplementation 
mean plasma 25(OH)D concentration was 66.1 (SD 17.8) nmol/L and only 1 person (0.03% 
of the population) was vitamin D deficient according to the UK cutoff of VDD (25 nmol/L) in 
low dose group. None of the older adults were vitamin D deficient according to UK cutoff of 
vitamin D deficiency in 24000 IU and 48000 IU dose groups.  After total supplementation, 
12.9 % of the population and 5.5% of the population were vitamin D deficient according to 







Table 4.5 : Relationship between cumulative sun exposure, demographic, dietary and anthropometric variables and plasma 25(OH)D 
concentration by the dose of supplementation after 12 month supplementation.  
Variables Post intervention plasma 25(OH)D concentration (Mean (SD)) 
 n Total sample n 12000 IU  n 24000 IU  n 48000 IU 
Mean 25(OH)D (SD) 308 66.2 (17.8) 102 54.7 (14.6) 104 65.0 (15.2) 102 78.8 (14.8) 
P value    < 0.0011 
Sun Exposure Score     
     < Median (10.5) 140 66.2 (18.2) 43 53.6 (15.2) 49 64.2 (14.5) 48 76.1 (15.2) 
     168 65.9 (17.5) 59 55.3 (14.3) 55 65.4 (15.9) 54 77.9 (14.6) 
Age (years)   
      
     1stquartile (< 72.5) 77 64.6 (21.5) 29 53.3 (13.7) 25 60.9 (19.9) 23 83.0 (20.0) 
     2ndquartile (72.5–75.0) 77 67.0 (17.6) 25 54.7 (16.0) 29 68.1 (12.7) 23 79.0 (16.0) 
     3rdquartile (75.1– 78.1) 77 65.6 (14.9) 27 57.6 (15.0) 27 64.8 (13.0) 23 75.6 (10.4) 
     4th quartile (>78.1) 76 67.1 (16.9) 20 51.7 (13.9) 23 65.1 (14.4) 33 77.9 (11.9) 
P value2  0.792  0.555  0.395  0.405 
Gender   
      
     Males 158 65.4 (17.1) 52 54.1 (15.3) 55 65.2 (14.2) 51 77.1 (13.9) 
     Females 150 66.8 (18.5) 50 55.3 (14.1) 49 64.5 (15.3) 51 80.3 (15.7) 
P value2  0.251  0.667  0.805  0.282 
Vitamin D intake (µg/day)         
     < Median (5.5) 154 66.0 (19.0) 54 53.7 (13.3) 54 64.6 (15.4) 46 82.2 (16.9) 
     > Median  150 66.4 (16.5) 45 56.2 (16.1) 49 65.1 (15.2) 56 75.8 (12.4) 
P value2  0.855  0.399  0.880  0.029 
Calcium intake (mg/day)   
      
     < Median (768.9) 154 66.4 (19.4) 49 54.7 (15.6) 58 63.1 (15.9) 47 82.3 (16.6) 
     > Median  154 65.9 (16.1) 53 54.5 (13.9) 46 67.2 (14.1) 55 75.8 (12.7) 
P value2  0.825  0.955  0.184  0.024 
BMI (kgm-2)         
     Normal (18.50 – 24.99) 109 70.0 (17.3) 41 58.2 (13.7) 30 70.3 (15.1) 38 82.5 (13.2) 
     Overweight (25.00 – 29.99) 143 65.8 (18.2) 47 52.9 (15.4) 51 65.7 (12.9) 45 79.3 (16.2) 
     Obese (> 30.00) 56 59.0 (15.3) 14 49.8 (13.1) 23 55.9 (16.4) 19 69.5 (10.6) 
P value3  0.001  0.102  0.002  0.006 





Figure 4.2 :  Percentage of  participants with serum 25(OH)D concentration 


































Vitamin D supplementation doses
< 25.0 nmol/L < 50.0 nmol/L
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Table 4.6 shows the anthropometric, demographic, dietary and sun exposure predictors of the 
endpoint plasma 25(OH)D concentration. The contributors to the explained variance of the 
endpoint plasma 25(OH)D concentration of the total sample were the dose of 
supplementation, baseline plasma 25(OH)D, FFM and BMI which, collectively contributed 
56.7% of the variance of the endpoint plasma 25(OH)D. Baseline plasma 25(OH)D 
concentration and FFM were the significant predictors for the endpoint plasma 25(OH)D  
concentration in low dose group which explained 59.9% of the variance of 25(OH)D 
concentration. Baseline plasma 25(OH)D concentration and BMI were the predictors of 
plasma 25(OH)D concentration in medium dose group. Those variables explained 38% of the 
variation in endpoint serum 25(OH)D concentration. Similarly,baseline plasma 25(OH)D 
concentration, BMI and vitamin D intake were the predictors of endpoint plasma 25(OH)D 
concentration in 48000 IU dose group which explained 24.9% of the variability of the 
endpoint plasma 25(OH)D concentration.  The variance explained by the models were 
decreased with increasing dose of vitamin D supplementation. SES was not retained in the 




























Table 4.6 Predictors of plasma 25(OH)D concentration after 12 months supplementation by the dose of supplementation* 
  
B SE β p CI 
Total predictors  
 
Plasma 25(OH)D 
Total sample (n=308)       
R2 56.7 
    
 
Constant 71.31 
    
 
     48000IU dose 
 
26.04 1.688 0.688 <0.001 22.92 – 29.36 
     24000 IU dose  12.15 1.687 0.322 <0.001 8.881 – 15.47 
     12000 IU dose  Reference     
     Baseline 25(OH)D (nmol/L)  0.397 0.036 0.433 <0.001 0.326 - 0.468 
     Fat Free Mass (kg) 
 
-0.252 0.070 -0.145 <0.001 -0.390– (-0.114) 
     Body Mass Index (kgm-2) -0.659 0.189 -0.146 <0.001 -1.02 – (-0.290) 
       
12000IU dose group (n=102)       
R2 59.9      
Constant 48.91      
     Baseline 25(OH)D (nmol/L)  0.567 0.05 0.736 <0.001 0.469 – 0.666 
     Fat Free Mass (kg)  -0.341 0.107 -0.206 0.002 -0.553 – (- 0.129) 
24000 dose group (n=104) 
     
 
R2 38.0 
    
 
Constant 84.82 
    
 
     Baseline 25(OH)D (nmol/L)  0.337 0.060 0.453 <0.001 0.218 – 0.456 
     Body Mass Index (kgm-2)  -1196 0.294 -0.328 <0.001 -1.779– (-0.612) 
48000 dose group  (n=102) 
     
 
R2 24.9 
    
 
Constant 96.5 
    
 
     Baseline 25(OH)D (nmol/L)  0.239 0.071 0.304 <0.001 0.097 – 0.381 
     Body Mass Index (kgm-2)  -0.938 0.338 -0.256 0.006 -1.620 – (- 0.277) 
     Vitamin D intake (µg/day)  -1.191 0.554 -0.191 0.034 -2.291 – (-0.091) 
*Stepwise multiple linear regression, Endpoint plasma 25(OH)D concentration was the independent variable while Body Mass Index, gender, age, dietary calcium intake, 
dietary vitamin D intake, cumulative SES were the dependent variables
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4.3.4 Relationships between plasma 25(OH)D concentration and PTH concentration  
Figure 4.3 shows the relationships between plasma 25(OH)D and PTH concentration in males 
and female at baseline (r = -0.323, p = <0.001 and r= -0.344, p <0.001, respectively). In both 
cases, there was a clear significant negative relationship between plasma 25(OH)D 
concentration and the PTH concentration. Similarly, figure 4.4 shows the negative 
associations between 25(OH)D concentration and the PTH concentration for both males and 
females after the total supplementation. 
 










Figure 4.3 : Relationship between plasma 25(OH)D concentration and PTH 
concentration in males (A) females (B) at baseline 
R = - 0.323, p = < 0.0001 
Plasma 25(OH)D concentration. = -0.291 (PTH) + 54.91 
 
R = - 0.344, p <0.0001 














Figure 4.4 : Relationship between plasma 25(OH)D concentration PTH concentration in 
males (A) and females (B) after the supplementation 
R = -0.281, p < 0.0001 
Plasma 25(OH)D concentration =  -0.247 (PTH) + 76.85 
R = -0.288, p  < 0.0001 
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Table 4.7 : Linear regression analysis between plasma 25(OH)D and PTH concentration 
before and after the supplementation by gender 
 
 Constant Regression 
coefficient for 
PTH conc. 
SE P  
At baseline      
     Males 54.91 -0.291 3.23 <0.001 
     Females   47.32 -0.247 32.11 <0.001 
     
After 
supplementation  
    
     Males 75.35 -0.226 2.977 <0.001 
     Females   76.85 -0.247 3.221 <0.001 
 
 
According to table 4.7, there was a negative significant relationship between plasma 25(OH)D 
and PTH concentration for both before and after the supplementation and for both males and 
females. The regression coefficient was approximately similar for both males and females.  
 
4.4 Discussion 
4.4.1 Main findings  
The aim of this study was to quantify the impact of cumulative sun exposure on plasma 
25(OH)D concentrations in older adults supplemented with monthly doses of 12000 IU, 
24000 IU and 48000IU vitamin D3 for one year. BMI and gender were the predictors of 
plasma 25(OH)D concentration before vitamin D supplementation while the dose of vitamin 
D supplement, baseline 25(OH)D concentration, FFM and BMI were the main predictors of 
plasma 25(OH)D concentration after the vitamin D supplementation in the total sample. None 
of the sun exposure variables predicted of plasma 25(OH)D concentration before and after the 
supplementation  in all dose groups.  
4.4.2 Interpretation of the main findings   
Change in plasma 25(OH)D concentration  
After 12 months supplementation, the plasma 25(OH)D concentrations in low, medium and 
high dose groups were increased in dose-dependent manner. The increase in plasma 25(OH)D 
concentration of 12000 IU, 24000 IU and 48000 IU dose groups were 14.3 (SD 12.6), 25.3 
(SD 18.0) and 40.9 (SD 19.8) nmol/L, respectively which were significantly higher than the 
baseline values of each dose group.  According to a past study of vitamin D supplementation 
in adult women aged 40-55 years whose the baseline serum 25(OH)D concentration was less 
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than 62 nmol/L (25 ng/mL) who were supplemented with 1000 IU of daily vitamin D for 12 
weeks showed 25 nmol/L (10 ng/mL) increase in serum 25(OH)D concentration was seen. 
Approximately this was a 1 nmol/L increase with the intake of 1 µg supplemental vitamin D. 
This  study too reported 1 nmol/L increase in plasma 25(OH)D concentration with 1 µg intake 
of vitamin D  (Aspray et al., 2018).  Similar increases in serum 25(OH)D concentrations are 
reported by some other studies of older adults (Vaes et al., 2018, Brooks and Greene-
Finestone, 2017, Zhu et al., 2010).  O’Sullivan et al., 2019, reported 0.6 nmol/L increase in 
plasma 25(OH)D concentration, with 1 µg of supplemented vitamin D in Irish adults whose 
median age was 44 years. Another study conducted using postmenarchal adolescents who 
were supplemented with 150000 IU  every 3 months for a one year period showed the serum 
25(OH)D concentration increased from 19 to 57 nmol/L after supplementation period. 
Approximately this increase is 1 nmol/L of serum 25(OH)D with the intake of 1 µg of vitamin 
D intake per day (Ward et al., 2010). The increase in plasma 25(OH)D concentration in this 
study participants was similar to the increase of plasma 25(OH)D with the younger 
participants who supplemented with the same amount of vitamin D. In 12000 IU and 24000 
IU dose groups 16% and 5.5% of the participants were vitamin D deficient according to the 
US cutoffs of vitamin D deficiency. In 48000 IU dose group none of the study participants 
was vitamin D deficient for any of the cutoff values. Therefore this study revealed that 48000 
IU dose is successful in improving plasma 25(OH)D concentration in older adults.  
Mean plasma 25(OH)D concentration of older adults of this study at baseline was 38.2 (SD 
19.2) nmol/L which was comparable with recent studies conducted in the UK recruiting older 
adults (Granic et al., 2015). This study  further demonstrated that the increase in plasma 
25(OH)D concentration among older adults whose baseline 25(OH)D concentration less than 
25 nmol/L was higher than the older adults whose baseline 25(OH)D concentration less than 
50 nmol/L, which was reported by some previous studies as well (Whiting et al., 2015, Ross 
et al., 2011). Low prevalence (only one person) of VDD in this study after the 
supplementation (according to SACN cutoff of < 25(OH)D nmol/L), implicated the success of 
the vitamin D supplementation programme in maintaining appropriate serum 25(OH)D 
concentration in older adults. According to the Public Health England Survey, conducted in 
2016/2017, 27% of older adults aged 65 years and over had a serum 25(OH)D concentration 
below 25 nmol/L (NDNS, 2019) which is very similar to the value reported by our study 
(29%). Therefore sample of older adults in our study is approximately similar to the 
representative sample of older adults in the UK. 
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Association of sun exposure and plasma 25(OH)D concentration  
Since the SES score was not associated with plasma 25(OH)D throughout the study, one 
could tentatively conclude that supplementation was more successful than sunshine exposure 
in improving vitamin D status of older adults.   However, the use of this questionnaire like all 
others in the literature are crude measures of sun exposure and do not fully capture the 
complexity of personal sun exposure over time.   This argument is further supported by the 
work of SACN who were unable to quantify the relative contribution of sunshine exposure to 
vitamin D status for the UK population in their DRV report.   In chapter 3 (RCT) I have 
provided a detailed overview of the impact of vitamin D supplementation dose on 25(OH)D 
concentrations as well as maintaining adequate vitamin D status after 12 months using a 
number of commonly reported cut-offs.   The results from this chapter appear to suggest that 
in addition to supplementation, BMI and gender also influence 25(OH)D concentrations at 
baseline and after 12 months.  Making any direct comparisons of the relative contribution of 
these predictors to sunshine exposure should be made with caution for the aforementioned 
reasons. 
In contrast to our findings, a study conducted in Dublin (530N) reported that daily ambient 
UVB dose was more effective in improving plasma 25(OH)D concentration compared to 
vitamin D supplementation in Irish adults who supplemented with 200 IU/day of vitamin D3 
for one year (O’Sullivan et al., 2019).  Methods used to assess sun exposure and the dose of 
vitamin D supplements might be attributed to this inconsistent finding. UVB radiation dose of 
the area using the data from weather station was used by O’Sullivan et al., 2019, which is 
different from the personal ambient UVB radiation dose. In our study we used sun exposure 
questionnaire to gathered the data about personal sun exposure. The doses that used in our 
study were correspondent to 400 IU/day, 800 IU/day and 12000 IU/day, which was higher 
than the dose used by O’Sullivan et al., 2019 (200 IU/day). Because of these disparities,  the 
findings of two studies cannot be compared. 
Thought the holiday visits and dark skin types were associated with baseline plasma 25(OH)D 
concentration, SES did not associated with the serum 25(OH)D concentration.  Low 
predictive ability of plasma 25(OH)D concentration by SES in this study might be attributed 
to the limitation of the sun exposure questionnaire which had vague questions about the sun 
exposure habits. In addition, some sun exposure related variables were not captured by this 
questionnaire such as time of the day of sun exposure, clothing, duration of sun exposure, the 
frequency of sunblock usage and SPF factor. 
 
   
118 
The positive association of dark skin and plasma 25(OH)D concentration at baseline reported 
in this study was unexpected. Literally, dark skin has more melanin that blocks the 
penetration of UVB radiations to the skin, thus reduce the synthesis of vitamin D (Chen et al., 
2007).  In the same study they stated that the dark-skinned individuals had the highest 
threshold for synthesizing detectable previtamin D3 resulting in high vitamin D status 
compared to the fair-skinned individuals. Contradictory finding in this study might be 
attributed to the limitation of Fitzpatrick skin types in determining melanin density (Eiler et 
al., 2013). In this study the majority of the individuals who had dark skin types were males 
(55%) and they had better vitamin D status compared to females. Therefore, positive 
association of fair skin and plasma 25(OH)D concentration might be hidden by being males. 
On the other hand, dark-skinned people might stay in sunlight for a long time period without 
applying sunblock which facilitates vitamin D synthesis.  Some previous studies too reported 
the positive association between dark skin types and the vitamin D status (Touvier et al., 2015 
et al, Ginter et al., 2013, Bogh et al., 2010).  
Wider determinants of plasma 25(OH)D concentration 
Some previous studies showed the positive association of vitamin D intake and serum 
25(OH)D concentration in older adults (Bertrand et al., 2010, McCullought et al., 2010). 
According to the ANOVA analysis vitamin D intake was positively associated with plasma 
25(OH)D concentration before supplementation. However, this finding was not confirmed by 
the regression analysis, before and after the supplementation. Recent few studies on older 
adults and adults have also reported the similar null finding of the association of vitamin D 
intake and 25(OH)D concentration (Gungert and Berthold 2015, Freedman et al., 2013, 
Hedlund et al., 2013). Very low vitamin D intake (3.8 (SD 2.6) µg/day) by our study 
participants might be the reason for this null finding (Thuesen et al., 2012). In this study, 
similar to some previous studies, BMI, age and gender were also played the role in predicting 
baseline plasma 25(OH)D concentration (Buyukuslu et al., 2014, Freeman et al., 2013). The 
negative association of FFM and BMI plasma 25(OH)D concentration was not masked by the 
vitamin D supplements. 
Relationship between 25(OH)D and PTH concentration  
Many studies in older adults reported the negative association of serum 25(OH)D 
concentration and PTH concentration (Chang et al., 2017, Jungert and Neuhauser-Berthold, 
2015, Arabi et al., 2012) similar to this study.  Age, gender, ethnicity, sex hormone level, 
calcium status and kidney function are some of the factors that significantly associated with 
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PTH concentration in previous studies (Hill et al., 2010, Adami et al., 2008). However, a 
positive association of PTH concentration and gender before or after the supplementation was 
not reported in this study.  
4.4.3 Strengths and limitations of the study 
To our knowledge, this is the first study that determined the relationship between cumulative 
sun exposure and plasma 25(OH)D concentrations in a RCT of a large group of free-living 
older adults at a Northern latitude, where cutaneous production of vitamin D is not possible 
all year around. Standard intervention with relevant doses, which corresponds to 400, 600 and 
1200 µg of dietary vitamin D per day, using randomized double-blind study design in both 
men and women are also strengths and novel aspects in this study. Determining the effect of 
one-year cumulative sun exposure added a novelty to this study. Use of a wide range of 
variables such as sun exposure, dietary, anthropometric, socio-demographic, biochemical that 
associated with 25(OH)D concentration was an added advantage to this study. The RCT 
design used in this study provide the strong design to test the impact of sun exposure 
behaviors on vitamin D status since the bias introduced by “as-needed” supplement taking is 
minimized.   
This study had a few limitations. Estimation of UVB radiation exposure by self-reported sun 
exposure questionnaire was the main limitation of this study. True ambient UVB radiation of 
the older adults might be underestimated by the sun exposure questionnaires. Also this 
questionnaire did not include the questions about the duration of sun exposure, details about 
sunblock usage, time of the day of the sunlight exposure and sun protection habits. Also 
personal sun exposure measured during the past year at five time point might not reflect the 
true ambient UVB exposure of the whole year. In addition, older adults were selected for this 
study from the GP’s registry, thus older adults who were more health conscious might 
participated in the study. Therefore, there was a healthy selection bias and selected older 
adults might not represent the general population in the UK. Further, the vitamin D status was 
measured only at baseline and at the end of the supplementation, which does not reflects the 
year-round vitamin D status of the older adults. Therefore it might not accurate to determine 
the association between plasma 25(OH)D concentration which measured at two-time points 
and cumulative sun exposure data of the whole year.  
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4.4.4 Public Health implications and future studies  
This study highlights that vitamin D supplementation was powerful in improving vitamin D 
status in older adults compared to the sunlight exposure. This study opens a debate on the 
recommendation for sun exposure and vitamin D supplementation in older adults. The 
positive effect of vitamin D supplementation on plasma 25(OH)D concentration compared to 
sun exposure in older adults was an important finding in this study. This finding can be used 
in future studies of determining the required oral dose of vitamin D for older adults to 
optimize the vitamin D status.  However, future studies are needed for accurate measurements 
of personal sun exposure the tools such as dosimeters. Further, recruiting the representative 
sample of older adults in the UK is necessary in order to establish accurate guidelines for sun 
exposure. Also as the sun exposure guidelines are widely differed according to the skin types. 
However the Fitzpatrick skin type classifications have some limitations in assessing melanin 
density, therefore futures studies are needed with accurate methods of determining the 
melanine density.  
 
4.4.5 Conclusions 
Gender and BMI were the negative predictors of plasma 25(OH)D concentration, while 
baseline plasma 25(OH)D concentration, the dose of vitamin D supplementation, FFM and 
BMI were the positive predictors of plasma 25(OH)D concentration after the total 
supplementation. The sun exposure score did not predict endpoint plasma 25(OH)D in any of 
the dose groups, before or after the supplementation. Therefore doses of vitamin D 
supplementation was more effective in improving vitamin D status of older adults compared 
to the sun exposure.  In addition, baseline plasma 25(OH)D concentration, gender, FFM and 
BMI were more prominent factors that contributed to vitamin D status in older adults 






   
121 
Chapter 5 : Serum 25(OH)D Concentrations in Relation to Sunlight 
Exposure, Lifestyle Factors and Musculoskeletal Outcomes in Biomarker of 
Risk of Colon Cancer Study (BORICC) Follow-up (BFU) study 
5.1 Introduction  
Muscles and bones are two major components of the MSK system that is essential for body 
structure, strength and movement. During aging, bone and muscle mass reduce which cause 
poor QOL (Atlantis et al., 2008). The balance between bone synthesis and bone resorption is 
altered with the relative increase in resorption during aging (Szule, 2006). Similarly, the 
changes in muscle mass and function get reduce during aging (Mitchell et al., 2012). There is 
a substantial literature that links serum 25(OH)D concentration (the widely-accepted marker 
of vitamin D status) and MSK outcomes (Dawson-Hughes, 2008). However, older adults are 
at high risk of VDD as a result of the poor dermal capacity of vitamin D synthesis (Gennari, 
2001) and low dietary intake of vitamin D (Bailey et al., 2010). Therefore vitamin D is a 
particularly important critical nutrient for older adults. In addition to vitamin D status, age, 
gender, body composition, physical activity, ethnicity and genetics affect the MSK outcomes 
in older adults (Assunção et al., 2017, Tyrovolas et al., 2015). 
Muscle depletion is one of the body composition changes which occurs in cancer patients. 
Muscle depletion of cancer patients is characterized by a reduction in muscle size and 
increased infiltration by inter and intramuscular fat, called myosteatosis (Fearon et al., 2011). 
It is reported that the incidence of muscle depletion varies from 15 to 70 % for patients treated 
for CRC (Martin et al., 2013). It has been identified that vitamin D plays a preventive role in 
CRC (Woolcott et al., 2010). A review of case-controlled studies has established that there is 
an inverse relationship between serum 25(OH)D concentration and the incidence of polyps 
and adenomas in the colon (Moon et al., 2013). Similarly, dietary vitamin D3 intake and 
sunlight exposure were lower in CRC patients compared to controls in a case-control study  
reported by Robsahm et al., (2004). Similarly, Ng et al., (2008) reported that higher vitamin 
D3 concentration was associated with lower CRC incidence, reduced polyp recurrence and 
better overall survival of CRC patients.  
Similar to muscle health, nearly all cancers can have significant negative effects on the 
skeleton. Cancer is a major risk for both generalized and local bone loss, independent of 
cancer type (Reuss-Borst et al., 2012). Cancer-associated bone loss is the result of multiple, 
inter-related factors. These include both the direct effects of cancer cells and the effects of 
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therapies used in cancer treatment. Further, the skeleton is also the most common site of 
metastatic disease, as cancer cells grow within the bone, induce osteoblasts and osteoclasts to 
produce factors which stimulate further cancer growth. Accordingly, the optimal management 
of skeletal health is important for cancer patients, for their survival and longevity (Ng et al., 
2008). 
Quantitative Ultrasound (QUS) is a convenient and widely used screening tool for 
osteoporosis (Hien et al., 2005). Two parameters generated by QUS are the Speed of Sound 
(SOS) and the Broadband Attenuation (BUA). The SOS is the division of transmission time 
of the sound waves by the bones and broadband attenuation of sound refers to the slope 
between attenuation of sound signals and its frequency. Attenuation occurs because the 
energy is absorbed by the soft tissue and bone when the sound waves travel through them. 
Stiffness Index (SI), is derived from the above basic measurements, by the most sophisticated 
QUS equipment (International Osteoporosis Society, 2001). Therefore SOS, BUA and SI are 
associated with BMD. Thus are used as the measures of fracture prediction (Chin and Ima-
Nirwana, 2013). Heel bone qualitative ultrasound scanner is widely used equipment to 
measure SOS, BUA and SI in Os Calcis (Hien et al., 2005). Similarly, to assess muscle 
functions, many studies used TUG test and GS. Both these tests are recommended to use as 
the measures of muscle function in the elderly (Bohannon, 2001, Podsiadlo et al., 1991). GS 
is considered as a tool to assess the upper extremity muscle function (Bohannon, 2008) and 
presence of sarcopenia (Cruz-Jentoft et al., 2010), while TUG test is considered as a measure 
of the lower extremity muscle function (Bohannon, 2008).  
Sun exposure habits such as frequency and duration of sun exposure, holiday visits, season, 
sunblock use and sun avoidance habits have been demonstrated as the factors that associated 
with the serum 25(OH)D concentration (Mei et al., 2017, Kimlin et al., 2014). In addition, 
demographic characteristics, BMI, body composition, and dietary intake of vitamin D are also 
associated with serum 25(OH)D concentration (Kimlin et al., 2014, Freedman, 2013). The 
latest findings on the impact of those factors on serum 25(OH)D in older adults who are at 
risk of colon cancer in the UK are relatively limited.  
Therefore, we hypothesised that there is a positive relationship between serum 25(OH)D 
concentration,  MSK outcomes and sun exposure variables in older adults who are at 
moderate risk of CRC. Therefore, the aims of present study were; 
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1) to identify the association between serum vitamin D status and  MSK outcomes in 
older adults 
2) to identify the association between the sun exposure behavious, and vitamin D status 
in free-living older adults who are at moderate risk of CRC.  
Objectives of this chapter of the PhD thesis were; 
1) to investigate relationships between sun exposure behaviours and serum 25(OH)D 
concentration in participants in the BFU study. 
2) to investigate the relationship between serum 25(OH)D concentration and muscle 
function in participants in BFU study. 
3) to investigate the relationship between serum 25(OH)D concentration and bone health  
in older adults in BFU study. 
5.2 Methods  
5.2.1 Participants’ selection 
Participants were recruited from those who had taken part in the original Biomarkers of Risk 
of Colon Cancer (BORICC) Study 1 and 2 approximately 12 years ago. In the BORICC 
Follow-Up (BFU) Study, participants who met the inclusion criteria (section 5.2.2) were sent 
invitation letters and those individuals who were interested in taking part in the study were 
asked to contact the research team by telephone or by email. During the telephone calls, 
participants were given a time and date for the study visit at the North Tyneside General 
Hospital (NTGH). If the participant requested further information about the study, they were 
invited to participate in the “show-case” event which was a one-hour session that described all 
the aspects of the study.  Study packs including a FFQ, sun exposure questionnaire and 
physical activity questionnaire, were sent to participants by post, 2 weeks prior to their study 
visits. According to the power calculation of BFU study in detecting an association between 
25(OH)D and muscle function, considering 95% confidence interval, 5% margin error and 2.8 
kg of GS difference, 385 participants would be needed. Further details about the recruitment 
of participants are described in 2.3 and 2.4 under Chapter 2.  
5.2.2 Inclusion and exclusion criteria  
All individuals who participated in the original BORICC study 1 and BORICC study 2 were 
eligible for this study. Exclusion criteria included: actively undergoing chemotherapy or 
radiotherapy treatment, being unable to provide consent or being unable to attend the study 
center at NTGH.  
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5.2.3 Ethical approval, funding and sponsorship 
A favorable opinion for the study was obtained from the West Midlands – Coventry & 
Warwickshire Research Ethics Committee (REC reference 16/WM/0421). All study 
procedures were conducted according to the guidelines laid down in the declaration of 
Helsinki. Informed consent to review medical records, collect blood and other biological 
samples, obtain dietary, lifestyle, sun exposure, anthropometric and physical capability data 
was obtained from all participants. Sample collection and participant recruitment were funded 
by the MRC as part of the Centre for Ageing & Vitality (Ref: MR/M501700). Sponsorship of 
the study was provided by the Northumbria NHS Foundation Trust, Research Support Unit.  
5.2.4 Sunshine exposure, dietary intake, anthropometry and demographic variables 
All questionnaires were posted to the participants two weeks prior to the study visit. During 
the study visits in the NTGH, all questionnaires, including sun exposure questionnaire and 
FFQ were checked for the missing or incomplete details by a member of the research team 
and corrections were made, if necessary.  
Demographic and medical information 
Age, gender, ethnicity and date of birth were gathered using the questionnaires that used to 
gather information about sun exposure, medical and health history.  Past medical history of 
the participants was collected by face to face discussion with the participants using a short 
“Patient Health History Questionnaire” (Annexure F) by a medical practitioner. Presence or 
absence of selected disease conditions, date of diagnosing, the stage of the diseases and the 
medications given were recorded in this questionnaire. 
Body weight, height and body fat %  
Body weight also measured using the TANITA TBF-300MA bio-impedance scale to the 
nearest 0.1kg and the measurement was taken only once. Body fat % was measured using the 
same scale to nearest 0.1 kg. Body height was measured using the Stadiometer (Seca) to the 
nearest 0.1 cm. Two height measurements were taken and the mean value was recorded. 
Sun exposure  
Sun Exposure Questionnaire (Annexure H) was used to gather information about sun 
exposure habits during the previous year. This questionnaire included the details about, 
gender, age, occupation (indoor or outdoor), Fitzpatrick skin type (I to V), frequency and 
duration of sun exposure, sun avoidance habits, clothing habits, use of sunblock, use of 
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sunbeds, details about mountain climbing/skiing, skin exposure area and details about holiday 
visits.  
Muscle function 
GS and TUG tests were used to assess the muscle function of the study participants. Portable 
hydraulic hand dynamometer (Jamar, 12-0240, SN 04201084, USA) was used to measure the 
GS. Three measures from each hand were taken and the mean value of all 6 values was used 
in the analysis. Time taken to walk 3 m distance in his/her usual speed was recorded as the 
TUG test. The test was performed three times and the mean value was considered for the 
analysis. Further details about muscle function tests were described in Chapter 2 under section 
2.4.5. 
Bone densitometry 
Heel bone ultra-sound scanner (Achilles, EXPII, UK) was used to measure the bone mass at 
the heel bone (Os Calcis) of the participants. BUA, SOS (m/sec) and SI were recorded twice 
in both right and left Os Calcis. Mean SOS, BUA and SI values were calculated from those 
four measurements.  Further details about bone densitometry measures were described in 
Chapter 2 under the section 2.4.11.  
Dietary intake  
Details about the habitual diet of the previous year were collected using the validated FFQ 
employed by the EPIC Study (Bingham et al., 1997) (Annexure J). This questionnaire 
consisted of commonly consumed 10 food groups and the participants were asked to record 
the frequency of consumption of those foods. 
Blood samples and biochemical analysis  
Random non-fasted venous blood samples were collected by venipuncture for the analysis of 
serum 25(OH)D and PTH concentration.  All the blood samples were collected from study 
participants from May 2017 to April 2018. Total serum 25(OH)D and PTH concentration 
were analysed by Roche method  and sandwich test principle of electrochemiluminescence 
technology, respectively in the Newcastle laboratories, Freeman Hospital, Newcastle upon 
Tyne. Further details of laboratory analysis of blood samples were described in chapter 2 
under  section 2.5.  
5.2.5 Data and statistical analysis  
SPSS statistical package for Windows version 24.0 was used for the data analysis. Older 
adults who used vitamin D supplements were also included in present analysis. Variables that 
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were not normally distributed were log transferred (natural log) to obtain normal or near 
normal distribution prior to statistical analysis. A P value less than 0.05 was considered 
statistically significant. Summary data were expressed as mean, SD, frequencies, percentages 
and bar graphs, as appropriate.  The one-way ANOVA was used to determine the differences 
between the means of demographic, biochemical, sun exposure and anthropometric variables 
that had three or more independent groups. Similarly, the student’s t - test was used to 
determine the differences between the means of demographic, biochemical, sun exposure and 
anthropometric variables that had two independent groups.  The Bonferroni test was used for 
post hoc comparisons between means. Partial and simple correlation analysis were performed 
to identify the relationship between serum 25(OH)D concentration, MSK function with and 
without adjusting for BMI and gender, respectively. Student’s t-test was used to compare 
measures of muscle function and bone health in those with serum 25(OH)D concentration 
above and below 50 nmol/L based on IOM classification of adequacy. ANCOVA was used to 
compare measures of muscle function and bone health in those with serum 25(OH)D 
concentration above and below 50 nmol/L based on IOM classification of adequacy, adjusting 
for the confounders.  
5.3 Results  
5.3.1 Basic Characteristics  
Table 5.1 shows the basic characteristics of the study participants. The proportion of males 
and females was equal in this study. Mean age and serum 25(OH)D concentration of the 
participants were 66.8 (SD 8.3) years and 66.3 (SD 28.8) nmol/L, respectively. Their GS and 
TUG tests values were 27.6 (SD 9.2) kg and 9.1 (SD 4.0) s, respectively.  The bone health-
related parameters, BUA, SOS and SI at the Os Calcis were 106.8 (SD 20.7), 1564.9 (SD 
40.7) m/sec and 91.0 (SD 18.9), respectively. Majority (48.9%) of the study participants had 
BMD according to the T score of the heel bone. Only 4% of older adults were in the category 
of risk for osteoporosis.The majority of the participants (61.7%) had a history of non-
communicable diseases (either hypertension, diabetes, cardiovascular diseases, cancer or a 
combination of these conditions). Out of 20 supplement users, 9 individuals used 
multivitamins which contained vitamin D. However the amount of vitamin D present in those 
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Table 5.1: Basic characteristics of BFU Study participants (n=47) 
Characteristics  Mean (SD) / n (%) 
     Age (years) 66.8 (8.3) 
     Gender (n (%))  
        Males 23 (48.9) 
        Females  24 (51.1) 
     Body Mass Index (kgm-2) 28.3 (4.7) 
     Weight (kg) 81.5 (17.6) 
     Height (cm) 169.2 (10.6) 
     Grip Strength (kg) 27.6 (9.2) 
     Timed – Up and Go test (s) 9.1 (4.05) 
     Broad Band Attenuation   106.8 (20.7) 
     Speed of Sound (m/s) 1564.9 (40.7) 
     Stiffness Index  91.0 (18.9) 
     T score at heel bone  -0.708 (1.43) 
         >-1.0 (% (n)) : Normal BMD 18 (38.3) 
         -1.0 – (-2.5) (% (n)) : Low BMD 23 (48.9) 
          < 2.5 (% (n)) : Risk for osteoporosis 4 (8.5) 
     Dietary vitamin D intake (µg/day)  3.0 (1.4) 
     Dietary calcium intake (mg/day) 891.5 (404.8) 
     Serum 25(OH)D conc. (nmol/L) 66.4 (28.8) 
     Plasma Parathyroid Hormones (PTH) conc. (Pmol/L) 4.5 (1.43) 
     Having a history of NCDs n (%) 
        Yes 29 (61.7) 
        No 18 (38.2) 
     Use of vitamin D supplements  
        Yes 20 (42.5) 
        No 27 (57.5) 
     Having polyps  
        Yes 10 (21.3) 
        No 37 (78.7) 




     Body fat % 29.7 (7.9)                   38.6 (5.4) 
     Waist Circumference  (cm) 102.4 (15.0)             90.7 (11.1) 
     Hip Circumference (cm) 106.3 (9.4)               103.8 (9.2) 
 
 
5.3.2 Factors associated with serum 25(OH)D concentration 
Table 5.2 presents the association between sun exposure variables, demographic, 
anthropometric, biochemical parameters and serum 25(OH)D concentration of the study 
participants. Having the holiday visit was the only sun exposure variable that had a significant 
relationship between serum 25(OH)D concentration, which showed the highest serum 
25(OH)D concentration among the holiday visitors (p=0.042). Older adults who used vitamin 
D containing supplements had the highest serum 25(OH)D concentration compared to non-
users (p=0.003).  
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Table 5.2: Association between sun exposure, demographic, anthropometric, dietary, 
biochemical parameters and total serum 25(OH)D concentration study participants 
Variables n (%) Serum 25(OH)D conc  
(nmol/L) 
P value1 
Blood collected season    
     Winter  22 (46.8) 59.4 (30.4) 0.124 
     Summer  25 (53.2) 72.4 (26.5)  
Frequency of outdoor activities     
    More than 2 times/week  13 (25.5) 60.1 (29.7) 0.370 
    Everyday 34 (74.5) 68.7 (28.5)  
Out-door duration at weekdays    
    < 2 hours 24 (46.8) 65.6 (33.1) 0.860 
    > 2 hours  23 (48.9) 67.1 (24.2)  
Out-door time at weekends    
    < 2 hours 14 (29.8) 77.1 (36.9) 0.163 
    > 2 hours  33 (70.2) 61.7 (23.8)  
Sun avoidance behaviours     
    Try to avoid direct sun 7 (14.9) 64.0 (26.8) 0.780 
    Sometimes stay in the sun 26 (55.3) 69.0 (27.5)  
    Enjoy staying in the sun 14 (29.8) 62.5 (33.4)  
Deliberately wear less clothes     
    Never/rarely 11 (6.4) 61.3 (35.9) 0.372 
    Sometimes 10 (21.3) 78.3 (17.4)  
    Usually 20 (42.6) 60.8 (22.1)  
    Always  6 (12.8) 73.8 (46.2)  
Use of sun cream    
     Yes 33 (25.5) 67.0 (26.9) 0.815 
     No 14 (74.5) 64.8 (33.9)  
Holiday visits    
    Yes 25 (53.2) 75.3 (31.9) 0.042 
    No 22 (46.8) 58.4 (23.7)  
Number of days of holiday visits    
     <15 days 17 (70.8) 73.2 (33.3) 0.700 
     >15 days 7 (29.2) 78.7 (25.1)  
Outdoor frequency during holidays    
    Often 19 (79.2) 75.3 (27.6) 0.184 
    Not often 5 (20.8) 55.0 (21.3)  
Skin type    
    Type I & II 11 (23.4) 64.2 (26.9) 0.728 
    Type III, IV & V 36 (76.6) 66.9 (27.5)  
Gender    
     Males 23 (48.9) 61.3 (29.7) 0.243 
     Females  24 (51.1) 71.2 (27.7)  
Body Mass Index (BMI)    
     Normal weight 14 (29.8) 77.4 (32.0) 0.087 
     Overweight and obese  33 (70.2) 61.6 (26.5)       
Age     
     <Median (67 years) 25 (53.2) 67.5 (27.4) 0.764 
     >Median 22 (46.8) 64.9 (30.9)  
Vitamin D supplement use     
     Yes 27 (57.4) 74.8 (30.1) 0.003 
     No 20 (42.6) 51.6 (23.6)  
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Table 5.2 continue…..    
Variables n (%) Serum 25(OH)D conc  
(nmol/L) 
P value1 
Vitamin D intake     
     <Median (2.74 µg/day) 23 (48.9) 67.4 (29.9) 0.806 
     >Median  24 (51.1) 65.3 (28.3)  
Parathyroid Hormones (PTH)     
     <Median (4.30 Pmol/L) 22 (46.8) 74.6 (31.9) 0.098 
     >Median  25 (53.2) 54.8 (24.5)  
History of  NCDs    
     Yes 29 (61.7) 67.8 (27.8) 0.654 
     No 18 (38.2) 63.9 (27.8)  
Presence of Polyps    
    Yes  10 (21.27) 58.6 (35.7) 0.130 
     No 37 (78.73) 68.4 (26.8)  
1ANOVA for the variables that had more than two categories, Student’s t test for the variables that had two 
categories 
 
Table 5.3 describes difference in serum 25(OH)D concentration of holiday visitors and non-
visitors in relation to socioeconomic status, dietary intake, supplement use and frequency of 
outdoor activities. This association remained the same after adjusting for the socioeconomic 
status, dietary intake, supplement use and frequency of outdoor activities. The association 
between serum 25(OH)D and holiday visits was not altered after adjusting for the 
socioeconomic status, dietary intake, supplement use and frequency of outdoor activities. 
Table 5.3 : Differences between holiday visitors and non-visitors in relation to 
socioeconomic status, dietary intake, supplement use and frequency of outdoor activities 
Characteristics  Holiday 
visitors  
Non-holiday visitors P value1 P value2 
Serum 25(OH)D concentration  75.3 (31.9) 58.4 (23.7) 0.042  0.047 
Index of Multiple Deprivation   6.9 (2.7) 6.6 (2.7) 0.667  
Dietary vitamin D intake 2.9 (1.3) 3.1 (1.5) 0.585  
Vitamin D supplement use     
     Yes 10 10   
     No 12 15 0.773  
Frequency of outdoor activities        
     30 min – 2 hours 9 5   
     >2 hours 13 20 0.201  
1 ANOVA 
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5.3.3 Factors associated with MSK outcomes 
Table 5.4 demonstrates the relationship between age, gender, PTH concentration, BMI, 
presence of polyps and MSK outcomes. GS and SI were significantly associated with age 
which showed the highest value for the young participants (p= 0.017 and 0.05, respectively). 
Except  TUG test, all parameters of MSK outcomes were significantly associated with gender, 
which reported the highest value for the males. Older adults who had the lowest PTH 
concentration had the highest GS. Though the BMI was not significantly associated with any 
of the MSK functions, Body fat percentage was significantly associated with GS which 
showed the highest GS value for the adults with a low-fat percentage. Only 17.3% of males 
had low GS compared to the reference value of 30 kg, while 45.8% of females had GS below 
the reference value of 20 kg (Bohannon, 2008). Similarly percentage of older adults who had 
TUG value higher than 10.85 s which is the cut-off value for sarcopenia (Martinez et al., 
2015) was 19.6%. Thirteen percent (n=3) of males and 25% (n=6) of females who had GS 
values below the reference range were older than 65 years and 70 years, respectively. 
Similarly, the relationships between musculoskeletal functions  (GS, TUG and SI) and  body 
fat percentage for males and females are illustrated in figure numbers 5.3, 5.4, 5.5, 5.6, 5.7, 
5.8, 5.9, 5.10 and 5.11. 
    






Table 5.4 : Factors associated with musculoskeletal function in BFU Study participants 
 GS TUG SI SOS BUA 
Age (years)      
    <Median (67.0) 30.5  (9.3) 8.7 (4.1) 96.1 (20.3) 1575.2 (44.2) 107.8 (25.6) 
    >Median 24.1  (7.9) 9.5 (4.0) 85.1 (15.6) 1553.1 (33.5) 105.4 (11.5) 
     P value  0.017 0.341 0.050 0.069 0.193 
Gender      
    Male 34.6 (7.0) 8.6 (2.4) 100.8 (18.2) 1579.9 (42.8) 112.6 (26.2) 
    Female 21.3 (5.7) 9.6 (5.2) 81.5 (14.4) 1550.6 (33.4) 100.8 (9.0) 
    P value1 <0.001 0.640 <0.001 0.014 <0.001 
PTH (Pmol/L)      
    <Median (4.30) 31.2 (10.3) 9.2 (4.1) 90.0 (15.9) 1559.0 (32.1) 110.2 (10.9) 
    >Median 24.5 (7.03) 8.9 (4.1) 91.9 (21.7) 1570.6 (47.5) 103.5 (25.9) 
     P value1 0.013 0.817 0.739 0.344 0.429 
Body Mass Index (kgm-2)      
     <Median (28.67) 26.9 (8.5) 8.9 (3.8) 89.2 (18.5) 1563.1 (40.1) 107.1 (12.3) 
     >Median 28.0 (9.9) 9.2 (4.4) 92.8 (19.5) 1566.8 (42.1) 106.3 (26.2) 
     P value1 0.687 0.858 0.527 0.760 0.419 
Body fat percentage (%)      
    <Median (35.5) 30.8 (8.5) 8.3 (2.1) 96.5 (21.0) 1574.9 (47.9) 107.9 (27.2) 
    >Median 24.8 (9.0) 9.8 (5.2) 86.2 (15.81) 1556.2 (31.6) 105.6 (11.1) 
     P value1 0.030 0.317 0.068 0.126 0.063 
Having polyps      
     Yes 29.1 (10.7) 9.4 (1.7) 91.4 (17.2) 1561.6 (33.4) 110.3 (13.6) 
     No 27.0 (8.7) 9.0 (4.5) 90.8 (19.6) 1565.8 (42.9) 105.7 (21.8) 
     P value1 0.525 0.816 0.934 0.775 0.536 








Figure 5.1 : Relationship between age and Grip Strength (GS) in males 
 
 




























































Reference   
range for males 
> 30 kg 
Reference   range 
for females : < 20 
kg 
R = -0.594 
P = 0.004 
R = -0.284 





























































Body fat percentage (%)
R = 0.076 
P = 0.745 
R = -0.244 
P = 0.262 
Healthy range for 
males : 13 – 24% 
Healthy range for 
females (23% - 34%)
 : 
24 – 35% 
Reference   range 









































































Body fat percentage (%)
Reference range 
for sarcopenia 
10.85 s  
P = 0.163 
R = 0.280 
P = 0.074 
R = 0.743 
Healthy range for 


































































Body fat percentage (%)
P = -0.291 
P = 0.179 
P = 0.076 
R = 0.745 
Healthy range for 
females : 24 - 35% 
Healthy range for 
males : 13 – 24% 
Reference GS range 








































































Body fat percentage (%)
P = -0.244 
R = 0.262 
P = 0.399 
R = 0.114 
Healthy range for 
females : 24 – 35% 
Reference range for 
females > 20 kg 
Healthy range for 









Figure 5.11 : Relationship between body fat % and Timed-Up and Go test in females 
 
5.3.4 : Relationship between MSK function and serum 25(OH)D concentration 
Table 5.5 illustrates the simple and partial correlations between MSK function and serum 
25(OH)D concentration. Both muscle health and bone health was not significantly associated 
with serum 25(OH)D concentration with or without adjusting for BMI, gender.  
 
Table 5.5 : Simple and partial correlations between serum 25(OH)D concentration and 
MSK function in older adults  
 
Variables  




Muscle function     
     Grip Strength (kg) 0.016 0.914 0.038 0.818 
     Timed Up and Go test (s) 0.193 0.200 0.119 0.465 
Bone health  









     Speed of Sound (m/s) -0.097 0.528 0.037 0.822 
     Broadband Ultrasound Attenuation -0.075 0.618 -0.045 0.781 

































Body fat percentage (%)
P = 0.176 
R = 0.421 
Healthy range for 






When the serum 25(OH)D concentration was dichotomized at 50 nmol/L (IOM criterion of 
adequacy), there were no significant differences in MSK outcomes in those with low versus 
adequate serum 25(OH)D concentration with and without adjustment for BMI and gender. 
However, the mean age was higher in those with low compared with adequate serum 
25(OH)D concentration (Table 5.6).  
Table 5.6 : Comparison between Musculoskeletal function by low and adequate serum 
25(OH)D concentration 
 
Variables  Serum 25(OH)D 
< 50 nmol/L 
(n=18) 
Serum 25(OH)D 
> 50 nmol/L 
(n=29) 
P value1  P value2 
 Serum 25(OH)D (nmol/L) 38.7 (7.7) 83.4 (23.1) - - 
 Parathyroid Hormones (Pmol/L) 4.7 (1.4) 4.5 (1.4) 0.613 0.289 
 Speed of Sound (m/s) 1569.5 (38.4) 1562.1 (42.4) 0.553 0.057 
 Broadband Attenuation 167.3 (20.8) 160.8 (17.7) 0.229 0.380 
 Stiffness Index  93.9 (19.0) 89.2 (19.0) 0.431 0.659 
 Grip Strength (kg) 28.6 (9.1) 26.8 (9.3) 0.543 0.274 
 Timed – Up and Go test (s) 9.2 (1.9) 9.0 (4.9) 0.861 0.156 
1 Student’s t test 2ANCOVA test adjusted for BMI and gender 
 
5.4 Discussion 
5.4.1 Main findings  
The aims of this study were to identify the association between sun exposure behaviours and 
serum 25(OH)D concentration and to identify the relationship between MSK outcomes and 
serum 25(OH)D concentration in older adults who are at moderate risk of CRC. This study 
reported that serum 25(OH)D concentration did not significantly associate with MSK 
outcomes in older adults who are at moderate risk of CRC. Moreover, this study found that 
having holiday visits was the only positive significant factor associated with serum 25(OH)D 
concentration.  
5.4.2 Interpretation of main findings  
Vitamin D status  
In this study, none of study participants was VDD based on the UK cut-off (25 nmol/L) of 
VDD. According to the US cut-offs of vitamin D insufficiency (50 nmol/L), only 38.3% the 
participants in this study were vitamin D insufficient.  Many case control studies and SR 
report a lower serum 25(OH)D concentration in CRC patients compared to controls (Song et 
al., 2016, Chandler et al., 2015, Ma et al., 2011, Woolcott et al., 2010).  A case control study 
of patients whose age was 45 – 75 years, showed lower serum 25(OH)D concentration among 
CRC patients compared to the controls (Woolcott et al., 2010).  The reported serum 25(OH)D 
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concentrations of cases and controls of this study were 57.9 and 62.4 nmol/L, respectively 
(Woolcott et al., 2010). Another case control study of adults whose mean age was 58 years 
also reported lower serum 25(OH)D concentration in cases (54.6 nmol/L)  compared to the 
controls (59.6 nmol/L) (Chandler et al., 2015). Further this study reported that serum 
25(OH)D concentration in CRC cases and controls were 21.9 (SD 8.3) and 23.9 (SD 9.8) 
nmol/L, respectively, which was lower than the value reported in this study.  Whilst the lower 
25(OH)D observed in CRC patients relative to controls might be due to differing vitamin D 
behaviours (sun exposure, diet, supplements) between these patients, it is also known that 
CRC itself might increase turnover of vitamin D metabolites via upregulation of macrophage 
and immune system activation through regulation by 1,25(OH)D (Gregory et al., (2010); 
Golden et al., (2012). 
Low prevalence of VDD in this study group indicated that this participants were 
comparatively healthy. Nearly half of the population had vitamin D containing 
supplementations and it might be the reason for this low prevalence of VDD in our study 
population. Alternatively, nearly half of the participants had holiday visits and it was a 
positive significant factor associated with the serum 25(OH)D concentration which might be 
attributed for the better vitamin D status in this population. Though the mean dietary vitamin 
D intake (3.0 + 1.4 µg/day) was below the recommended intake of 10 µg/day, vitamin D 
containing dietary supplements use and the sun exposure through holiday visits contributed to 
the better vitamin D status.  
Sun exposure variables and serum 25(OH)D concentration  
A recent case control study in CRC patients aged  20 – 85 years old, reported that risk for 
colon cancer was low in the patients who had frequent sun exposure during the previous 
summer (Valles et al., 2018). Gorham et al., (2007) and Garland et al. (1990) compiled a 
number of epidemiological studies and noted that there was a strong negative correlation 
between latitude, sun exposure, and poor vitamin D status and the risk for developing many 
deadly cancers, including colon, breast, ovarian, and melanoma. According to the present 
study, having holiday visits was a significant factor that positively associated with the serum 
25(OH)D concentration. Though it was not significant, this  study showed the seasonal 
variation in serum 25(OH)D concentration similar to some of the previous studies (Hedlund et 
al., 2013, Freedman et al., 2013, Mie et al., 2007). In addition, older adults who had habits of 
having fewer clothes and more frequent outdoor activities for a long time had higher serum 
25(OH)D concentration compared to their respective counterparts. Therefore, the details 
about the sun holidays, clothing habits, duration and frequency of sun exposure are important 
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factors to be included in the sun exposure questionnaires to assess vitamin D status. The low 
sample size might be attributed to the non-significant relationship of sun exposure variables 
and serum 25(OH)D concentration.  
Relationship between serum 25(OH)D concentration and muscle function  
The cut-off values for GS for males and females for the sarcopenia were 30 and 20 kg, 
respectively (Filippin et al., 2017) which are lower than the mean values reported in the 
present study. According to Martinez et al., (2015), cut-off value for the TUG test was 10.85 s 
for sarcopenia, which was higher than the mean value of our study. Therefore we can 
postulate that the muscle health of this study participants was relatively satisfactory. In line 
with our findings, some cross-sectional studies indicated that serum 25(OH)D concentration 
was not positively associated with muscle function in older adults. A study carried out in the 
US recruiting,  black, hispanic and white male participants whose age was 30 – 79 years 
stated that serum 25(OH)D concentration was not associated with lean body mass, muscle 
strength or physical function (Ceglia et al., 2011). In contrast, some cross-sectional studies 
showed the positive relationship between serum 25(OH)D concentration and muscle functions 
in older adults (Berners et al., 2018, Haaf et al., 2018). Berners et al., (2018) also reported a 
positive association between serum 25(OH)D and muscle function in a cross sectional study 
of mobility limited adults whose mean age was 77.6 years. A study of older adults aged 65 – 
88 years, living in Netherlands, stated the positive relationship between serum 25(OH)D 
concentration and physical performance (Haaf et al., 2018). A cross-sectional study of 
postmenopausal women stated that women with hypovitaminosis D had significantly lower 
GS, short physical performance battery and gait speed compared to the women with normal 
level of serum 25(OH)D concentration  (Iolascon et al., 2015).  Present study reported the 
differences in muscle function variables between the older adults who had polyps and older 
adults who did not have polyps.  The relationship between vitamin D status and muscle 
function is inconsistent across studies. The different findings between studies might be 
attributed to the ethnicity of the participants, assay methods used in the analyzing serum 
25(OH)D concentration, level of vitamin D status of the participants, SES, living status (free 
living or institutionalized), methods used in assessing muscle function and other factors which 
may influence muscle function which may not have been accounted for in the analyses.   
Absence of the positive relationship between serum 25(OH)D concentration and muscle 
function in this study might be partly attributed to the  low prevalence of VDD and narrow 
range of the serum 25(OH)D concentration. The association of serum 25(OH)D  concentration 
and muscle function might be undetectable as a result of this narrow range between serum 
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25(OH)D concentration. According to our previous study of older adults in Newcastle upon 
Tyne, the association of serum 25(OH)D with muscle function can be seen only in older 
adults with serum 25(OH)D concentration below 25 nmol/L, which partly explained by 
previous  finding (Ranathunga et al., 2019). Relatively satisfactory muscle function of this 
study participants might be a one of the reasons for not existing the positive association 
between serum 25(OH)D concentration and muscle function in this study participants. Some 
SR and case control studies stated the depletion of muscle function and mass among cancer 
patients (Christensen et al., 2014, Martin et al., 2013, Fearon et al., 2011). However, the 
majority of our study participants was healthy and only 21.2% of participants had polyps in 
present study. This might be the reason that we did not observe the poor muscle function in 
this group. Low statistical power resulted from low sample size in this study also might be 
another reason for the unexpected result regarding the association of serum 25(OH)D and 
muscle function.  
Relationship between serum 25(OH)D concentration and bone health 
A significant association between serum 25(OH)D and bone health was not reported in this 
study. Supporting to these findings, a cross sectional study conducted in Palestine recruiting 
postmenopausal osteoporotic and normal adult women reported that there was no direct 
correlation between BMD measured at the total hip and Femoral neck and serum 25(OH)D 
concentration in both the osteoporotic and normal women (Kharroubi et al., 2017).  There are 
published research that focused on bone health parameters in CRC patients.  A follow-up 
study of 9.5 years in 1471 postmenopausal women of 60 years old, showed that low BMD 
increased the risk of CRC and they further reported that low BMD was associated with 20% 
of CRC (Ganry et al., 2008).  
A study conducted in Italy, recruiting 134 older adults showed that serum 25(OH)D 
concentration was significantly and positively associated with total bone and the cortical bone 
cross-sectional area in the tibia (Mosele et al., 2013). Another cross-sectional study of older 
people whose age was 65 – 88 years conducted in Netherlands, reported a positive 
relationship between serum 25(OH)D concentration and BMD. They reported that heel bone 
BUA and SOS also were higher in high 25(OH)D groups. They explained that BMD and total 
BMC increased up to serum 25(OH)D concentration of 50 – 60 nmol/L (Kuchuk et al., 2009). 
A postmenopausal women’s study whose age was 48 – 65 years in Italy, pointed out that the 
women with serum 25(OH)D concentration below 25 nmol/L had low BMC and high level of 
bone turn over markers (Napoli et al., 2014). In contrast, a prospective study of men and 
women aged 66 – 96 years conducted in Iceland revealed that though  maintaining serum 
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25(OH)D concentration above 30 nmol/L would be advantageous for the bone health, having 
higher values than this did not show the additional benefit for the bone health 
(Steingrimsdottir et al., 2014), which partly explain the findings regarding the association 
between bone health and serum 25(OH)D concentration in present study. However, all these 
studies were varying in participants’ characteristics, vitamin D status of the participants, the 
technology used to assess the bone health and the bone site assessed which resulted in 
difficulty in comparing our study findings with previous studies. Further, lack of studies in 
past literature which assessed bone quality using heel QUS measures made our results 
difficult to compare with previous studies.  Low statistical power and the cross-sectional 
nature of the study, might have contributed to the unexpected finding of this study.  
5.4.3 Strengths and limitations  
This study is one in the limited number of studies that identified the relationship between 
serum 25(OH)D concentration and the heel bone parameters measured using QUS technique 
in older adults with moderate risk of CRC. Identifying the relationship between muscle 
function and serum 25(OH)D concentration in the same study was an advantage. In addition 
the use of a more comprehensive questionnaire to assess the sun exposure was a strength to 
this study. Questions on sunblock use, details about holiday visits, the time duration of the 
outdoor activities, clothing habits, sun avoidance habits and frequency of outdoor activities 
were included in the questionnaire  in our study. But all these questions were not include in 
the same questionnaire that used in the previous studies. Our study had several limitations. 
The low sample size was the main limitation which caused low statistical power. Recruired 
sample size was 385 individuals. This number is several times higher than the numbers recruited to the 
current study. Participants of this study were the volunteers who took part in a study of 12 
years ago and thus older adults were not a group of randomly selected older adults living in 
the UK. Therefore this findings may not be able to generalize for the total population in the 
UK.  
5.4.4 Public health implications  
This study emphasized the importance of sun holidays to improve vitamin D status in older 
adults who are at moderate risk of CRC. Based on our findings we can hypothesize that, 
information on sunny holidays, frequency and duration of sun exposure, are the important 
questions to be included in sun exposure questionnaires to use as a proxy indicator of vitamin 
D status of older adults. Lack of significant positive association of sun exposure details and 
serum 25(OH)D concentration highlighted the need for developing validated sun exposure 
questionnaire to capture sun exposure details more precisely.  
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5.4.5 Conclusions  
 In conclusion, serum 25(OH)D concentration was not associated with MSK outcomes of 
older adults who are at moderate risk of CRC. Having holiday visits was the only behavioural 
factor that positively associated with serum 25(OH)D concentration in free living older adults 
with moderate risk of colon cancer in Newcastle upon Tyne. Further studies are needed, 
recruiting a large sample of participants that represent older adults in the UK and accurate 



























Chapter 6:  Relationship Between Plasma PTH Concentration and 
Musculoskeletal Outcomes in Older Adults 
6.1 Introduction  
Parathyroid Hormone (PTH) is a peptide hormone that is responsible for maintaining calcium 
and phosphorus homeostasis (Berqwitz et al., 2010). PTH plays a role in bone health   
(Datta et al., 2014) and muscle function (Houston et al., 2008). At a mechanistic level, it has 
been observed that increased PTH concentration activates osteoclast cells in bone tissues and 
thereby increased the rate of bone loss which leads to lower bone mass (Lips, 2001). Further, 
comparatively low PTH concentration influences the bone mass by regulating IGF – 1, which 
has an anabolic effect on bones (Tahimic et al., 2013). PTH plays a role in muscle function by 
influencing muscle protein metabolism, modulating type II muscle fibres, controlling 
mitochondrial O2 uptake and synthesis of ATP in muscle cells (Mosekilde et al., 2005). Some 
cross sectional studies (Bird et al., 2018, Renoud et al., 2014) and longitudinal studies 
(Houston et al., 2008, Dhesi et al., 2002) have reported that elevated PTH concentration was 
associated with greater muscle loss and poorer muscle function (Mosekilde et al., 2005).  In 
contrast, a 5 years follow-up study indicated that serum PTH concentration was not associated 
with muscle functions or falls in older people (Faulkner et al., 2006). In the same way, the 
cross sectional studies in older people have reported the positive association between PTH 
concentration and bone mass (Kota et al., 2015, Samrook et al, 2004), while a follow-up 
study of older adults (Abiri et al., 2012) and a cross sectional study of adults (Fujiyoshi et al., 
2013) showed a negative association between PTH concentration and BMD. Therefore, prior 
findings of the association between PTH and MSK function are divergent.  
There is a negative relationship between serum 25(OH)D concentration and PTH 
concentration (Han et al., 2014). In addition various factors regulate PTH concentration, such 
as vitamin D status, stage of life, time of the day, ethnicity, dietary calcium and phosphorus 
intake, kidney function, physical activity, drug use, age and gender (Patel et al., 2007, Fraser 
et al., 2007, Vieth et al, 2003). PTH concentration increases with increasing age, as a result of 
lower serum 25(OH)D, impaired kidney function, low calcium intake and impaired calcium 
absorption (McKenna, 1992). Normal blood levels of PTH vary according to the laboratory 
that measured the PTH concentration. Most of the laboratories have stated the normal level of 
PTH as 15 - 65 Pg/mL (Pallan et al., 2012). As muscle function, muscle mass and bone mass 
reduce with increasing age (Araujo et al., 2014), maintaining appropriate PTH concentration 
at older ages may be important to optimize MSK outcomes. Whether the association between 
PTH and MSK outcome is independent of serum 25(OH)D is questionable (Arabi et al., 
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2012). Also prior findings of the association between PTH and MSK outcomes are not 
consistent. Relatively few studies investigating the relationship between PTH concentration 
and MSK outcomes in older adults have been conducted. We hypothesized that  PTH 
concentration might influence the  MSK outcomes in older adults.  
The aim of this study was to determine the association between vitamin D biomarker (PTH) 
and MSK health in older adults using two study designs.  
Therefore objectives of this chapter were, 
1 to investigate relationships between PTH concentration, 25(OH)D concentration and 
muscle function of older adults in both the VDOP and BFU studies.  
2. to investigate relationships between PTH concentration, 25(OH)D concentration and 
bone health of older adults in both the VDOP and BFU studies.  
6.2 Methods 
6.2.1 Study designs  
Data from two studies, Vitamin D in Older People (VDOP) study and the Biomarkers of Risk 
of Colon Cancer (BORICC) Follow-Up (BFU) study were used in the present study. The 
VDOP study is a double-blind, RCT that designed to test the effect of three doses of monthly 
oral vitamin D3 supplements (12000 IU, 24000 IU and 48000 IU) on BMD of older adults. 
The BFU Study is a long-term (12+ years) follow-up study of participants in BORICC study 
which was designed to discover and validate novel biomarkers of bowel cancer risk and to 
determine their relationships with habitual diet and nutritional status. Further details of the 
designs of these two studies were described in Chapter 2 of this thesis under the sections of 
2.1.1 and 2.2.1.  
6.2.2 Selection of the participants 
The VDOP study consisted of a total of 379 community dwelling men and women aged 70+ 
years or older, resident in Newcastle upon Tyne. Out of 379 participants recruited, 343 older 
adults completed the trial, thus VDOP follow-up study consisted of 343 older adults. A total 
of 47 older adults from the BORICC study participated in the BFU study. Further details 
about the selection of participants, inclusion and exclusion criteria of both studies were 
described in the Chapter 2 under the sections of 2.1.2 and 2.2.2.  
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6.2.3 Sunshine exposure, dietary intake, anthropometry and demographic variables  
Muscle function and bone health  
GGS and TUG were used to measure the upper and lower body muscle strength, respectively 
in both studies. In the BFU study, heel bone ultra-sound scanner (Achilles, UK) was used to 
measure the bone outcomes at the heel bone (Os Calcis). The Speed of Sound (SOS), 
Stiffness Index (SI) and Broad Ultrasound Attenuation (BUA) were the bone outcomes that 
measured using heel bone ultrasound scanner. Further details about these measures were 
described in Chapter 2 under the subsections of 2.4.5 and 2.4.11.   
Demographic information and dietary information  
Demographic information was gathered using questionnaires in both studies. CalQuest dietary 
calcium and vitamin D intake questionnaire, which was adopted from Calquest (Nelson et al., 
1998) was used to gather the information about the food intake of the in the VDOP study. The 
validated FFQ employed by the EPIC (European Prospective Investigation into Cancer and 
Nutrition) Study (Bingham et al., 1997) was used in the BFU study. 
Anthropometry and body composition  
In both studies, weight and height were measured. Body composition was measured in VDOP 
study, while the fat percentage was measured in the older adults of BFU study.  Body weight 
and body composition (fat % in the BFU study) were measured using TANITA TBF-300MA 
bio-impedance scale in both studies. Height was measured using stadiometer.  FM and FFM 
were also recorded in the VDOP study.  
6.2.4 Laboratory Analysis  
In VDOP study, plasma PTH concentration was measured by immunoassay (IMMULITE® 
1000 Immunoassay System) at Siemens Healthcare Diagnostic, Ltd, Camberley, UK. In BFU 
study, plasma PTH concentration was analysed by the sandwich test principle of 
Electrochemiluminescence technology at Newcastle Laboratories, Freeman Hospital, 
Newcastle upon Tyne. The reference range for PTH concentration used by these laboratories 
was 10.4 - 60.4  Pg/mL (~1.1 – 6.4 Pmol/L) (with normal serum calcium concentration). In 
VDOP study, total plasma 25(OH)D concentration values were obtained by summing up the 
values for 25(OH)D2 and 25(OH)D3, which were measured using LC-MSMS in Siemens 
Healthcare Diagnostics Ltd, Camberley, UK. In BFU study, serum 25(OH)D concentration 
was measured using Roche Immunoassay method in Newcastle Laboratories, Freeman 
Hospital, Newcastle upon Tyne.  
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6.2.5 Statistical Analysis  
Data of the total sample of 379 older adults recruited for the VDOP study was used in the 
baseline data analysis while data from all participants who completed the intervention trial 
(n=343) were used in the follow-up data analysis. Older adults who used vitamin D 
supplements were omitted in the data analysis related to VDOP study. Data from 47 
participants of BFU study was used in the present study. SPSS statistical package for 
Windows version 24.0 was used for analysing the data. A p value <0.05 was considered as 
statistical significant. Summary data were expressed as mean, SD, frequency and percentages, 
as appropriate. Laboratory cut-off value of 10.4 - 60.4  Pg/mL was used to identify the older 
adults with hyperparathyroidism (> 60.4 Pg/mL), hypoparathyroidism (<10.4 Pg/mL) and 
normal (10.4 – 60.4 Pg/mL) which was defined by the Newcastle Laboratories, Freeman 
Hospital, Newcastle upon Tyne. Simple correlation analysis was used to identify the factors 
associated with PTH concentration for both studies. Partial correlation was used to identify 
the association between PTH concentrations, MSK outcomes adjusted for age, gender, BMI, 
FM and serum 25(OH)D concentration for both studies. ANCOVA was used to investigate 
the association between serum 25(OH)D, PTH concentrations, muscle function of VDOP 
study participants adjusted for age, gender, BMI, FM and serum 25(OH)D concentration by 
the dose of vitamin D supplementation.  The same test was used to investigate the 
associations between PTH status (categorised as hyperparathyroidism and normal) and MSK 
outcome variables adjusting for age, gender and BMI. Stepwise linear regression was used to 
identify the significant predictors of MSK outcomes for both studies.  
6.3 Results  
6.3.1 Vitamin D in older people (VDOP) study  
Table 6.1 presents the basic characteristics of participants’ of the VDOP study at baseline. 
Mean age and BMI of the older adults were 75.0 (SD 4.21) years and 27.0 (SD 3.9) kgm-2, 
respectively. Mean plasma 25(OH)D and PTH concentrations were 39.9 (SD 20.1) nmol/L  
and 48.7 (SD 23.5) Pg/mL, respectively. Mean GS and TUG tests were 28.6 (SD 13.21) kg 
and 11.4 (SD 3.01) s, respectively. Percentages of males and females in the study population 
were approximately similar. About 9% of the population used vitamin D containing dietary 
supplements at baseline. According to reference range (10.4 – 60.4 Pg/mL) stated by the 
laboratories, 21.5 % of the VDOP participants were in the stage of hyperparathyroidism at 





Table 6.1 : Characteristics of VDOP study participants at baseline (n=379) 
Characteristics  Mean (SD) 
Age (years) 75.0 (4.21) 
Gender (Male n (%)) 198 (52.2) 
Weight (kg)  75.7 (13.6) 
Body Mass Index (kgm-2) 27.0 (3.9) 
Fat Mass  (kg) 24.7 (8.3) 
Fat Free Mass (kg) 50.8 (10.2) 
Serum PTH concentration (Pg/mL) 48.7 (23.5) 
Serum 25(OH)D concentration (nmol/L) 39.9 (20.1) 
Grip Strength (kg) 28.6 (13.2) 
Timed-Up and Go test (s) 11.4 (3.1) 
Calcium intake (mg/day) 835.7 (388.1) 
Vitamin D intake (µg/day) 3.8 (3.2) 
Serum PTH status   
     Hyperparathyroidism (n(%)) 81 (21.5) 
     Hypoparathyroidism (n(%)) 1 (0.3) 
     Normal (n(%)) 295 (78.2) 
Use of vitamin D supplements (n (%))  
     Yes 34 (9.0) 
     No  343 (91.0) 
  
 
Table 6.2 summarises the outcomes of the partial correlation analysis between PTH 
concentration, demographic, anthropometric, dietary, biochemical and muscle function 
variables before and after vitamin D supplementation. Plasma 25(OH)D concentrations, BMI 
and body weight were significantly correlated with PTH concentration before and after the 
supplementation. GS and TUG tests were not significantly associated with PTH concentration 
either at baseline or at the endpoint after adjusting for age, gender, BMI, FM and serum 
25(OH)D concentration. Based on the GS cut-off values for sarcopenia for males (30 kg) and 
for females (20 kg), 32.3% and 53.6% of males and females were sarcopenic, respectively. 









Table 6.2 : Simple and partial correlation between PTH concentration, demographic, 
anthropometric, dietary, biochemical and muscle function variables before and after 12 
months vitamin D supplementation  
 Before supplementation  After supplementation1  
Variables  








Simple correlation      
   Age (years) 0.160 0.002 0.077 0.159 
   BMI (kgm-2) 0.208 <0.001 0.113 0.039 
   Weight (kg) 0.164 0.001 0.148 0.006 
   Height (m) 0.002 0.967 0.103 0.059 
   Fat Mass (kg) 0.214 <0.001 0.098 0.074 
   Fat Free Mass (kg) 0.024 0.644 0.114 0.037 
   Serum 25(OH)D concentration (nmol/L) -0.307 <0.001 -0.270 <0.001 
   Calcium intake (mg/day) -0.042 0.427 0.067 0.230 
   Vitamin D intake (µg/day) -0.052 0.325 -0.071 0.205 
     
Partial correlation      
   Grip Strength (kg) 0.030 0.5592 0.015 0.7912 
   Timed-Up and Go test (s) -0.027 0.6012 -0.039 0.4832 
1 Pooled data from three treatment groups.  
2Adjusted for age, gender, BMI, FM and plasma 25(OH)D concentration 
 
Table 6.3 shows PTH, 25(OH)D concentrations, muscle function and bone health parameters 
by the dose of vitamin D supplementation, adjusting for age, gender, BMI, FM. PTH 
concentration reduced after vitamin D supplementation with no significant differences 
according to vitamin D dose. As expected, serum 25(OH)D concentration was increased in a 
dose dependent manner following vitamin D supplementation. GS was reduced after the 
supplementation in all dose groups with the lowest reduction in high dose group. Similarly, 
the time taken to walk 3 m distance was increased in all three dose groups with the lowest 











Table 6.3 : PTH concentration and MSK outcomes at baseline and after 12 months  by 
dose of supplementation 
Variables Total sample 12000 IU 24000 IU 48000 IU P value1 
 (n=379) (n=113) (n=114) (n=116)  
PTH2 at baseline (Pg/mL) 48.7 (23.5) 48.6 (25.5) 47.4 (23.3) 50.1 (21.3) 0.547 
PTH at 12 month (Pg/mL) 42.9 (21.6) 43.9 (21.5) 44.8 (24.5) 39.6 (18.0) 0.410 
   Δ PTH (Pg/mL) -5.5 (17.6) -3.0 (18.5) -3.1 (18.1) -10.4 (15.4) 0.068 
      
Serum 25(OH)D at baseline (nmol/L) 40.0 (20.1) 41.6 (19.9) 39.5 (20.6) 38.8 (19.7) 0.914 
Serum 25(OH)D at 12 month (nmol/L) 66.5 (18.0) 55.9 (15.6) 64.6 (15.3) 79.0 (15.1) < 0.001 
   Δ Serum 25(OH)D (nmol/L) 26.7 (20.2) 14.3 (12.6) 25.3 (18.0) 40.6 (19.9) < 0.001 
      
GS3 at baseline (kg) 28.6 (12.2) 28.5 (13.4) 28.8 (12.9) 28.2 (12.1) 0.878 
GS at 12 month (kg) 23.2 (12.1) 24.7 (10.1) 26.2 (12.6) 25.6 (9.4) 0.188 
    ΔGS (kg) -5.4 (12.8) -2.7 (11.7) -3.1 (7.9) -2.4 (7.7) 0.898 
      
TUG4 at baseline (s) 11.4 (3.1) 10.8 (2.5) 11.6 (2.9) 11.8 (3.5) 0.098 
TUG at 12 month (s) 11.8 (3.2) 11.4 (2.6) 11.9 (3.7) 11.9 (3.2) 0.833 
   ΔTUG (s) 0.4 (2.5) 0.6 (2.2) 0.4 (2.8) 0.1 (2.5) 0.490 
1ANCOVA, between three dose group, adjusted for age, gender, BMI, FM, plasma 25(OH)D 
2 Parathyroid Hormones 3Grip Strength  4Timed-up and go test 
 
According to Table 6.3, TUG and GS were not associated with PTH concentration before or 
after vitamin D supplementation.  
Table 6.4 : Relationship between PTH status and MSK function before and after total 
vitamin D supplementation  






Grip Strength (kg) 28.0 (15.2) 28.5 (12.6) 0.752 
Timed-Up and Go test (s) 11.5 (3.3) 11.4 (3.1) 0.960 






Grip Strength (kg) 25.3 (10.8) 25.7 (9.8) 0.975 
Timed-Up and Go test (s) 12.4 (3.7) 11.7 (3.1) 0.201 
1PTH concentration > 60.4 Pg/mL 
2ANCOVA, adjusted for age, gender, BMI, plasma 25(OH)D concentration 
 
Table 6.4 shows the PTH concentration at baseline, after 12 months supplementation and 
changes of PTH concentration and its association with muscle function variables at baseline 
and after the supplementation in VDOP study. PTH concentration at baseline, 12th month and 
change in PTH concentration were not significantly associated with TUG test and GS for any 







Table 6.5 : Simple correlation between PTH concentration and muscle function variables at baseline, at 12 month and the (Δ) change of 
muscle function variables in VDOP study 
 Baseline total 
sample 
PTH After 12 months Change in PTH concentration 
  Total 
sample 
12000 IU 24000 IU 48000 IU Total 
sample 
12000 IU 24000 IU 48000 IU 
GS1 Baseline  R =0.049   
P= 0.347 
        
GS at follow-up  R= 0.013 
P = 
0.814 




R = 0.026 
 P = 0.791 
    
GS change       R=0.038 
P = 0.493 
R=0.056 
P = 0.567 
R = -0.057 
P = 0.560 
R = 0.139  
P = 0.158 
TUG2 baseline  R=0.052  
P = 0.318 
        
TUG at follow-up  R=0.027 
P = 
0.628 
R = -0.009 




R = 0.060  
P = 0.538 
    
TUG change       R = -0.006 
P = 0.913 
R = -0.154 
P = 0.121 
R = 0.150  
P = 0.125 
R = -0.090  
P= 0.363 







Table 6.6 shows the predictors of muscle function variables before and after the 
supplementation. Age and female gender were negative predictors of GS at both baseline and 
after the supplementation. FFM and height were the significant positive predictors for GS at 
baseline and after the supplementation. Serum 25(OH)D concentration was retained as a 
positive predictor for GS after the supplementation. Percentage of the variance of GS, 
explained by the predictors were 36% and 56% before and after the supplementation, 
respectively. Age was a positive predictor of TUG test at both baseline and after the 
supplementation, while height was a negative predictor of TUG test at both baseline and after 
the supplementation. FM was a positive product of TUG test at baseline while BMI was a 
positive predictor for the endpoint TUG test. PTH concentration was not retained in any of the 
models. 
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Table 6.6 : Linear regression analysis1 predicting GS and TUG before and after the 
vitamin D supplementation.  
Muscle function variables Constant β B SE CI P value 
Before supplementation        
Grip Strength  (R2 = 36.0)  
     
     Fat Free Mass (kg) -0.566 0.266 0.344 0.105 0.137 – 0.551 <0.001 
     Height (cm)  0.193 0.276 0.106 0.069 – 0.484 0.009 
     Age (years)  -0.133 -0.429 0.138 -0.701 – (-0.157) 0.002 
     Gender (Females vs males)  -0.179 -4.758 1.779 -8.296 – (-1.221) 0.009 
       
Timed-Up and Go test (R2 = 15.5)       
     Age (years) 5.49 0.306 0.225 0.036 0.153 -0.296 <0.001 
     Fat Mass (kg)  0.218 0.079 0.019 0.043 – 0.116 <0.001 
     Height (cm)  -0.229 -0.075 0.023 -0.120 – (-0.030) <0.001 
     Gender (Females vs males)  -0.146 -0.881 0.434 -1.734 – (-0.028) 0.043 
       
After the supplementation        
Grip Strength  (R2= 56.4) 
-1.737      
     Gender (Females vs males)  -0.410 -8.051 1.158 -10.329 – (-5.774) <0.001 
     Height (cm)  0.232 0.256 0.067 0.123 – 0.388 <0.001 
     Age (years)  -0.125 -0.279 0.088 -0.471 – (-0.124) 0.002 
     Fat Free Mass  (kg)  0.191 0.163 0.067 0.031- 0.296 0.014 
       
Timed –Up and Go test (R2 = 14.0) 0.506      
     Age (years)  0.257 0.196 0.040 0.118 – 0.274 <0.001 
     Body Mass Index (kgm-2)  0.197 0.156 0.041 0.075 – 0.236 <0.001 
     Height (cm)  -0.132 -0.044 0.017 -0.078 – (-0.010) 0.012 
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6.3.2 BFU Study  
Table 6.7 presents the basic characteristics of the participants in the BFU Study. Mean age 
and BMI were 66.8 (SD 8.3) and 28.3 (SD 4.7) kgm-2, respectively. The mean PTH 
concentration was 42.9 (SD18.7) Pg/mL. The proportions of males and females were 
approximately equal.  
Table 6.7 : Basic characteristics of participants in the BFU Study (n=47) 
Characteristic  Mean (SD) 
     Age (years) 66.8 (8.3) 
     Males (n (%))  23 (49) 
     Body Mass Index (kgm-2) 28.3 (4.7) 
     Weight (kg) 81.5 (17.6) 
     Height (m) 169.2 (10.6) 
     Waist Circumference (cm) 96.5 (14.3) 
     Hip Circumference (cm) 105.0 (9.3) 
     Fat percentage (%) 34.2 (8.1) 
     Current serum 25(OH)D nmol/L  66.3 (28.8) 
     Plasma Parathyroid Hormones (Pg/mL) 42.9 (18.7) 
     Grip Strength (kg) 27.6 (9.2) 
     Timed Up and Go test (seconds) 9.1 (4.05) 
     Broadband Ultrasound Attenuation  106.7 (20.3) 
     Speed of Sound  (m/s) 1564.9 (40.6) 
     Stiffness Index  90.9 (18.9) 
     Dietary vitamin D intake (µg/day) 3.0 (1.4) 
     Dietary calcium intake (mg/day) 891.4 (404.8) 
     Having a history of NCDs (n (%))  
        Yes 29 (61.7) 
        No 18 (38.2) 
     Use of vitamin D supplements  
        Yes 20 (42.6) 
        No 27 (57.4) 
     Serum PTH states   
         Hyperparathyroidism1     6 (12.8) 
         Normal2 41 (87.2) 
 1PTH concentration > 60.4 Pg/mL 2PTH concentration, 10.4 – 60.4 pg/mL 
 
 
Table 6.8 demonstrates the correlation coefficient between PTH concentration, demographic, 
anthropometric, biochemical parameters and MSK outcomes in older adults. None of the 
anthropometric, dietary and muscle function variables was significantly correlated with PTH 
concentration. Bone health outcome measures, SOS, SI and BUA were significantly 
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Table 6.8 : Correlation between PTH concentration, demographic, anthropometric and 
biochemical parameters in older adults  
Variables  
(Dependent variable: PTH conc (Pg/mL) 
Correlation 
coefficient 
P value  
Simple correlation (n=47)   
     Age (years) 0.143 0.338 
     Body Mass Index (kgm-2) -0.024 0.875 
     Fat percentage (%) 0.051 0.738 
     Serum 25(OH)D concentration (nmol/L) -0.122 0.413 
     Vitamin D intake (µg/day) -0.044 0.770 
     Calcium intake (mg/day) -0.017 0.911 
     Weight (kg) -0.158 0.290 
     Height (height) -0.252 0.088 
     Waist Circumference (cm) -0.146 0.328 
     Hip Circumference (cm) -0.078 0.603 
   
Partial correlations (n=47)   
Muscle function variables    
     Grip Strength (kg) -0.037 0.8201 
     Timed-Up and Go test (s) -0.042 0.7921 
Bone health variables   
     Speed of Sounds (m/s) 0.377 0.0141 
     Stiffness Index  0.402 0.0081 
     Broadband Ultrasound Attenuation 0.382 0.0121 
1Adjusted for age, gender, Body Mass Index and serum 25(OH)D concentration 
 
Table 6.9 demonstrates the predictors of muscle function and bone health outcomes selected 
by stepwise linear regression analysis. Age and gender were the only significant predictors of 
GS which were the negative predictors of GS. This model explained 62% of the variability of 
the GS. None of the variables was retained for the model for the TUG test. Female gender was 
a significant negative predictor of MSK outcomes, while PTH concentration was a significant 
positive predictor of SOS and SI. Variance explained by the models for SOS, BUA and SI 
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Table 6.9 : Linear regression1 analysis of predictors of MSK outcomes in BFU Study 
participants (n=47) 
Variables Constant β B SE CI P value 
Grip Strength (R2 = 62.0) 55.75 
     
     Gender (Females vs males)  -0.715 -13.000 1.732 -16.496 – (-9.505) <0.001 
     Age (years)  -0.294 -0.319 0.103 -0.528 – (-0.111) 0.004 
       
Timed-Up and Go test  No variables were retained 
       
Speed  of Sound (R2 = 22.8) 1541.29      
     Gender (Females vs males)  -0.452 -36.346 11.341 -59.234 – (-13.459) 0.003 
     Parathyroid Hormones (Pg/mL)  0.322 9.336 4.090 1.083 - 17.590 0.028 
       
Broad Band Attenuation (R2 = 8.6) 112.60      
     Gender (Females vs males)  -0.293 -11.753 5.781 -23.404 – (-0.103) 0.048 
       
Stiffness Index (R2 = 43.9) 127.88      
     Gender (Females vs males)  -0.608 -22.783 4.556 -31.984 – (-13.582) <0.001 
     PTH (Pg/mL)  0.346 4.666 1.660 1.314 - 8.019 0.008 
     Age (years)  -0.302 -0.695 0.272 -1.245 – (-0.146) 0.014 
1
Stepwise linear regression adjusted for serum 25(OH)D concentration 
6.4 Discussion  
The aim of this study was to investigate the association between PTH concentration and MSK 
outcomes in older adults, adjusting for serum 25(OH)D concentration. In the cross-sectional 
(BFU) study, PTH concentration was positively associated with bone health outcomes in older 
adults, independent of serum 25(OH)D concentration, but not with the muscle function. In 
RCT (VDOP study) PTH concentration was not associated with muscle function at both 
before and after vitamin D supplementation. 
6.4.1 Interpretation of findings  
Relationship between PTH and bone health  
In agreement with our study, some prior studies have reported the positive associations 
between PTH concentration and bone health outcomes.  A study conducted in the UK 
recruiting osteoporotic postmenopausal women showed that patients with blunted PTH 
concentration showed the protection against PTH mediated bone loss (Sahota et al., 2004). 
Another two previous RCTs involving postmenopausal women showed that, injection of PTH 
reduced the risk of vertebral fractures (Neer, 2010, Greenspan et al., 2007). The mechanism 
underlines the positive association of PTH concentration and bone mass is well established. 
PTH increases calcium absorption in the small intestine by up-regulating the production of the 
active metabolite of vitamin D (1,25(OH)2D) in the kidneys which facilitate the increase in 
BMD (Abel et al., 2005). It is believed that continuous exposure to the high concentration of 
PTH results in catabolic effects on the skeleton, while exposure of intermitted low dose of 
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PTH results in an anabolic effect on bone.  The low dose of PTH stimulates IGF – 1 thereby 
facilitate bone formation (Silva and Bilezikian, 2015). In addition, it is reported that 
intermittent PTH administration directly acts on osteoblasts to promote osteoblastogenesis, 
reduce osteoblast apoptosis, and reactivates inactive lining cells of the bones which ultimately 
supports bone formation. Also, the low dose of PTH stimulates the expression of genes that 
signals bone formation, such as the osteoblast-specific transcription factor Runx2, 
Osteocalcin, Alkaline Phosphatase, Collagen type I alpha 1 (COL1A1) (Silva and Bilezikian, 
2015). The reason for the positive association of PTH concentration and bone health 
outcomes in our study might be due to the comparatively low PTH concentration of the study 
participants that did not reach the level of hyperparathyroidism. Only 19% of our participants 
were in the category of hyperparathyroidism in cross sectional study. In addition mean PTH 
concentration of older adults was 42.9 Pg/mL which was lower than the value reported Kota 
et al., 2013 (53.1 Pg/mL) in a study of adults whose mean age was 62.5 (SD 6.5) years. This 
particular study showed the negative association between PTH concentration and BMD. 
However hyperparathyroidism can be categorized as, primary and secondary 
hyperparathyroidism. Primary hyperparathyroidism is characterized by the independent high 
production of PTH, with the presence of hypercalcemia or normal-high serum calcium levels 
(Cordellat, 2012).  The available data of this study was not sufficient to decide whether the 
participants had secondary or primary hyperparathyroidism. 
In contrast to this study the negative associations between high PTH concentration and bone 
mass have been reported by some studies (Kota et al., 2013, Zhae et al., 2007). One of the 
mechanisms identified so far, to support this negative association is the stimulation of 
osteoclast cells by PTH through the action of RANK receptors located in osteoblast, and 
subsequently increase the bone resorption process (Rolighed et al., 2014).  
Relationship between PTH and muscle function  
The association between PTH concentration and muscle function was not found in either 
study. Some previous studies (Renound et al., 2014, Houston et al., 2008, Cosman et al., 
2007) have reported the negative association between elevated PTH concentration and muscle 
function. The mechanisms underline this negative association between hyperparathyroidism 
and muscle function are increased protein catabolism, decreased number of type 2 muscle 
fibres, increased intracellular energy-rich phosphate compounds, and mitochondrial oxygen 
uptake (Mosekilde et al., 2005). Further higher, PTH levels are primarily the result of 
increased skin pigmentation and thereby reduce vitamin D production in the skin (Cosman et 
al., 2007). In contrast, Abboud et al., 2017 stated that PTH has an anabolic effect on muscle 
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function as a result of increased the uptake and retention of 25(OH)3D in the skeletal muscle 
cells. The reason for this null finding in this study might be attributed to the low range of PTH 
concentration in BFU study (21.7 – 71.7 Pg/mL) and a low statistical power resulted by low 
sample size.  I reported that female gender and age were negatively associated with MSK 
outcomes in both studies, which is a universally agreed phenomenon.  Bone mass reduces 
with increasing age as a result of the hormonal and body compositional changes, activity 
patterns and psychological influences (Neer, 2010).  
6.4.2 Strengths and Limitations 
Determining the relationship between MSK outcomes and PTH concentration in two study 
designs,  large sample size in a RCT and cross sectional study is a novel approach in this 
study. Association of PTH and MSK outcome before and after high doses of vitamin D 
supplementation is also an advantage of this study. Adjusting the statistical models developed 
for MSK outcomes for the various factors such as demographic, anthropometric and 
biochemical variables were added advantage to this study. Limitation of this study includes a 
low sample size in the cross sectional study. Therefore, the findings cannot be generalized for 
the general population in the UK. In addition, the insufficient data to identify older adults with 
primary and secondary hyperparathyroidism in this study is a limitation.  The method that I 
used to measure MSK outcomes is not the gold stand methods of assessing bone mass, which 
also a limitation in this study.  
6.4.3 Public health implication  
A positive association between PTH concentration and bone health outcome reported in this 
study highlights the importance of maintaining appropriate PTH concentration below 
hyperparathyroisms to optimize bone health. According to our study PTH concentration 
between 21.7 – 71.7 Pg/mL would be beneficial for better bone health outcomes. As PTH 
concentration did not show an association with muscle function, future studies are required 
with a large representative sample of the general public and with the combination of different 
methods of assessing muscle function and bone health outcomes.  
6.4.4 Conclusions  
In conclusion, serum PTH concentration had a positive association with bone health in older 
adults but not with muscle function.  Advancing age and female gender were significant 
predictors for bone parameters at the heel bone while age, gender, FM, FFM, BMI and height 
were the predictors of muscle function. Further studies are needed to confirm the findings 
with  large sample size and with the slandered methods of assessing muscle function and bone 
health.  
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Chapter 7 : The 12 Years Change in 25(OH)D Concentration in a Group of 
People at Moderate Risk of Colorectal Cancer 
7.1 Introduction  
Colorectal Cancer (CRC) is the third most commonly diagnosed malignancy and the fourth 
leading cause of cancer death in the world, accounting for about 1.4 million new cases each 
year (Ferlay et al., 2013). CRC is the 4th most common cancer in the UK, accounting for 12% 
of all new cancer cases. Research reports stated that there are around 41,700 new CRC cases 
in the UK every year (Cancer Research UK, 2015). CRC develops from malignant 
transformation of the epithelium of the large intestine (Ferrer-Mayorga et al., 2019). Many 
epidemiological and observational studies have reported that VDD is associated with high 
incidence of CRC and mortality from CRC (Chandler et al., 2015, Mohr et al., 2015, Ma et 
al., 2011). Inverse associations between sun exposure and mortality from CRC also have been 
reported (Mondul et al., 2017). Studies have proved that large intestine is the organ that 
consisted of the highest expression of VDR (Ferrer-Mayorga et al., 2019). In vitro studies 
reported that calcitriol inhibits proliferation, sensitizes to apoptosis, and promotes 
differentiation of colon carcinoma cells, through the regulation of genes and the modulation 
of signalling pathways in tumour cells (Krishnan et al., 2010).  
Sunlight exposure is the main source for vitamin D, while diet provides minor contribution to 
vitamin D status (Fraser and Milan 2013). Older people are believed to be at risk of 
developing VDD as a result of low cutaneous synthesis, poor dietary intake and low physical 
activity (Cashman et al., 2014, Freedman et al., 2013).  Among older people whose age is 
higher than 65 years, the skin 7-DHC concentrations is  about 25 % compared to a person of 
20–30 years old (McLaughlin et al., 1985). Seasonal variation in the serum 25(OH)D 
concentration was reported in many studies of older adults (Patwardhan et al., 2015, Touvier 
et al., 2015, Freedman et al., 2013). Therefore, older adults live in higher latitudes are 
believed to have sub optimum vitamin D status during winter months as a result of low 
sunlight availability (Holick et al., 2011). Though vitamin D rich food items are limited, 
SACN, 2016, stated that RNI for vitamin D is 10µg/day for older adults (SACN, 2016). Many 
studies reported that older adults are not meeting the RNI for vitamin D (Granic et al., 2015, 
Hill et al., 2005). 
Understanding vitamin D status, its determinants both cross-sectionally and over time might 
provide strategies to optimize vitamin D status in people at risk of CRC.  From a bone health 
perspective, these patients should maintain an ideal vitamin D status.  As discussed later in 
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this chapter, the potential benefit to CRC risk of maintaining higher 25(OH)D remains 
speculative but based on the existing evidence, it can be concluded that maintaining a 
concentration of 25(OH)D > 25 nmol/L would have tangible benefits to health.    
Therefore, the aim of this study was to identify the change in vitamin D status and vitamin D 
intake during a 12 year period in older adults who are at moderate risk of CRC. Therefore the 
objectives of this chapter were, 
i) to identify the change in serum 25(OH)D concentration of older adults who are at 
moderate risk of CRC during the 12 year period from BFU study. 
ii) to identify the change in dietary vitamin D intake of older adults who are at moderate 
risk of CRC during the 12 year period from BFU study.  
7.2 Methods  
7.2.1 Recruitment of participants  
After approximately 12 years, participants in the BORICC (Biomarker of Risk of Colon 
Cancer) study were invited to participate in the present study called BORICC Follow-Up 
(BFU) Study. The original BORICC study was conducted in 2006 with the objective of 
developing and validating novel biomarkers of bowel cancer risk and to determine their 
relationships with habitual diet and nutritional status. A total of 47 older adults from  the 
original BORICC study agreed to participate in the BFU study. Further details about the 
recruitment of participants, inclusion and exclusion criteria of original BORICC study and 
BFU study were described in Chapter 2 under the subsections of 2.3 and 2.4.  
7.2.2 Anthropometry, socio-demographic information, dietary intake 
Anthropometry (weight, height, FM, FFM, WC, HC), socio-demographic information, dietary 
intake, history of NCD dietary supplement use and serum 25(OH)D concentration were 
measured at follow-up. Serum 25(OH)D concentration of follow-up study was measured 
using the Roche method in Newcastle Laboratories, Freeman Hospital. Socio-demographic 
information was gathered using a questionnaire. The FFQ used in this study is based on the 
EPIC study and can be found in Appendix J of the thesis. In-house software based on 
MaCance and Widdowson’s 7th Edition Food Composition tables was used to quantify the 
vitamin D intake. Dietary vitamin D intake which gathered using FFQ of the same 
participants 12 years ago was obtained from the past records. However this value was 
obtained only for 37 older adults. The baseline serum 25(OH)D which measured using IDS 
Radioimmunoassay in 12 years ago also was gathered from the past records. BMI and the use 
of vitamin D supplements 12 years ago were also gathered from the past records.  
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7.2.3 Statistical analysis 
Characteristics of the older adults at baseline and follow-up study were presented as mean an 
SD. To evaluate the seasonal changes of serum 25(OH)D, older adults were grouped into two, 
based on the time of blood sampling. Older adults sampled during April – September and 
October to March were categorized as Summer and Winter sampling, respectively. Seasonal 
change of serum 25(OH)D concentration at follow-up study as well as vitamin D status at 
baseline and follow-up were presented in a bar graph.  Vitamin D status was presented in a 
bar graph. To identify the vitamin D status of older adults at baseline and follow-up studies, 
older adults were grouped into two based on the both SACN cut-off of VDD (25 nmol/L) 
(SACN, 2016) and IOM cut-off of vitamin D insufficiency (50 nmol/L) (IOM, 2011). Parallel 
plots were used to present the changes in vitamin D intake and vitamin D status during 12 
year period. The supplement uses were also included in these parallel plots. However, the 
details of the amount of vitamin D intake from supplements were not available in this study. 
Baseline and follow-up serum 25(OH)D concentration and dietary intake were compared 
using paired Student’s t test. ANOVA test was used to compare the serum 25(OH)D 
concentration between the seasons.  
7.3 Results  
Table 7.1 shows the characteristics of the participants at baseline and at follow-up. The mean 
age of the participants was 66.8 (SD 8.3) years at follow-up. Percentage of males and females 
and the BMI of the participants were approximately equal at baseline and at follow-up. Serum 
25(OH)D concentrations at baseline and at follow-up were 79.2 (SD 38.3) nmol/L and 66.4 
(28.8) nmol/L, respectively. Similarly, dietary vitamin D intake at baseline and at follow-up 
were 3.9 (SD 1.7), 3.0 (SD 1.4) µg/day, respectively. Percentage of older adults who used 
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Table 7.1 : Characteristics of older adults at baseline and follow-up studies  




P value  
 Mean (SD) / n (%)  
     Body Mass Index (kgm-2) 28.3 (4.7) 28.2 (4.8) 0.6881 
     Serum 25(OH)D (nmol/L) 66.4 (28.8) 79.2 (38.3)2 0.2151 
     Dietary vitamin D intake (µg/day)  3.0 (1.4) 3.9 (1.7) 0.0571 
     Use of vitamin D supplements    
        Yes 20 (42.5) 12 (25.5)  
        No 27 (57.5) 34 (72.3) 0.1923 
     Season of sampling     
        Summer 25 (53.2) 16 (51.6)  
        Winter 22 (46.8) 15 (48.3) 0.106 
    
     Age (years) 66.8 (8.3)   
     Gender (n (%))    
        Males 23 (48.9)   
        Females  24 (51.1)   
     Weight (kg) 81.5 (17.6)   
     Height (m) 169.2 (10.6)   
     Waist Circumference (WC) (cm) 96.6 (14.3)   
     Hip Circumference (HC) (cm) 105.0 (9.3)   
     Fat percentage (%) 34.3 (8.1)   
     Plasma PTH (Pmol/L) 4.6 (1.4)   
     Dietary calcium intake (mg/day) 891.5 (404.8)   
     Gender (n (%))    
        Males 23 (48.9)   
        Females  24 (51.1)   
     Having a history of NCDs (n(%))    
        Yes 29 (61.7)   
        No 18 (38.2)   
     Had polyps at baseline screening    
        No 37 (78.7)   
        Yes 10 (21.3)   
1 Paired t test    2 Out of 47 older adults, serum 25(OH)D data were  available only for 37 individuals  
3 Chi-squared  test 
 
Figure 7.1 summarises the vitamin D status of the participants at follow-up and baseline (12 
years ago). At follow-up, 16 participants were in the D status group of 25 – 50 nmol/L, 
compared only 7 people at baseline, 12+ years ago. The percentage of older adults in the 
serum 25(OH)D group > 75 nmol/L at baseline and follow-up was equal. None of the older 
adults at follow-up study had serum 25(OH)D concentration less than 25 nmol/L. Only one 
participant had serum 25(OH)D concentration less than 25 nmol/L at baseline. Though it was 
not significant, mean serum 25(OH)D concentration at follow-up (66.4 SD 28.8) nmol/L was 
lower than the baseline serum 25(OH)D concentration (79.2 SD 38.3) nmol/L (p=0.215). 
Figure 7.2 further illustrates the individual change in the vitamin D status of older adults 
during 12 year follow-up period.  
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Figure 7.1 : Vitamin D status of the participants at baseline and at follow-up studies 
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Figure 7.3 depicts the seasonal differences of serum 25(OH)D concentration at follow-up. 
Mean serum 25(OH)D concentration in winter sample (n=22)  was  59.4 (SD 30.4) nmol/L 
while mean serum 25(OH)D concentration in summer sample (n=25)  was 72.4 (SD 72.4) 





Figure 7.3 Serum 25(OH)D concentration during summer and winter 
 
Figure 7.4 shows the change of dietary vitamin D intake of individual older adults during the 
12 year period. Mean vitamin D intake of older adults at follow-up (3.0 SD 1.4) µg/day was 
not significantly different to mean vitamin D intake at baseline (3.9 SD 1.7) µg/day.  
Participants who took vitamin D supplements were included on figure 7.4. The two 
participants who had vitamin D intakes > 8 µg/day were supplement users and from the FFQ 
data appeared to have fish and meat intake (the two greatest sources of vitamin D in the UK 







































Season of blood collected
n = 25
n = 22
P = 0.124 
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Figure 7.4 : Change of individual dietary vitamin D intake during 12 years period 
among older adults (n=37) 
7.4 Discussion 
7.4.1 Main findings 
According to SACN cut-off of VDD (25 nmol/L), only one participant was vitamin D 
deficient at baseline, while none of the older adults were vitamin D deficient at follow-up.  
Sixteen older adults were in the vitamin D status group of  25 – 50 nmol/L at follow-up which 
increased from 7 participants at baseline during the 12 year follow-up period. Overall the 
vitamin D status of the older adults was quite satisfactory at both follow-up and baseline. One 
reason for the marginally worse [but not statistically significant] vitamin D status at follow up 
might be attributed to the method used in assessing serum 25(OH)D concentration. At the 
baseline assessment, the IDS EIA method was used to assess vitamin D status and this method 
has been shown to over-report the serum 25(OH)D concentration (Enko et al., 2014). 
7.4.2 Discussion of main findings  
Compared to the previous studies conducted in older adults in the UK, mean serum 25(OH)D 
concentration of our study participants at both baseline and follow-up studies were 
comparatively  satisfactory. According to a study conducted in Newcastle, UK in older adults, 
mean serum 25(OH)D concentrations were 27, 45, 43 and 33 nmol/L during spring, summer, 
autumn and winter, respectively (Hill et al., 2015). Further, the serum 25(OH)D concentration 
of BFU study  participants at both baseline and follow up were higher than the baseline value 
reported in the VDOP study (38.2 nmol/L) (Aspray et al., 2018). According to another study 
conducted in London, serum 25(OH)D concentration of older adults was 42.7 (SD 22.0) 
nmol/L (Jolliffe et al., 2016). A study of Irish older adults’ serum 25(OH)D concentration 
ranged from 38.5 – 69.6 nmol/L (Forstyhe et al., 2012). Therefore, the serum 25(OH)D 
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concentration values reported in our studies were comparably high compared to the values 
reported for the older adults in the UK in previous studies. None of the participants was 
vitamin D deficient according to the UK cut-off of VDD (25 nmol/L) at follow-up. According 
to US cut-off, 17 older adults were vitamin D inadequate at follow-up. One reason for the 
better vitamin D status in this population might be attributed to the method used in assessing 
serum 25(OH)D concentration. At the follow-up Roche method was used, which might over-
reported the serum 25(OH)D concentration (Enko et al., 2014). Also a considerable number 
of people consumed vitamin D containing supplements which might cause for higher serum 
25(OH)D concentration. In this study reduction in serum 25(OH)D was not significant.  In 
contrast to our study, Elstgeest et al., 2018 showed that during a 13 year follow-up periods, 
serum 25(OH)D concentrations increased in 32.4% of the older cohort of 65 – 88 years, while 
there was a 69.8% increase 25(OH)D in the younger cohort of 55 – 65 years age during 6 year 
follow-up period. 
Mean vitamin D intake at baseline and at follow-up of our study were also comparative to the 
values reported by recent studies of older adults in the UK (Granic et al., 2015, Hill et al., 
2005), which ranged from 2.9 to 5.7 µg/day. At baseline and at follow-up time points, none of 
the participants met the RNI of vitamin D (10 µg/day) (SCAN, 2016).  
Several studies have demonstrated the seasonal changes in serum 25(OH)D in older adults 
which showed the highest value during summer (Touvier et al., 2015, Freedman et al., 2013, 
Hedlund et al., 2013, Darling et al., 2012). However, the seasonal variation showed in our 
study was unexpected. We reported the highest serum 25(OH)D concentration during winter 
and the lowest value during spring. Some previous studies showed that, vitamin D3 produced 
in the skin takes some time to show as 25(OH)D in the serum which varying from 2 weeks to 
6 months (Lawson et al., 1979). This concept partly explains our unexpected finding.  
Several mechanisms of the vitamin D in CRC prevention have been proposed. Mainly, the 
vitamin D and its metabolites reduce the incidence of several types of cancer by inhibiting 
tumor angiogenesis, stimulating mutual adherence of cells, enhancing intercellular 
communication through gap junctions and thereby strengthening the inhibition of 
proliferation. Vitamin D metabolites also help in maintaining the normal calcium gradient in 
the colon epithelial crypts and high serum concentration of 25(OH)D are associated with 
noticeably decreased proliferation of high-risk epithelial cells in the colon (Garland et al., 
2006). However study findings on the association of vitamin D and CRC are not consistent.  
An ecological study conducted in US during 1970 – 1994 reported that solar UVB radiation 
dose was associated with reduced risk of cancer of the breast, colon, ovary, and prostate. They 
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further reported that the annual number of premature deaths from cancer due to lower UVB 
exposure was 21,700. Therefore this particular study concluded that increased UVB exposure 
or supplementary vitamin D consumption, could be helpful to reduce most of cancer 
incidences (Grant 2002). They highlighted that 1,25(OH)2D was the form of vitamin D that 
played a role in cancer prevention (Grant, 2002).  
One of the study similar to this study, which was a 9 year follow-up study of postmenopausal 
women who were at risk of colon cancer, reported that those in the highest intake of total 
calcium and vitamin D were at a 45% reduced risk of colorectal cancer (RR, 0.55; 95% CI, 
0.32-0.93) compared with the women who consumed low levels of both nutrients (Zheng et 
al., 1998). Another prospective cohort study of 35,216 women in US aged 55-69 years who 
did not have the  history of cancer reported that intakes of calcium and vitamin D were 
significantly and inversely associated with the risk of CRC after adjusting for the age (Bostick 
et al.,1993). A case control study (age, race and sex matched) of 8 year follow-up period 
conducted recruiting 25620 volunteers age higher than 35 years in Washington reported that 
risk of getting colon cancer decreased by three-fold in people with a serum 25(OH)D 
concentration of 20 ng/ml or more. They further found that the risk of getting colon cancer 
was reduced by 80% in the individuals whose serum 25(OH)D concentration between 52.4 – 
117.3 nmol/L (21 – 47 ng/mL). However, they reported that the highest 25(OH)D quintile had 
a non-significantly higher risk of colon cancer than the other groups from 49.9 – 102.3 
nmol/L (20 - 41 ng/mL).  They explained that these unexpected findings might be due to the 
fact that, at the very high 25(OH)D concentrations, some unnecessary metabolites are unable 
to be removed from the plasma which possibly increases the risk of CRC (Garland et al., 
1989). A study conducted in Canada examined the association between sulfur dioxide and 
ultraviolet-light-blocking aerosols in 20 Canadian cities, and age-adjusted breast and colon 
cancer mortality rates in the surrounding cities. Further, statistically significant positive 
associations were found between these two measures of air pollution and age-adjusted 
mortality rates for CRC. Therefore they highlighted that low vitamin D synthesis in the skin at 
the high level of pollution might cause for the increased incidence of CRC (Gorham et al., 
1989).  
A pooled analysis of a vitamin D RCT and prospective studies of vitamin D status and cancer 
risk [n 2,304] suggests those participants with a 25(OH)D concentration > 100 nmol/L had a 
substantial reduction in risk of all invasive cancers (including colorectal cancer) suggesting 
that maintaining a 25(OH)D concentration above 100 nmol/L might be protective against 
cancer risk  (McDonnell et al., 2016).  It is noteworthy that only 7 out of the 47 participants in 
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the BFU study achieved this concentration of 25(OH)D and so it remains unclear as to 
whether these patients are truly at risk of CRC based on their vitamin D status. 
There is a debate among scientist regarding the effect of vitamin D on CRC.  The active 
hormonal form of vitamin D [1,25(OH)D)] exhibits cancer-preventative effects by inhibiting 
proliferation and promoting differentiation through a genomic pathway, but also has non-
genomic actions  through altering serum calcium concentration (Feskanich et al. 2004). A 
case control study conducted in Los Angeles, reported that vitamin D intake was not 
associated with the development of CRC (Peters et al., 1992).  A follow-up study (13.5 years) 
of women (n=61463) with CRC reported, 572 new cases of CRC which did not associate with 
vitamin D intake (Terry et al., 2002). A case control study of adults men and women (cases 
were with colorectal cancer) showed that dietary vitamin D intake was not associated with 
CRC (RR = 1.04, 95% CI 0.65-1.67) (Kampman et al., 1994).  
7.4.3 Strengths and limitations  
To best of our knowledge this is the first follow-up study conducted in the UK recruiting 
older adults who are at moderate risk of CRC to evaluate the change in serum 25(OH)D 
concentration over 12 year period.  Assessing dietary vitamin D intake in the same group 
using the same tool is an advantage to this study. However the methods used to assess the 
serum 25(OH)D in two studies are different. The baseline serum 25(OH)D was measured 
using IDS Radioimmunoassay, while Roche immune assay was used in follow-up study. 
Change in the vitamin D status in two studies cannot be compared accurately. The very low 
sample size might be the main limitation of this study. Baseline serum 25(OH)D 
concentration was available only for 37 older adults, which we cannot compare the baseline 
and follow-up values accurately. In addition there was a selection bias in the BORICC study. 
The participants of BORICC study were the patients who referred for the investigation of 
gastrointestinal symptoms and underwent screening by flexible sigmoidoscopy. Therefore the 
participants were not the representative sample of the general population.   
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7.4.4 Public health implications 
This study showed that whilst there was no significant change in vitamin D status over a 12 
year period in older adults at moderate risk of CRC, there was an apparent increase in the % 
of those with 25(OH)D concentrations < 50 nmol/L at follow up (7 v’s 16 individuals 
respectively). Whilst the true implication of this finding for overall CRC risk remains 
unknown, it would be prudent for these patients to maintain serum 25(OH)D concentrations > 
50 nmol/L.  Such a recommendation might also have benefits to individual bone health as this 
threshold underpins the population RDA for vitamin D (Ross et al. 2010).  
7.4.5 Conclusions 
This study concluded that the number of older adults with VDD increased from 7 to 16  
during 12 years period in older adults who were at moderate risk of CRC. Though the serum 
25(OH)D and vitamin D intakes of older adults were reduced during 12 years period, these 
reductions were not statistically significant. Future studies are required to confirm this finding 









Chapter 8: General Discussion and Conclusions 
8.1 Overview of the PhD study  
A reduction in MSK function is one of the characteristics of aging which impacts on QOL 
(Carson et al., 2018). Vitamin D plays a role in MSK health through genomic and non 
genomic pathways (Ceglia and Harris, 2013).  However, the vitamin D supply required for the 
optimum MSK function is not universally agreed.   Different thresholds are used to define 
“vitamin D adequacy” by SACN and IOM for the UK and for the US populations, 
respectively. The SACN uses 25(OH)D concentration 25 nmol/L as the basis for setting the 
RNI for vitamin D based on the MSK outcomes (SACN, 2016), while IOM uses 25(OH)D 
concentration 50 nmol/L as the basis for setting the RDA for vitamin D based on the bone 
outcomes (Ross et al., 2011). These different thresholds used by the SACN and IOM are 
attributed to the different outcomes used in setting DRVs, geographical variation in vitamin D 
status, different response to vitamin D supplementation and differences in sunlight exposure. 
Sun exposure is considered as the marker of vitamin D supply and it is believed that about 
90% of the vitamin D is supplied by the skin synthesis upon UVB radiation exposure (Fraser 
and Milan, 2013).  However, assessing the relative contribution of sun exposure to vitamin D 
status in older adults is challenging due to the complexities associated with personal UV 
exposure in people.    
Previous studies have demonstrated both anabolic (Iwaniec et al., 2007) and catabolic (Visser 
et al., 2003) effects of PTH (a functional biomarker of vitamin D) on MSK outcomes. 
However, whether the association between PTH concentration and MSK function is 
independent of serum 25(OH)D concentration is uncertain. VDD is widespread worldwide, 
especially in countries located in higher latitudes where sunlight availability is low at certain 
times of the year. Older people have less capacity for dermal synthesis of vitamin D due to 
lower availability of 7-dehydrocholesterol, poor kidney and liver function and low outdoor 
activities which reduces sunlight exposure (Gennari, 2001).  
This PhD study attempted to determine the effect of vitamin D supply on muscle function and 
to determine the association between commonly-used vitamin D biomarkers [25(OH)D and 
PTH] and muscle function and bone health in older adults using two different studies from the 
North East of England (55° North). In addition, this PhD study attempted to quantify the 




The hypotheses of this PhD study are: 
1. Lower serum 25(OH)D concentrations will be associated with poorer  MSK outcomes  
2. Vitamin D supplementation at doses equivalent to 400 IU/day, 800 IU/day and 1600 
IU/day for 12 months will result in improvements in  muscle function in dose 
dependent manner.  
3. Sunshine exposure assessed by newly adapted questionnaires will predict vitamin D 
status in the cross sectional analyses and will modulate the response to vitamin D 
supplementation in the RCT analysis. 
4. PTH concentration will influence MSK outcomes in both cross sectional and RCT 
analyses.  
The two study designs used in this PhD and discussed in more detail in Chapter 2 are: 
i) A RCT of three doses of supplemental vitamin D in older adults (Vitamin D in Older 
People Study (VDOP) Study). 
ii) A cross sectional study of older adults who participated in the BORICC Follow-Up (BFU) 
Study. 
Objectives 
The specific objectives of this project were:  
1. to investigate the effects of three doses of supplemental vitamin D3 (12000 IU, 
24000 IU, 48000 IU) monthly for 12 months on markers of muscle function in 
older adults from VDOP study.  
2. to quantify the contribution of cumulative sun exposure to serum 25(OH)D  
concentration among older adults supplemented with vitamin D3 monthly for one 
year from VDOP study. 
3. to investigate relationships between i) sun exposure behaviours and serum 
25(OH)D concentration and ii) serum 25(OH)D concentration and MSK outcomes 
in participants in the BFU study. 
4. to investigate relationships between PTH concentration, 25(OH)D concentration 
and MSK outcomes of older adults in both the VDOP and BFU studies. 
5. to identify the change in serum 25(OH)D concentration and dietary vitamin D 
intake of older adults who are at moderate risk of CRC during the 12 year period 







8.2 Discussion of Main Findings 
8.2.1 Effect of vitamin D supplementation on muscle function  
Analysis of data from the VDOP Study showed that vitamin D3 supplementation at the doses 
of 12000 IU, 24 000 IU and 48 000 IU monthly for 12 months had no effect on muscle 
function in older adults aged  > 70 years. Therefore our study did not generate the evidence to 
support 2nd  hypothesis. A positive effect of vitamin D supplementation on muscle function 
was not observed  even in older adults whose baseline serum 25(OH)D concentration below 
25 nmol/L. However, only 27% of the participants in VDOP Study had serum 25(OH)D 
concentration below 25 nmol/L at baseline. If having low vitamin D status initially is a 
determinant of response to vitamin D supplementation (Stockton et al., 2011)  then the fact 
that almost three quarters of the participants had adequate vitamin D status at baseline might 
be the reason for the absence of a positive effect of vitamin D supplementation on muscle 
function. Alternatively, or in addition, it may be necessary to raise serum 25(OH)D 
concentration above the highest concentration achieved in this intervention study (i.e. 79.0 
nmol/L for the 48000 IU group) to demonstrate a benefit for MSK health but this suggestion 
is very speculative. Except only 0.9% of the participants in the low dose group, all of the 
participants who had 25(OH)D concentrations < 25 nmol/L at baseline became vitamin D 
sufficient after the intervention, demonstrating the efficacy in supplementation in 
improvement in 25(OH)D concentrations. However, there was no improvement in the GS or 
TUG test based on the improvement in the vitamin D status.  
This PhD study also attempted to identify the circulating 25(OH)D concentration required for 
the optimum MSK function in older adults. The IOM recommends serum 25(OH)D > 50 
nmol/ for optimum bone health. Furthermore, Holick et al., 2011 suggested that serum 
25(OH)D concentration higher than 75 nmol/L might be sufficient for most of the health 
outcomes. There has been some support for the idea that achieving serum 25(OH)D 
concentration > 90 - 100 nmol/L following vitamin D supplementation would optimize MSK 
outcomes (Kotlarczyk et al., 2017; Bischoff-Ferrari et al., 2006).   However, data from this 
PhD thesis does not lend support for the use of higher 25(OH)D thresholds above 90-100 
nmol/L for optimal muscle function.    
8.2.2 Relationship between serum 25(OH)D concentration and MSK function 
The relationships between serum 25(OH)D concentration and MSK outcomes was 
investigated  in both the BFU Study and in the RCT (VDOP Study) under this PhD study. 
Baseline plasma 25(OH)D concentration less than 25 nmol/L had a negative association 
between upper GS in the VDOP study. This finding supported the recommendation from 
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SACN that “For the protection of MSK health, serum 25(OH)D concentration should not fall 
below 25 nmol/L throughout the year” (SACN, 2016). However in the BFU Study, serum 
25(OH)D concentration was not associated with either muscle function (GS and TUG) or 
bone health (heel bone density measured by ultrasound) in older adults. Therefore second 
hypothesis was partly accepted. In the BFU Study, mean serum 25(OH)D concentration was 
79.2 (SD 38.3) nmol/L and none of the participants had serum 25(OH)D concentration below 
25 nmol/L. The better vitamin D status, narrow range in serum 25(OH)D concentration (27 - 
149 nmol/L) and low sample size in the cross sectional study might be attributed to this null 
finding.  It is also likely that muscle function was already adequate in these older participants. 
8.2.3 Determinants of vitamin D status including sun exposure 
The determinants (sun exposure, demographic, dietary and anthropometric) of serum 
25(OH)D concentration in BFU study and baseline plasma 25(OH)D concentration of the 
VDOP study were identified in this PhD study. In addition, the association between mean 
SES of one year period and serum 25 (OH)D was identified  in VDOP study after 12 months 
supplementation. In RCT before vitamin D supplementation, dark skin types and holiday 
visits predicted plasma 25(OH)D concentration along with age, female gender and BMI. 
However, SES was not associated with serum 25(OH)D concentration at baseline in VDOP 
study. Though SES was not associated with serum 25(OH)D concentration, questions about 
holiday visits, sun exposure season and skin type predicted baseline serum 25(OH)D 
concentration. SES did not predict serum 25(OH)D concentration after total supplementation 
in any of the dose groups. Baseline plasma 25(OH)D concentration and the dose of vitamin D 
supplements were the noticeable predictors of endpoint plasma 25(OH)D concentration in all 
dose groups.  
In BFU study holiday visit was the only significant sun exposure predictor of serum 25(OH)D 
concentration which was also a predictor of baseline plasma 25(OH)D concentration of the 
VDOP Study. Findings of both studies showed good agreement of using the details about 
holiday visits to use as a proxy indicator of vitamin D status in older adults.  The general 
limitation of a sun exposure questionnaires might be attributed to the non-significant 
associations between SES and  serum 25(OH)D concentration. According to these findings, 
3rd hypothesis of this PhD study can  partly be accepted, but only for the older adults who do 
not use vitamin D supplements. In VDOP study, the sun exposure questionnaire consisted of 
four broad questions on skin types, frequency of sun exposure, skin exposure area and the 
area of sunblock use at home and at holiday visits. The sun exposure questionnaire used in the 
BFU Study was more comprehensive than the one that used in VDOP Study. Because it 
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consisted of 14 questions which gathered details about skin types, duration of outdoor 
activities at weekends and in weekdays, sun avoidance habits, clothing style, sunblock use 
and the details about sun holidays. Aggregating the answers of sun exposure questions to 
drive SES might lead for a crude measure of sun exposure, which resulted in null finding 
regarding the association of serum 25(OH)D concentration and sun exposure after vitamin D 
supplementation.   
Dietary vitamin D did not associate with serum 25(OH)D concentration in either studies. The 
influence of sun exposure variables and diet on plasma 25(OH)D concentration is minimum 
compared to vitamin D supplementation, anthropometric and demographic variables. 
Therefore vitamin D supplementation is more effective in improving vitamin D status 
compared to sun exposure and dietary vitamin D intake in older adults. 
8.2.4 Relationship between PTH concentration and MSK function  
The relationship between PTH and MSK function of older adults in both studies were 
explored in this PhD study. A significant association between PTH concentration and muscle 
function in either study was not reported. However, there was a significant positive 
association between PTH concentration and bone health parameters in the cross sectional 
study. Therefore our findings partly supported 4th hypothesis of this PhD study. This finding 
should be interpreted with caution. Because a past research described that PTH has an 
anabolic effect on bone tissues at a low concentration while the catabolic effect at the higher 
concentration (Silva and Bilezikian, 2015). The positive association of PTH concentration and 
bone health outcomes reported in this study might be attributed to the low range of PTH 
concentration that did not reach the level of hyperparathyroidism. Therefore the identified 
PTH concentration range between 21.7 – 71.7 Pg/mL in this study would be advantageous to 
have a positive association between bone health outcomes in older adults.  
8.2.5 Change in serum 25(OH)D concentration during 12 years period 
Change in serum 25(OH)D concentration during a 12 year period in older adults who are at 
moderate risk of CRC was investigated in this study. Prevalence of VDD (serum 25(OH)D 
concentration < 50 nmol/L) of older adults was increased from 14.9% to 38.3% during a 12 
year period. The reduction in vitamin D intake and serum 25(OH)D concentration during 12 
years period were not statistically significant. However, serum 25(OH)D concentration values 
at baseline and at follow-up studies cannot be entirely compared, as the methods used assess 
the vitamin D concentrations are different. At baseline serum 25(OH)D concentration was 
measured by IDS immunoassay method while at follow-up, Roche immunoassay was used. 
Whilst there have been a number of excellent literature sources attempting to harmonize 
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vitamin D status data in other studies, mainly national surveys through the use of calibration 
equations, to my knowledge most of these calibration efforts have focused on recent 
mainstream assay platforms such as LC-MS/MS, Diasorin Liaison Total and  Roche assays.  
These three assays alone are used by 58% of the 926 laboratories in the 2017 Vitamin D 
DEQAS and represent just 10% of the total number of analytical platforms used in the scheme 
(total = 30).  The manual IDS ELIA kit used to assess 25(OH)D at baseline in the CRC risk 
participants was a popular assay from 2002-2010 but has now been replaced by automated 
platforms.   The Roche assay used to assess 25(OH)D in the 12 year follow up study is now a 
commonly used automated clinical assay which was launched in 2009.  Thus, the lack of 
calibration data between the manual IDS EIA and the automated Roche assay makes any 
meaningful adjustment difficult in this study and for these reasons no attempt was made at 
trying to harmonize the two sets of 25(OH)D data.   
8.3 Strengths and Limitations 
One of the main strengths of this PhD study was the use of two study designs, RCT and a 
cross sectional study to test the hypothesis. Prior studies reported the contradictory finding on 
the association between plasma 25(OH)D and MSK outcomes in older adults depending on 
the study designs.  Therefore the hypothesis could be tested by overcoming the limitations of 
each study design. The cross sectional study showed the snapshot of the association of serum 
25(OH)D, PTH concentration and MSK outcomes in older adults. In a cross sectional study 
design, the true association of serum 25(OH)D concentration and MSK outcomes might be 
masked by other factors such as socioeconomic, demographic, environmental and biological 
factors.  
Determining the association of serum 25(OH)D concentration and MSK outcomes in a large 
sample of free living older adults in the RCT added strength to this PhD study. This is the first 
RCT conducted in the UK to identify this association in older adults. Assessment of several 
variables that potentially influence muscle function such as body composition, anthropometric 
variables, PTH concentration and dietary intake was an advantage to this PhD study. There is 
a disagreement among scientist regarding the optimum serum 25(OH)D concentration 
required to optimize the health outcomes and for the cutoff value of the serum 25(OH)D 
concentration for the VDD. Therefore use of three different doses that correspondent to the 
RNI value for the vitamin D in the UK, RDA value for the vitamin D in the US and the value 
below the Tolerable Upper Intake Level to investigate the effect of vitamin D 
supplementation on muscle function added a novelty to this PhD study. Investigation of the 
relative contribution of cumulative sun exposure of a whole one year period to plasma 
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25(OH)D concentration, compared to the vitamin D3 supplementation was also a novel 
approach in this study. In BFU study we followed up the older adults of moderate risk of CRC 
for 12 years period and determined the association between serum 25(OH)D concentration 
and MSK outcomes which also added a novelty to this study. In addition this is the first study 
conducted in the UK to identify the changes of serum 25(OH)D concentration of older adults 
who are at moderate risk of CRC.  
However, this PhD study had some limitations. Not having a placebo group in the RCT was 
the main limitation of VDOP study. In addition, in the RCT, determining the plasma 
25(OH)D concentration before and after the supplementation, might not reflect the year 
around vitamin D status of older adults. Further the population of both studies were not 
randomly selected from the community, thus we cannot generalize our findings for the 
general population of the UK. The low sample size of the cross sectional study was another 
limitation. On the other hand use of only GS and TUG test to evaluate muscle function might 
not reflect the true muscle function of the older adults. Similarly, the use of Ultra Sound 
technique might not accurate in assessing bone quality and it is not an ideal tool to diagnose 
fracture risk. The use of a questionnaire to assess the sun exposure might also lead to 
underestimation of actual personal sun exposure of older adults.  
8.4 Public Health Implications  
Without doubt, the most important finding in this PhD study regarding the determinants of 
vitamin D status was the clearly evident dose response relationship between supplemental 
vitamin D and improvement in vitamin D status over 12 months i.e. throughout a whole year 
and during a full winter in Newcastle.  A dose of vitamin D equivalent to 10 µg/day (i.e. 
12,000IU monthly) was sufficient to keep all participants above a 25(OH)D concentration of 
25 nmol/L.  These findings reinforce the advice from SACN regarding the population DRVs 
for vitamin D in the UK where the RNI for all people > 4 years of age including those in at 
risk groups is 10 µg/day.   As this study failed to find positive associations between dietary 
sources of vitamin D and serum 25(OH)D, the PhD findings lend support to the use of 
supplements in meeting vitamin D requirements in older adults.  The weaker associations 
between holiday visits, being female, age, BMI and having darker pigmented skin and 
25(OH)D concentrations in VDOP participants at baseline suggests that these factors may 
also have relevance in informing public health advice in terms of reducing VDD although the 




8.5 Future Studies  
Past research findings reported that, incorporating physical activity intervention along with 
the vitamin D supplementation would help to improve the muscle function compared to 
vitamin D supplementation along (Antoniak and Greig, 2017).  Future studies are 
recommended, incorporating the physical activity along with the vitamin D supplementation 
trial to test the effect of vitamin D supplementation on muscle function in older adults. 
Similarly, a prior study revealed that the effect of vitamin D supplementation can be seen only 
in the older adults whose baseline serum 25(OH)D concentration less than 25 nmol/L 
(Stockton et al., 2011). Therefore future studies are required to carry out recruiting the older 
adults whose baseline 25(OH)D concentration less than 25 nmol/L. New studies are also 
needed using the combination of several methods of assessing MSK outcomes such as use of 
the falls data, Short Physical Performance Battery Score, gait speed, computer tomography 
and use of DEXA. In addition improving RCT design with a placebo group would be an 
advantage in future studies to evaluate the effect of vitamin D supplementation compared to 
the vitamin D supplement non-users.  Use of sun exposure questionnaire is an indirect method 
of assessing sun exposure, which is less accurate and underestimates the personal sunlight 
exposure (Diffey, 2007). Therefore it is worth to conduct future studies using direct methods 
of assessing personal sun exposure such as the use of dosimeters. Future studies are needed to 
carry out recruiting a large representative sample of older adults in the UK to confirm these 
findings.  
8.6 Conclusions  
From this PhD study I can conclude that older adults with serum 25(OH)D concentration < 25 
nmol/L may have poor muscle function than those with serum 25(OH)D concentration higher 
than 25 nmol/L. PTH concentration did not associate with muscle function but showed the 
evidence for an association with heel bone QUS. Whilst vitamin D supplementation at doses 
of 12000 IU, 24000 IU and 48000 IU monthly for 12 months increased 25(OH)D 
concentration in a dose dependent manner, it had no effect on GS and TUG performance in 
older adults. As observed in the RCT, vitamin D supplementation appeared to overwhelm the 
effect of sun exposure on 25(OH)D concentration. In the cross sectional study, sunny holidays 
were positively associated with serum 25(OH)D concentration in older adults. In conclusion, 
vitamin D supplementation does not improve muscle function in older adults with a low 
prevalence of VDD  [25(OH)D < 25 nmol/L)].  In line with SACN recommendations it may 
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Dear    ………                          
 
Thank you very much for your participation in the BORICC Study several years ago. We are 
writing to inform you that we are conducting a follow-up study to investigate the effects of 
ageing (12+ years) and lifestyle factors on changes in biomarkers (a biological marker) of 
bowel cancer risk.  
 
We have organised three showcase events at North Tyneside General Hospital for participants 
from the original BORICC Study to provide you with information on the findings from the 
study 12+ years ago and on what we plan to do in the follow-up study. It will also be an 
opportunity for you to see the equipment that we will be using, to try out some of our tests, 
such as hand grip strength, and to ask questions about the new project. Light refreshments will 
be provided. 
 
We would like to invite you to participate in one of these showcase events which have been 
organised at different times of the week to try to accommodate everyone.  
The following are the event dates: 
 11am on Thursday 31st August 
 4pm on Thursday 31st August 
 11am Saturday 2nd September  
 
If you would like to attend, please confirm your attendance by returning the enclosed card or 
by contacting the research team (details below). In addition, please let us know if these dates 
are unsuitable for you and you are interested in attending a future event. If you are interested 
in taking part in the study but would prefer not to attend a showcase event, please indicate this 
on the card. 
 
Dr. Fiona Malcomson  
Human Nutrition Research Centre 
Newcastle University 
1st Floor Biomedical Research Building 
Campus for Ageing and Vitality 
Newcastle upon Tyne 
NE4 5PL 
Telephone: 0191 2081141 (please ask for Fiona or another member of the BFU Study team) 
Mobile: 07791642754 
Email: fiona.malcomson@newcastle.ac.uk    
 









1. Invitation  
You are being invited to take part in a research follow-up study conducted by Northumbria 
NHS Foundation Trust and Newcastle University. Before you decide whether you would like 
to take part, please take time to read the following information carefully. You may wish to 
discuss the study with relatives, friends and your GP. Please contact the research team if there 
is anything that is not clear to you, if you have any questions or would like more information. 
 
Your decision will not affect any other aspect of the care that you may be receiving, or may 
receive in the future, at the hospital. If you do decide to participate, we will ask for your 
permission to inform your GP, so that they are aware of your participation in the study. Thank 
you very much for taking the time to read this. 
 
2. Why is this study being performed? 
 
Bowel problems are common and lifestyle factors, such as diet and physical activity, are 
known to be important in the development of certain diseases of the large bowel (colon). 
Ageing is also a strong contributor to changes in the large bowel and disease development. In 
the original BORICC Study, we found that diet affects certain proteins and genes in the cells 
of the large bowel. In this follow-up study, we would like to investigate the effects of ageing 
(over a period of about 10 years) on cells in the large bowel and to what extent these changes 
are affected by lifestyle factors. We hope that this study will give us a better understanding of 
the relationship between ageing, diet and physical activity and the health of the bowel.  
 
3. Why have I been asked to participate in the study? 
You have been invited to participate in this follow-up study because you took part in the 
original BORICC Study about 10 years ago. As we are taking follow-up measurements, we 
will recruit the original participants from the BORICC Study so that we can compare the data 
from 10 years ago with data collected in this later study.  
4. Do I have to take part? 
It is for you to decide whether you wish to take part. If you decide to participate in this study, 
you will be asked to sign a consent form. Even if you do decide to take part in this study, you 
can withdraw at any time. If you decide to withdraw from the study, you will not have to tell 
us why and it will not affect your treatment in any way. 
5. What will I have to do as a volunteer? 
 
As mentioned above, if you decide that you wish to volunteer, then you will be invited to sign 
a consent form.  
 
We would like to collect the following information and samples during a clinic appointment 
at North Tyneside General Hospital, which will last around 1 hour: 
 Medical history 
 Height, weight, waist and hip measurements 
 Body fat percentage measured using bioimpedance weighing scales with footplates 
 Blood samples (seven 5ml tubes, equating to no more than 35ml) 
 Sigmoidoscopy and collection of 10 rectal biopsies (please see below) 
 One inner cheek swab 
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 Musculoskeletal function tests (timed up and go, hand grip strength and heel 
ultrasound tests) 
 
We would also like you to do the following at home: 
 Complete a food frequency questionnaire (this will take approximately 30 minutes) 
 Complete a lifestyle questionnaire (this will take approximately 5 minutes) 
 Complete a sunlight exposure questionnaire (this will take approximately 10 minutes) 
 Collect two urine samples and one stool sample - we will provide you with 
instructions and pots for sample collection 
 Wear a physical activity monitor (a small wrist-worn device) for one week  
The above questionnaires, physical activity monitor and sample collection pots will be posted 
to you in advance. We will then ask you bring these along with you to your hospital 
appointment.  
 
6. Does the study involve any invasive tests? 
To obtain small samples of tissue (biopsies) from the bowel wall we will need to perform a 
short camera examination of your bowel called a sigmoidoscopy. We plan to take ten pinch 
biopsies from the bowel wall at a distance of 10cm (4 inches) from the back passage. This 
will be performed by a clinician trained in this endoscopic examination who will examine for 
any conditions which may cause pain, such as fissures or haemorrhoids, before proceeding. 
The procedure is associated with some discomfort but this is usually mild. The procedure 
should not be painful and is normally carried out without the need for anaesthetic or sedation. 
If you were to find the procedure too uncomfortable then you would, of course, be able to ask 
the clinician to stop. In our previous study, we completed 81 similar procedures and did not 
encounter anybody who found the procedure too uncomfortable to ask the doctor to stop. You 
should not experience any pain during the taking of biopsies from the bowel wall.  
 
7. How does the follow-up study differ from the original BORICC Study? 
The sigmoidoscopy used to collect the bowel wall samples is a less invasive procedure than 
that used in the original BORICC study. In the original study, bowel wall biopsies were 
collected during colonoscopy or flexible sigmoidoscopy procedures which require bowel 
preparations (such as enemas, suppositories or strong laxatives). In contrast, a sigmoidoscopy 
does not require you to take any bowel preparation and the camera does not have to go 
through the bends in the bowel. The procedure should take only approximately 15 minutes. 
We will also be taking some additional information from you in this follow-up study which 
we did not collect in the original BORICC Study: 
 Physical activity data collected by a physical activity monitor worn on your wrist for 
one week 
 Sunlight exposure data (to measure vitamin D) collected from a questionnaire 
 Physical capability data collected from two muscle function tests (the ‘timed stand up 
and go test’ the ‘hand grip strength’ test and the heel ultrasound test). The ‘timed stand 
up and go’ test involves sitting on a chair, standing up, walking to a cone and 
returning to sit back down on the chair. The handgrip strength involves sitting and 
resting your arm on an armchair, then gripping and squeezing a dynamometer (a small 
device that measures force) as hard as you can. The heel ultrasound test involves 
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placing your foot in the heel ultrasound machine’s footwell and sitting still for 
approximately 10 seconds whilst the device makes the measurements. 




8. What are the risks of sigmoidoscopy examination and biopsies? 
Some people may experience some bloating, cramping, abdominal discomfort and excess 
wind after the procedure. This is usually from the air that we puff in to the bowel in order to 
expand it during the examination, which we try to minimise. If these side effects do occur, 
they are unlikely to last for more than 24 hours and usually resolve without the need for any 
treatment. 
The sigmoidoscopy examination is generally considered a safe procedure, but it does carry a 
very small risk of complications. It is important that you understand this before deciding 
whether or not to participate. There is a very small chance (1 in 65,000) of a perforation (a 
puncture) of the bowel. Although very rare, a perforation will usually require surgery. 
Significant bleeding is also a rare (1 in 10,000) potential complication. The risk of bleeding or 
perforation is higher with each biopsy that is being taken. There are no other known lasting 
adverse effects of this test. If you were to suffer any of the following symptoms within 48 
hours after a sigmoidoscopy, you are advised to consult a doctor immediately: 
 Severe abdominal pain 
 Significant rectal bleeding 
 Fever  
 
9. What happens if anything goes wrong? 
If, in the very unlikely event, taking part in this study causes any harm to you, there are no 
special compensation arrangements, but you will still be entitled to complain through the 
usual hospital procedures. If you are harmed due to someone’s negligence or wrongdoing then 
you may have grounds for legal action, but you may have to pay for it. You may withdraw 
from the study at any time without explaining why and this will not affect any future care that 
you may receive. 
 
10. Will my information be confidential? 
Yes, all of the information we will collect from you during the study will be strictly 
confidential. This information will be kept securely while the study is taking place. Only the 
research team will have access to the study data. Furthermore, your information and data will 
be anonymised and you will be given a specific study ID number. Specific details, which 
could identify you, will only be available to the research team. Your GP will be informed that 
you are taking part in this study. 
 
11. What will happen to the samples collected in this study? 
The samples that are collected will be examined at laboratories in Newcastle University. All 
samples will be stored securely. We will perform tests to look for various markers of cell and 
metabolic activity. We will try to link these changes with your habitual diet, based on the 
information you gave us in the food frequency questionnaire, and physical activity levels, 
based on your lifestyle questionnaire and physical activity monitor data.  
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After the study has finished, the samples will be stored in our laboratory freezers in 
accordance with government regulations. Your name and details will not be recorded on the 
samples. All of the samples will be anonymised, meaning that the data resulting from your 
samples cannot be traced to yourself. 
We will keep the samples so that we can do further testing if new techniques or markers are 
discovered, without having to collect any new samples. We may send samples to 
collaborating research institutes for additional analyses but this will not be for financial gain. 
 
12. How often will I need to visit the hospital if I decide to volunteer for the study? 
You will be asked to attend the hospital for approximately 1 hour on one occasion only. We 
will reimburse any travel expenses incurred.  
 
13. What benefits will I get from the study? 
You will not directly benefit from volunteering to participate in this study. However, we will 
give you feedback on your diet and lifestyle which you may find useful. The research may 
well help us understand how ageing and lifestyle factors, such as diet and physical activity, 
affect large bowel health and consequently the development of diseases of the large bowel, 
such as bowel cancer. This may lead to the development of prevention and/or treatment 
strategies. Once the study is completed, a summary of the findings can be made available to 
you upon request.  
 
14. Do I need to take a day off work? 
We understand that people lead busy lives. If appointments during usual working hours do not 
suit your lifestyle, then we may be able to work flexibly in order to accommodate you. You 
can discuss this in more detail with one of the members of the research team. 
 
15. Who has reviewed the study? 
The West Midlands – Coventry & Warwickshire Research Ethics Committee has reviewed 
the study (REC reference 16/WM/0424). 
16. Who is performing the research? 
 Professor John Mathers is Professor of Human Nutrition and Director of the Human 
Nutrition Research Centre (HNRC) at Newcastle University 
 Mr. Mike Bradburn is a consultant surgeon at Wansbeck General Hospital 
 Dr. Laura Greaves is a Research Fellow at Newcastle University 
 Dr. Fiona Malcomson is a Research Associate at Newcastle University  
 Mr. Abraham Joel is a Teaching and Research Fellow at Northumbria NHS 
Foundation Trust and will be conducting this research as part of his PhD project 
 Mrs. Stella Breininger is a PhD student at Newcastle University and will be 
conducting this research as part of her PhD project 
 Mrs. Thilanka Ranathunga is a PhD student at Newcastle University and will be 
conducting this research as part of her PhD project 
 Mr. Khalil El Gendy is a MD student at Newcastle University and will be conducting 




17. Who should I contact if I have questions or would like additional information? 
Dr. Fiona Malcomson 
BFU Study Research Team 
Human Nutrition Research Centre 
Newcastle University 
1st Floor Biomedical Research Building 
Campus for Ageing and Vitality 
Newcastle upon Tyne 
NE4 5PL 
Telephone: 0191 2081141 (please ask for Fiona or another member of the BFU Study 
research team) 
Mobile: 07791642754 
Email: fiona.malcomson@newcastle.ac.uk   
  
In addition, you may contact the Patient Advice Liaison Service (PALS) for confidential 
advice, support and information on health-related matters.  
 





Telephone: 0800 0320202 
Email: northoftynepals@nhct.nhs.uk 
 
18. What should I do next if I would like to volunteer? 
 
If you think that you would like to volunteer in this study, we invite you to contact the 
research team in writing or by telephone, when we will provide more information about the 
study and answer any further questions. If you are willing to participate, we will arrange your 
study visit at the hospital and send you a consent form (to be signed and brought to the 
hospital study visit), the questionnaires to be completed, together with the sample collection 
pots and a physical activity monitor. 
 
Please contact us if you have any questions or would like any additional information. Study 











Appendix C : Participants Study Interest form : BFU study 
BFU Participant Study Interest Form 
Participant ID:      Date: 
Recorded by:  




Telephone Number:  _____________________________________ 
Mobile Number:   ________________________________________ 
Email:  _________________________________________________ 
Dominant Hand (for accelerometer): 
Right   □    Left □ 
Checklist: 
 Ensure participant understands study information  □    
 Answered any additional questions    □ 
 Checked participant does not have dementia  □ 
 Checked participant is not on the following medication:   
warfarin, rivaroxaban, apixaban, clopidogrel, dipyridamole □ 
 Described study pack      □ 
 Checked participant is able to travel to attend hospital visit □ 
 Arranged participant study visit for: 
Time:_________________     Date:   _______________________ 
N.B. Ensure there are at least 2 weeks in between phone call and study visit to allow 
time for posting of study pack and wearing of accelerometer. 
Or 









Appendix D : Potential Participants call logs : BFU study 
 
BFU Potential Participants Call Log 
 
Please record the details of any calls made to the BFU (BORICC Follow Up) team (Fiona, AJ, 
Stella and Khalil) in the table below. 
Please ask the caller for their name, telephone number and the best day and time to call them, 
and let them know that a member of the research team will return their call as soon as 
possible. 
In the meantime, we are contactable by email at: Fiona.malcomson@ncl.ac.uk or by mobile 
telephone: 07791642754 
Thank you very much. 
Date Name 
Telephone number 
(home and/ or mobile) 
Best time to contact 
    
    
    
    
    
    
    
    
    
    









Appendix E : At-Home Sample and Questionnaire Collection Record Sheet 
Participant ID :                                                         
At-Home Sample and Questionnaire Collection Record Sheet 
Thank you very much for taking the time to complete the BFU Study questionnaires and 
sample collection. Please make sure you bring these to your study visit at the hospital. Please 
make sure you bring your accelerometer and sleep log with you to the study visit also. 
To help you, please find below checklists that you can tick when you have completed the 
questionnaires and collected the samples.  
Questionnaires: 
Questionnaire Completed (√) 
Food Frequency (FFQ)  
Lifestyle  
Sunlight exposure  
Sample collection: 
For the urine and stool samples, please also write down the date and the time that you 
collected each sample. 
Sample Collected (√) Date Time 
Weekday urine sample    
Weekend day urine sample    
Stool sample    
 
Physical activity: 
Item Completed (√) 
Accelerometer (worn 7 days)  
Accelerometer record sheet  











Patient Health History 
 
DOB:             Age: 
Ethnicity:      Bristol Stool Chart Type: 
 
Past Medical History (√ ) 
Cancer  ☐    IBD                            ☐ 
Asthma        ☐    Mental health disease      ☐ 
COPD       ☐    Type 1 diabetes          ☐ 
CVD    ☐    Type 2 diabetes         ☐ 
Hypertension      ☐    Liver disease:      
Osteoporosis      ☐    Alcohol-related                 ☐ 
Osteoarthritis   ☐    NAFLD             ☐   
Adenomatous Polyps   ☐    Hepatitis               ☐ 
Stroke     ☐    Primary biliary cirrhosis    ☐  
Chronic kidney disease ☐   
 
Details of conditions (e.g. type, date of diagnosis, stage): 
            
            
  ____________________________________________________________ 
Other conditions (and details):    
             
             
 
CRC family history 
Number of 1st degree relatives with CRC or adenomatous polyps:     
 
For female participants 
Number of children:       
Menopausal status: 




Please include details such as drug name, dose, date taken, treatment duration (acute or 
chronic) 
 
Check not on warfarin, apixaban, clopidogrel, dipyrimadole, rivaroxaban 
 
Current medication 
            
            
             
            
            
             
            
            
             
 







Appendix G : VDOP Sunshine Exposure Questionnaire 
Study number ___ ___ ___  Date of Birth  _____/_____/_____   Initials ___ ___ ___ 
VDOP Sunshine Exposure Questionnaire  
(Member of research team to ask participant following questions and record answers) 
 
 Whilst living at your home address, over the last three months, have you been outdoors in sunny weather often, occasionally, rarely or 
never?  
 When you went outside in sunny weather which parts of the body’s skin do you usually expose:  the head, hands, arms, legs, stomach 
or back?   
 Do you use sun block?  If so, which parts of the body do you use it on? 
  
Please tick the relevant boxes below for the last three months  
 Outdoors Body/skin exposure Sunblock 
 Often Occasionally Seldom/ 
never 
Head Hands Arms Legs Stomach/ 
back 




            
2 months 
ago 
            
Last month             
 
How often do you use a sunbed? 








Please list any holidays/visits abroad or to the South of England which you have taken in the last 3 months  
Please tick the relevant boxes below for every holiday/visit separately   [code 1=local; 2=UK<150miles south; 3=UK>150miles South] 
Please tick the relevant boxes below for every holiday/visit separately   [code 1=local; 2=UK<150miles south; 3=UK>150miles 
South; 4=Abroad] 
 Whilst away from home, over the last three months, have you been outdoors in sunny weather often, occasionally, rarely or 
never?  
 When you went outside in sunny weather which parts of the body’s skin do you usually expose:  the head, hands, arms, legs, 
stomach or back?   
 Do you use sun block?  If so, which parts of the body do you use it on? 
 
Holiday/ visit 1 
Where did you visit …………………………………… [         ] (add distance code) 
In which month did you visit …………………………………… 
Length of stay  …………………………………… 
 Outdoors Body/skin exposure Sunblock 
 Often Occasionally Seldom/ 
never 
head hands arms legs Stomach/ 
back 




            
2 months 
ago 
            
Last month             
Holiday/ visit 2 







In which month did you visit  …………………………………… 
Length of stay  …………………………………… 
 
 Outdoors Body/skin exposure Sunblock 
 Often Occasionally Seldom/ 
never 
head hands arms legs Stomach/ 
back 




            
2 months 
ago 
            
             
Last month             




Appendix H : BFU Sun exposure questionnaire 
 
 
   




















This is a questionnaire about your 
habitual sun exposure. When you answer 
the questions, please think about sun 






Gender :   Male ⁭   Female ⁭        
 
2. Age : ______________ years             
3. Occupation : Indoors⁭    Outdoors ⁭    Both ⁭        
 




Description  Skin colour  Please tick  
i Burns easily, never tans White,  very fair  
ii Burns easily, tans minimally White, fair  
iii Burns moderately, tans 
gradually 
Cream white, fair   
iv Burns minimally, tans well Brown, typical Mediterranean 
Caucasian skin 
 
v Rarely burns, tans profusely Dark Brown, mid-eastern skin 
types 
 




5 (a) How often are you outdoors for at least half an hour between 10am – 3pm during the 
sunny months (April-September)?   
Less than once a week  ⁭      
     
1-2 times a week   ⁭      
   
More than 2 times a week  ⁭      
   
Every day    ⁭      
  
 
5 (b) How much time would you spend outdoors on a week days (Monday to Friday) during 
the sunny months (April-September)?  
Less than 15 minutes   ⁭            
Between 15 and 30 minutes  ⁭ 
Between 30 minutes and 2 hours        ⁭ 
 
More than 2 hours   ⁭ 
 
 
5 (c) How much time would you spend outdoors on a weekend (Saturday - Sunday) during the 
sunny months (April-September)?  
Less than 15 minutes   ⁭         
Between 15 and 30 minutes  ⁭ 
Between 30 minutes and 2 hours        ⁭ 
More than 2 hours   ⁭ 
 
6. When you are outdoors during the sunny months (April – September), do you stay in the 
sun or do you seek the shed?  
                          
I try to avoid staying in direct sunshine                  ⁭                    
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I sometimes stay in the sunshine                              ⁭   
I enjoy staying in the sunshine (e.g. to suntan)       ⁭ 
  
7. How would you deliberately wear less clothing so as to get direct sunlight on your skin  
(e.g sleeveless tops shorts)?  
         
Never      Rarely     Sometimes      Usually     Always              
  
   ⁭      ⁭       ⁭          ⁭       ⁭             
 
8. Please rank (by putting a number from 1- 4 in the box) in order what you most wear when 
you are outdoors during the sunny months (April to September).  
 
Please rank with 1 being most likely and 
4 being least likely 
Long sleeves and long trousers or tights       
                
Short sleeves and long trousers or skirt        
 
Short Sleeves and Short skirt or shorts                                                             
   
Swimwear or light beach clothes          
      
 
9.   When you are outdoor during the sunny months (April – September), how often would you 
wear maximum protection sun screen (SPF 15 to 30)? 
 
Never  Rarely  Sometimes    Usually   Always   Other               
     ⁭      ⁭      ⁭        ⁭         ⁭    ⁭  
 
10. Do you use a sun lamp or sun-bed regularly (at least once per week)? 
Yes ⁭   No ⁭          
 
11 (a) Have you been in the mountain or on a skiing holiday within last 3 months?  
   Yes ⁭      No ⁭  
          
11 (b) If yes, for how long? Please include total number of days of all holidays. 
 
……………………..  days          
 
12 (a) Have you been on holidays to a sunny places (including sunny weather in England) 
since last 3 months?          
Yes ⁭      No ⁭          
 
12 (b) If yes, for how long? Please include the total number of days of all 










13. Please complete the following table with information on any holiday(s) (including in the UK and broad) you have had in the last 3 months. 
 
 









Holiday Location Month(s) 
Length 
(days) 
How often were you 
outdoors? 
Please tick the parts of the body that 
were usually exposed to the sun 
Please tick which parts of 

















               
2 
 
               
3 
 
               
4 
 
               
5 
 






















































Appendix J : Food Frequency questionnaire – BFU study 
Food Frequency Questionnaire 
 
CODE:       
Date:        
 
Thank you for agreeing to take part in the study. This is a 
simple questionnaire designed to help us understand what 
kinds of food you normally eat. It is not a test, so there are 
no right or wrong answers.  
It is your usual diet we are interested in. 
 
All information will be treated in the strictest confidence. 
Thank you for your time 










About the food you eat 
 
The following questions are about the food you usually eat and how often you eat 
certain foods. Please read the following instructions before answering the 
questions.  
For each food there is an amount shown, either a “medium serving” or a common 
household unit such as a slice or teaspoon.  Please put a tick in the box to 
indicate how often, on average, you have eaten the specified amount of each 




For white bread the amount is one slice, so if you ate 4 or 5 slices a day, you 
should put a tick in the column headed “4-5 per day”. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
BREAD & SAVOURY 
BISCUITS 





























White bread and rolls 
 




For chips, the amount is a “medium serving”, so if you had a helping of chips 
twice a week you should put a tick in the column headed “2-4 per week”. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 

































         
 




Please put a tick in each box to indicate how often, on average, you have eaten 
each food during the past year. 
 
Please estimate your average food use as best you can, and please answer every 
question - do not leave ANY lines blank.  Please put a tick on every line. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 






























Beef: roast, steak, mince, stew 
casserole, curry or bolognese 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pork: roast, chops, stew, slice or 
curry 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Lamb: roast, chops, stew or 
curry 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chicken, turkey or other poultry: 
including fried, casseroles or 
curry 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Corned beef, Spam, luncheon 
meats 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Savoury pies, e.g. meat pie, pork 
pie, pasties, steak & kidney pie, 
sausage rolls, scotch egg 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     






























PLEASE PUT A TICK ON EVERY LINE. 
 
 
PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 

































Liver, liver pate, liver sausage 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fried fish in batter, as in fish 
and chips 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fish fingers, fish cakes 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Other white fish, fresh or 
frozen, e.g. cod, haddock, plaice, 
sole, halibut 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
Oily fish, fresh or canned, e.g. 
mackerel, kippers, tuna, salmon, 
sardines, herring 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
Shellfish, e.g. crab, prawns, 
mussels 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
20. BREAD & SAVOURY BISCUITS 
(one slice or biscuit) 
White bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Scones, teacakes, crumpets, 
muffins or croissants 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brown bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wholemeal bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cream crackers, cheese biscuits 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pitta bread, naan bread, chapati  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            


































PLEASE PUT A TICK ON EVERY LINE. 
 


































            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sugar coated cereals e.g. Sugar 
Puffs, Cocoa Pops, Frosties 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Non-sugar coated cereals e.g. 
Cornflakes, Rice Crispies 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
All Bran, Bran Flakes, Muesli  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wholegrain cereals e.g. Cheerios, 
Weetabix, Shredded Wheat 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
22. POTATOES, RICE & PASTA 
(medium serving) 
Boiled, mashed, instant or jacket 
potatoes 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chips, potato waffles 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Yorkshire pudding, pancakes, 
dumpling 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
White rice  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brown rice  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
White or green pasta, e.g. 
spaghetti, macaroni, noodles 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tinned pasta, e.g. spaghetti, 
ravioli, macaroni 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            































Please check that you have a tick on EVERY line 
 
251 
PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
22. POTATOES, RICE 







































              2 
 
 
             3 
 
 
             4 
 
 
               
5   
 
 
              6  
 
 













            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Lasagne, moussaka, cannelloni  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
23. DAIRY PRODUCTS & FATS 
 
       
Single or sour cream 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Double or clotted cream 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low fat yoghurt, fromage frais 
(125g carton) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Full fat or Greek yoghurt (125g 
carton) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dairy desserts (125g carton), 
e.g. mousse 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cheese, e.g. Cheddar, Brie, Edam 
(medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cottage cheese, low fat soft 
cheese (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Eggs as boiled, fried, scrambled, 
omelette etc. (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Quiche (medium serving) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




































PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
23.(b) The following on 


































            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Block margarine, e.g. Stork, 
Krona 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Polyunsaturated margarine, e.g. 
Flora sunflower 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Other soft margarine, dairy 
spreads, e.g. Blue Band, Clover 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low fat spread, e.g. Gold  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
24. SWEETS & SNACKS 
 
        
Sweet biscuits, chocolate, e.g. 
digestive (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweet biscuits, plain, e.g. Nice, 
ginger (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cakes e.g. fruit, sponge, sponge 
pudding (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweet buns & pastries e.g. flapjacks, 
doughnuts, Danish pastries, cream 
cakes (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fruit pies, tarts, crumbles 
(medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Milk puddings, e.g. rice, custard, 
trifle (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chocolates (small bar or ¼ pound 
of chocolates) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Ice cream, choc ices (one)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            





































PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
































Sweets, toffees, mints (one 
packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sugar added to tea, coffee, 
cereal (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Crisps or other packet snacks 
e.g. Wotsits (one packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peanuts or other nuts (one 
packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
25. SOUPS, SAUCES AND SPREADS 
 
      
Vegetable soups (bowl)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Meat soups (bowl)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sauces, e.g. white sauce, cheese 
sauce, gravy (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tomato based sauces, e.g. pasta 
sauces (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tomato ketchup, brown sauce 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Relishes, e. g. pickles, chutney, 
mustard (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low calorie, low fat salad cream 
or mayonnaise (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Salad cream, mayonnaise 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
French dressing (tablespoon)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            




































PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
































Other salad dressing 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Marmite, Bovril (teaspoon) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Jam, marmalade, honey, syrup 
(teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peanut butter (teaspoon) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chocolate spread, chocolate nut 
spread (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dips, e.g. houmous, cheese and 
chive (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
26. DRINKS 
 
         
Tea (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coffee, instant or ground (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coffee whitener, e.g. Coffee-
mate (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cocoa, hot chocolate (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Horlicks, Ovaltine (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wine (glass)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Beer, lager or cider (half pint)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Port, sherry, vermouth, liqueurs 
(glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
































Please check that you have a tick on EVERY line 
 
255 
PLEASE PUT A TICK ON EVERY LINE. 
 
































Spirits, e.g. gin, brandy, whisky, 
vodka (single) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low calorie or diet fizzy soft 
drinks (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fizzy soft drinks, e.g. Coca cola, 
lemonade (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pure fruit juice (100%), e.g. 
orange, apple juice (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fruit squash or cordial (glass)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
27. FRUIT (1 fruit or medium serving)       
*For very seasonal fruits such as strawberries, please estimate your average use when 




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pears  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Oranges, satsumas, mandarins, 
tangerines, clementines 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Grapefruit  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Bananas  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Grapes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Melon  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
*Peaches, plums, apricots, 
nectarines 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
*Strawberries, raspberries, kiwi 
fruit 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            































Please check that you have a tick on EVERY line 




FOODS & AMOUNTS AVERAGE USE LAST YEAR 
27. FRUIT (continued) 































Tinned fruit  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dried fruit, e.g. raisins, prunes, 
figs 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
28. VEGETABLES Fresh, frozen or tinned 
(medium serving) 




            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Spinach  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Broccoli  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brussels sprouts  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cabbage  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peas  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Green beans, broad beans, 
runner beans 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
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Marrow, courgettes  
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Cauliflower  
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Parsnips, turnips, swedes  
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
28. VEGETABLES 
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Sweet peppers  
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Beansprouts  
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Green salad, lettuce, cucumber, 
celery 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Mixed vegetables (frozen or 
tinned) 
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Beetroot, radishes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coleslaw  
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Baked Beans  
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Dried lentils, beans, peas  
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Tofu, soya meat (TVP), 
Vegeburger 
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YOUR DIET LAST YEAR, continued  
 
29. (a) What type of milk did you most often use? 
 
Select one only 
 
 Full cream……1 
Channel Islands……2 








29. (b) Approximately, how much milk did you drink each day, including 
milk with tea, coffee, cereals etc? 
 
 None……1 
Quarter of a pint (roughly 125mls)……2 
 Half a pint (roughly 250mls) ……3 
Three quarters of a pint (roughly 375mls) ……4 
     One pint (roughly 500mls) ……5 




30.  What kind of fat did you most often use for frying, roasting, grilling 
etc? 
 
Select one only 
 Butter……1 
Lard/dripping……2 
Solid vegetable fat……3 
Margarine……4 







31. How often did you eat food that was fried at home? 
 
Select one only 
 Daily……1 
1-3 times a week……2 
4-6 times a week……3 




32. How often did you eat fried food away from home? 
 
Select one only 
 
 Daily……1 
1-3 times a week……2 
4-6 times a week……3 




33. (a) How often did you add salt to food while cooking? 
 









33. (b) How often did you add salt to any food at the table? 
 










34. Do you follow a special diet? 
 Please tick all that apply. 
 
No……1 
Yes, due to a medical condition/allergy……2 
 Yes, to lose weight……3 
Yes, because of personal beliefs ……4 
                                                                                                                Yes other……5 
4/63 
 
35. Over the last year, how often have you eaten organic foods? 
 
Select one only. 
 Most days……1 
Once or twice a week……2 
Once a month……3 
 Never/hardly ever……4 
4/64 
 
36. Have you taken any of the following during the past year? 
 





 If YES, what type and when         
4/65 
b) Minerals (e.g. iron, calcium, zinc, magnesium) 




If YES, what type and when         
 
4/66 





If YES, what type and when         
 
4/67 
d) Other food supplements (e.g. oil of evening primose, starflower oil, 











37. During the course of last year, on average, how many times did you 
eat the following foods? 
 
Food Type      Times/week Portion size 
 
Vegetables (not including potatoes)       medium serving 
5/41 
Salads        medium serving 
5/43 
Fruit and fruit products (not including    medium serving 
fruit juice)        or 1 fruit 
            5/45  
Fish and fish products      medium serving 
5/47 
Meat, meat products and meat dishes 




38. How often do you eat fruit or vegetables from a garden or allotment? 
 
Select one only. 
 Most days……1 
Once or twice a week……2 
Once a month……3 






39. How would you most commonly eat the following vegetables? 
If you have not eaten the vegetable listed within the last year,  
please tick the ‘Not eaten ‘ box.  
 
Select one box only for each vegetable; 
 
     Raw    Boiled  Boiled       Steamed       Fried   Not eaten 
     < 10mins >10mins 
Asparagus                                                   
Artichoke                                                   
Beansprouts                                                   
Beetroot                                                  
Broad beans                                                  
Broccoli                                                  
Brussel Sprouts                                             
Cauliflower                                              
 
      Raw    Boiled  Boiled       Steamed       Fried   Not eaten 
  < 10mins >10mins 
Cabbage                                                   
Chick Peas                                                   
Courgette                                                   
Curly Kale                                                   
Green Beans                                                   
Leeks                                                    
Lentils                                                   
Lettuce                                                   
 Mixed veg frozen                                              
 Mixed veg canned                                             
Parsnip                                                   
Peas                                                    
Red Kidney Beans                                             
Runner Beans                                             
Spinach fresh                                             
Spinach frozen                                             
Sweetcorn fresh                                             




40. For the following foods, please list the top three makes and/or brands you 
most commonly consume.  





 Bread:    1:       
2:       
3:      Not eaten  
  
Breakfast Cereal 
     1:       
2:       






About you and your health 
 
41. For your age, would you say that your health was: 
 
Please tick one box on the scale of 1 to 5: 
 
  1 2 3 4 5 
very good      very poor 
5/51 
 
42. Which of the following best describes your daily work or other 
daytime activity that you usually do? 
 
Please tick one box only. 
 
I am usually sitting and do not walk about much……1 
 
I stand or walk about quite a lot, but do not  
have to carry or lift things very often     ……2 
 
I usually lift or carry light loads or have  
to climb stairs or hills often      ……3 
 
I do heavy work or carry heavy loads often    ……4 
5/52 
43. Please give the average number of hours per week you spend doing 
 sports and other activities.      
 
 Please write in the amount for each; if none write “0” 
 
a) Mildly energetic 




b) Moderately energetic 
(e.g. heavy housework or gardening, dancing, golf, 




(e.g. running, competitive swimming or cycling, 
tennis, football, squash, aerobics)                      5/64 
 
_____ hour/s     
  




Yes, I smoke daily  ……1 
Yes, I smoke occasionally ……2 
No, I used to smoke ……3 
No, I have never smoked ……4 
5/65 
 
44. If yes or you used to smoke, how much, on average, do you (or did 
you) smoke a day? 
Please write in the amount for each; if none write “0” 
 
Cigarettes  ____ 
          Cigars   ____ 
          Ounces tobacco ____ 
5/74 
 
45. In the past 12 months have you taken an alcoholic drink: 
 Please tick one box. 
 
Twice a day or more ……1 
Almost daily   ……2 
Once or twice a week ……3 
Once or twice a month ……4 
Special occasions only ……5 





46.  In a typical 7-day week, including the weekend, how many standard 
drinks of alcohol do you drink? (see the table below) 
Please write the number in the box below. 
 
I usually drink ____ standard drinks of alcohol per week 
5/76 
 
ONE STANDARD DRINK = ½ pint of beer 
    or ½ pint cider 
    or ½ pint lager  
    or 1 glass of wine, martini, or cinzano 
    or 1 small glass of Sherry or Port 
    or 1 measure of Spirits (gin, whiskey, vodka etc.) 
    or 1 measure liquor 
 
A PINT OF BEER, CIDER, OR LAGER COUNTS AS TWO STANDARD DRINKS 




47. (a) Do you have any long-term illness, physical or mental health 






























Appendix K : Physical Capability Tests Record Sheet 
Participant ID:                                      Date:                                
 
 
HAND GRIP STRENGTH 
Dominant hand: 
Test 
Left hand force 
 (kg) 


















Any comments (e.g. pain, problems): 
 

























Appendix L : Anthropometrics and Body Fat Percentage Record Sheet 
 
Participant ID :                                                        Date and time:       
 



























      
 











Appendix M : Bone Densitometry Record Sheet 
 
 
Participant ID:                                       
Date:                                
 
Bone Densitometry Record Sheet 
 
 





Stiffness index     
BUA     
SOS     
% Young adult     
T score     
% Age Matched     
Z score     
 
 



























































































Ranathunga et al., (2017) Osteoporosis Reviews 
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Relationship between sun exposure behaviors and muscle function and bone strength of 
older adults in North East England. By RMTK Ranathunga, FC Malcomson, TR Hill and 
JC Mathers Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle 
University, Newcastle-upon-Tyne, NE2 4HH, UK  
Use of sun exposure behavior as a proxy indicator of vitamin D status and function is still 
debated (1). The aim of this study was to investigate relationships between sun exposure 
behaviors and muscle function and bone strength in older adults. A total of 47 older adults 
were re-recruited from those who participated in a study of biomarkers of risk of colon cancer 
12 years ago in North East England (N◦55) (2). Current sun exposure behaviors including 
frequency and duration of sun exposure during weekends, weekdays and holiday visits, 
sunblock usage and sun avoidance behavior were collected using a sun exposure 
questionnaire. Muscle function was measured by Grip Strength (GS (kg) using a hand grip 
dynamometer) and Timed-Up and Go test (TUG) as the time (s) to walk 3 m distance. Bone 
strength was measured as Stiffness Index (SI) using a bone heel ultrasound scanner. One-way 
ANOVA was used to identify associations between sun exposure variables, muscle function 
and bone strength using SPSS package. Mean age of the adults was 66.8 (SD 8.3) years and 
the mean BMI was 28.3 (SD 4.7) kgm-2. Approximately 28% of the participants reported sun 
exposure 2 times per week, while 72% reported sun exposure every day in the sunny months. 
About 15% of participants avoided sun exposure and 30% enjoyed the sun exposure during 
the sunny months. Approximately half of the adults (49%) had had a holiday during the last 
three months. Individuals who always enjoyed the sun exposure had greater GS, SI and lower 
TUG test value compared with those i who avoided sun exposure or sometimes enjoyed the 
sun exposure. This difference was significant for GS (p=0.005) (Table 1). There were no 
significant associations between measures of musculoskeletal health and other sun exposure 
behaviors including holiday visits and the frequency of sun exposure.  
 Sun exposure behaviors 
GS (kg) TUG (s) SI 
Mean (SD) Mean (SD) Mean (SD) 
Sun avoidance    
Avoid (n=7) 18.72 (14.5) 11.69 (6.7) 79.21 (7.6) 
Sometimes avoid (n=24) 27.34 (18.1) 8.70 (4.0) 90.40 (8.4) 
Always enjoy (n=14) 32.11 (20.2)* 8.49 (1.4) 97.83 (8.3) 
p value 0.005 0.184 0.100 
Holiday visits    
Yes (n=21) 29.48 (10.3) 9.56 (4.1) 89.95 (18.5) 
No (n=23) 26.04 (7.9) 8.57 (4.1) 92.37 (20.0) 
p value 0.219 0.424 0.68 
Frequency of sun exposure    
More than 2 times/week (n=13) 29.16 (8.30) 9.57 (5.26) 99.11 (15.39) 
Everyday (n=33) 26.87 (9.52) 8.92 (3.61) 88.34 (19.40) 
p value 0.645 0.638 0.102 
GS – Grip Strength TUG – Timed-Up and Go test SI – Stiffness Index 
* Significantly differ between sun avoidance and always enjoy groups.  
Table 1 : Relationship between sun exposure behaviors, muscle function and bone strength 
In conclusion, older adults who avoided sun exposure had lower muscle strength than those 
who always enjoyed sun exposure.  
1. McCarty CA (2008) Am J Clin Nutr. 87(4):1097S-101S. 
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The association between circulating 25-hydroxyvitamin D concentration and Grip Strength  
and Timed-Up and Go test in 70+ year old adults : Baseline findings from the Vitamin D 
Supplementation in Older People (VDOP) study. RMTK Ranathunga1, TR Hill1, JC Mathers1, I 
Schoenmakers2 and TA Aspray3 1Institute of Cellular Medicine, Human Nutrition Research 
Center, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK 2MRC Human Nutrition 
Research, Cambridge, Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. 
3Institute of Cellular Medicine, Freeman Hospital, Newcastle-upon-Tyne, NE7 7DN, UK.  
 
  Vitamin D has important regulatory effects in muscle tissue(1).  Cross sectional studies 
demonstrate that circulating 25-hydroxyvitamin D (25OHD) [the indicator of vitamin D status] is 
associated with better muscle function but the optimal 25OHD concentration for muscle function 
is not universally agreed. The objective of this study was to identify the association between 
serum 25OHD concentration and Grip Strength (GS) and Timed-Up and Go test (TUG) using 
25OHD thresholds used in North America (≥50 nmol/l)(2) and the UK (≥25 nmol/L)(3) used to 
define nutritional adequacy for vitamin D.  
     A total of 377 male and female adults aged >70 years living in the North-East of England were 
recruited. GS (in kg) was measured by a hand grip dynamometer and TUG was measured as the 
time (in seconds (s)) to walk 2m distance. Serum 25OHD concentration was measured by LC-MS. 
Weight, height and body composition were also measured. In separate analyses, individuals were 
grouped according to the circulating 25OHD concentration < or ≥ 25 nmol/L and < or ≥ 50 
nmol/L.  Male and female older adults were grouped into two separately, based on the gender 
specific median values of GS and TUG test values. The odds ratios to have high GS and low TUG 
test values were identified using logistic regression analysis after adjusting for age, weight, height 
and body composition. 
 
   Males Females 
Classification n OR* CI p OR* CI p 
 GS        
SACN 25OHD < 25 nmol/L 102 0.371 0.163- 0.841 0.018 0.652 0.334- 1.272 0.209 
 25OHD >25 nmol/L 275 Reference   Reference   
IOM 25OHD < 50 nmol/L 271 1.202 0.61 – 2.341 0.588 0.739 0.355 – 1.538 0.419 
 25OHD  > 50 nmol/L 106 Reference   Reference   
 TUG test        
SACN 25OHD < 25 nmol/L 102 1.274 0.59 – 2.741 0.536 0.695 0.358 – 1.350 0.283 
 25OHD >25 nmol/L 275 Reference   Reference   
IOM 25OHD < 50 nmol/L 271 0.910 0.474-1.74 0.777 0.537 0.257-1.120 0.098 
 25OHD > 50 nmol/L 106 Reference   Reference   
   
Mean serum 25OHD concentration of older adults was 39.8 (+19.9) nmol/L. About 21.0 % of 
males and 33.7% of females had serum 25OHD concentration less than 25 nmol/L. Similarly, 67.9 
% of males and 76.2% of females had serum 25OHD concentration less than 50 nmol/L. Only for 
male, those with serum 25OHD concentration lower than 25nmol/L were significantly more likely 
to have lower GS compared to the individuals who had serum 25OHD concentration higher than 
25 nmol/L. However, there was no significant relationship between 25OHD status and TUG for 
either gender.  In conclusion, in male older adults, serum 25OHD concentration lower than 25 
nmol/L is associated with lower GS but there was no evidence of musculoskeletal benefit from 
having serum 25OHD concentrations higher than 50 nmol/L for either gender. Therefore, based 
on this cross sectional analysis, the optimum serum 25OHD concentration to maximize the muscle 
strength  for older  males is likely to be between 25-50 nmol/L.  
The VDOP study is supported by a grant (MP/ID19544) from Arthritis Research UK and partly supported by Newcastle 
University and funding from the core programme of the MRC Nutrition and Bone Health Group at MRC Human Nutrition 
Research funded by the UK MRC, grant code U10596037.    
     1. Ceglia L (2009) Curr. Opin. Clin. Nutr, 12, 628 - 633.  
     2. IOM (2011) Dietary reference intakes for calcium and vitamin D.  
     3. Scientific Advisory Committee in Nutrition (2016) Vitamin D and Health Report. 
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NO EFFECT OF MONTHLY SUPPLEMENTATION WITH 12000IU, 24000IU AND 48000IU VITAMIN 
D3 FOR 1 YEAR ON MUSCLE FUNCTION: THE VITAMIN D SUPPLEMENTATION IN OLDER 
PEOPLE (VDOP) STUDY. RMTK Ranathunga1, TR Hill1, JC Mathers1,I Schoenmakers 2 and TA 
Aspray3 1Institute of Cellular Medicine, Human Nutrition Research Center, Newcastle University, 
Newcastle-Upon-Tyne, NE2 4HH,UK 2MRC Human Nutrition Research, Cambridge, Medical School, 
University of East Anglia, Norwich, NR4 7TJ, UK 3Institute of Cellular Medicine, Freeman Hospital, 
Newcastle-upon-Tyne, NE7 7DN, UK. 
 
   The optimal dose of vitamin D supplementation for muscle function is not universally agreed. The 
objective of this study was to determine the effect of monthly supplemental vitamin D3 (12000IU, 
24000IU and 48000IU) for 12 months on Grip Strength (GS) and Time-Up and Go test (TUG) in 75+ 
years old adults living in the North-East of England. GS was measured by a hand grip dynamometer in 
kilograms (kg) and the TUG test measured by the time taken to walk 2m distance in seconds (s) in 
participants before and after vitamin D3 treatment. Fasting serum total 25(OH)D concentration of pre 
and post intervention was measured by LC-MS. Pre-intervention serum 25(OH)D, GS and TUG were 
39.9(+19.9) nmol/L, 28.5(+12.8) kg and 11.4(+3.1) s, respectively.  Using, Analysis of Variance 
(ANOVA), there was a significant dose-related response in serum 25(OH)D concentration after 12 
months of vitamin D supplementation (p<0.000). The change (Δ) in GS and TUG from pre to post-
intervention was unaffected by the three doses of vitamin D3. Results remained unchanged after 
adjustment (using ANCOVA) for age, gender and baseline serum 25(OH)D, GS and TUG.  Stratifying 
participants into having baseline serum 25(OH)D concentrations above and below the median in each 
vitamin D treatment arm had no effect on the change in GS and the TUG test.  In conclusion, vitamin 
D supplementation at 12000IU, 24000IU and 48000IU monthly for 12 months had no effect on GS and 
TUG test in older adults aged >75+ years.  This study was supported by a number of funding sources 
including Arthritis Research UK, MRC Human Nutrition Research (funded by the UK MRC) and 
Newcastle University. 
 
12000IU(n=112) 24000IU(n=113) 48000IU(n=114) 
  
 
Mean SD Mean SD Mean SD P p* 
Δs 25(OH)D (nmol/L)  14.27 16.63 25.32 18.02 40.86 19.75 <0.000 <0.000 
Δs GS (kg) -2.78 11.64 -3.62 8.67 -2.57 7.84 0.670 0.251 
Δs TUG test (s) 0.56 2.32 0.46 2.77 0.15 2.5 0.449 0.439 
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Sunshine exposure and serum 25OHD concentrations during a 12 month randomized 
control trial with high dose vitamin D supplementation: results from the Vitamin D 
Supplementation in Older People (VDOP) study(1). By RMTK Ranathunga1,2, TR Hill1,2, 
JC Mathers2,3, I Schoenmakers4 and TA Aspray3,5 on behalf of the VDOP study 
team.1Agriculture Food and Rural Development, Newcastle University, NE1 7RU, 2Human 
Nutrition Research Center, Newcastle University, NE1 7RU, 3Institute of Cellular Medicine, 
Newcastle University, NE4 4PL, 4MRC Human Nutrition Research, Cambridge, Medical 
School, University of East Anglia, Norwich, NR4 7TJ, 5Freeman Hospital, Newcastle upon 
Tyne, NE7 7DN.  
Assessing the relative contribution of sunshine exposure to vitamin D status in randomized 
control trials with vitamin D supplementation is of paramount importance. The objective of 
this study was to determine the effect of yearly sun exposure on serum 25OHD concentrations 
in older adults supplemented with 12 monthly doses of 12000IU, 24000IU and 48000IU 
vitamin D3.  Serum 25OHD concentration was measured by Tandem Mass Spectrometry at 
baseline and after 12 month supplementation in 327 adults aged >70 years(1). Sunshine 
exposure of the participants was assessed every three months (baseline, after 3 months, 6 
months, 9 months and after 12 months) by a questionnaire which assessed the frequency of 
outdoor activities, skin exposure area exposed to sun, sunblock usage, holiday visits and 
Fitzpatrick skin types. Of the 327 participants, 62% of participants began the 12 months 
supplementation during the time of year where there is no UVB radiation at the study location 
(550N), defined as October to March(2). Composite scores for each sun exposure variable were 
calculated from the mean of the five questionnaires (including baseline and 12 months follow-
up visits).  For each treatment arm of the trial, sunshine exposure variables as well as other 
socio-demographic, lifestyle and dietary factors were included as potential predictors of 
endpoint serum 25OHD using backward linear regression.  
In those participants receiving 12000IU monthly, summer sun exposure, skin exposure 
area exposed to sun and female gender were positively associated with endpoint vitamin D 
status while skin type IV, calcium intake and BMI were negatively associated with endpoint 
vitamin D status.  For participants randomized to 24000 IU and 48000 IU monthly, none of 
the sunshine exposure variables were significantly related to vitamin D status. The proportion 
of the variance in endpoint serum 25OHD concentration explained by the variables in the 
model were 36%, 21% and 16% for the 12000IU, 24000IU and 48000IU treatment arms, 
respectively. 
Sun exposure variables ß SE 95%CI P-value 
12000IU group (n=100, R2=0.36) 
Summer sun exposure (vs winter sun exposure) 0.321 2.702 4.311, 15.059 0.001 
Skin exposure area 0.396 10.017 24.234, 64.080 <0.001 
Fitzpatrick skin type IV (vs type I) -0.207 4.134 -17.74,-1.292 0.024 
Calcium intake  -0.185 0.005 -0.021, 0.000 0.041 
Females (vs males) 0.212 2.808 0.817,11.985 0.025 
BMI -0.237 0.373 -1.703,-0.219 0.012 
     
24000IU group (n=112, R2=0.21) 
Sunblock use 0.191 2.963 -0.152, 11.633 0.056 
BMI -0.392 0.379 -2.262, - 0.754 <0.001 
     
48000IU group (n=115, R2=0.16) 
Age -0.216 0.349 -1.436,-0.050 0.036 
BMI -0.359 0.379 -2.048, -0.559 0.001 
Endpoint serum 25OHD as dependent variable and frequency of outdoor activities, skin exposure area 
exposed to sun, Fitzpatrick skin types, sunblock usage, sun exposure season, length of holiday visits, 
holiday season, calcium and vitamin D intake, age, gender and BMI as dependent variables.  
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In conclusion, a number of sunshine exposure variables predicted endpoint vitamin D status in 
participants receiving 12000 IU monthly but vitamin D supplementation appears to overwhelm the 
effect of sun exposure on 25OHD concentration at higher doses in older adults.  
 
The VDOP study is supported by a grant (MP/ID19544) from Arthritis Research UK and partly supported by Newcastle University and 
funding from the core programme of the MRC Nutrition and Bone Health Group at MRC Human Nutrition Research funded by the UK 
MRC, grant code U10596037. 
 
1. Schoenmakers I, Francis M, McColl E et al. (2013) Trials 14:299. 
2. Webb A, DeCosta, B, and Holick M (1989) J Clin Endocrinol Metab, 68, 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
